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 ABSTRACT  
 
Bone marrow stem/progenitor cell (BMSC) therapy for cardiac repair in 
humans is yet to fulfil the exciting potential demonstrated in preclinical 
experiments. This thesis presents three clinical studies addressing some of 
the unresolved issues regarding the ideal delivery method, the effect of 
patient-related factors on progenitor cell concentration/function and the 
possible biological mechanism(s) of action.  
 
The first study describes the intramyocardial arm of the REGENERATE-IHD 
trial- a randomised controlled trial assessing the efficacy of mobilised BMSCs 
in patients with ischaemic heart failure. In summary, 30 patients were 
randomised 1:1 to receive injection of BMSCs suspended in autologous serum 
or serum alone (control group). All patients received a 5-day course of G-CSF 
prior to bone marrow harvest and intramyocardial injection. At 1-year, there 
was a significant increase in ejection fraction, the primary end-point, in 
patients treated with BMSCs. There were also significant improvements in the 
secondary end-points of NT-proBNP and symptoms.  
 
In the second study, progenitor cell concentration and function were assessed 
in patients with ischaemic heart failure (IHD), dilated cardiomyopathy (DCM) 
and acute myocardial infarction (AMI). Findings include ageing having an 
inverse association with circulating CD34+ cell concentration as well as 
blunting the effects of G-CSF on BMSC mobilisation. DCM patients had 
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significantly higher baseline circulating progenitor cell concentrations 
compared to IHD/AMI. 
 
The final study presents preliminary data regarding a novel imaging technique 
to detect angiogenesis which is recognised as a potential therapeutic effect of 
BMSCs. Nine patients with heart failure underwent nuclear imaging using a 
radio-tracer peptide with a high affinity for αvβ3, an angiogenesis-related 
integrin, before and after intracoronary infusion of BMSCs/serum. Preliminary 
results showed detectable baseline uptake of the radio-tracer suggesting a 
novel finding of persistent angiogenesis following remote myocardial infarction 
and also hint at a tantalising possibility that BMSC infusion may lead to 
therapeutic angiogenesis.   
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CHAPTER 1: INTRODUCTION 
Cardiovascular disease is the leading cause of morbidity and mortality 
worldwide. Despite the advances in medical and catheter-based therapy for 
acute myocardial infarction the 1-year mortality remains as high as 11%1-3 and 
the long-term prognosis for patients with heart failure and left ventricular 
systolic dysfunction (LVSD) remains poor4.  There is currently no treatment 
option that targets the primary problem of cardiomyocyte loss during an 
ischaemic insult which results in chronically impaired ventricular function. 
Hence, a need has been identified for novel therapies that target this issue 
and the discovery of adult stem plasticity has seen progenitor cell therapy 
emerge as an exciting therapeutic potential. It is hoped that cell therapy can 
ameliorate myocyte loss in the acute infarct setting and also improve cardiac 
function and symptoms in patients with chronically infarcted myocardium. 
Numerous cell types have been, and continue to be, investigated for their 
ability to contribute to cardiac repair. Bone marrow derived stem/progenitor 
cells (BMSCs) have been widely investigated clinically due to the ease of 
obtaining bone marrow and preclinical experiments demonstrating the 
potential of this cell type to transdifferentiate to a cardiomyocyte phenotype5, 6. 
The latter remains under considerable debate as this finding has not been 
consistently reproduced7, 8 although even in the absence of transdifferentiation 
improvement in cardiac function has been demonstrated9. Thus there are 
likely to be other mechanisms, such as cell fusion and paracrine effects, which 
may contribute to potential improvement. Furthermore, it remains unclear 
which fraction of the bone marrow (i.e. haematopoietic stem cells, CD34+ 
cells, endothelial progenitor cells, mesenchymal stem cells or even the 
 14 
monocyte/lymphocyte component) may contribute most to the process of 
potential repair or whether is requires a combination of two or more of these 
cell types. 
 
Despite these uncertainties, the past decade has seen a steady increase in 
the number of clinical trials being performed to assess the safety and efficacy 
of different cell types and delivery methods for the purposes of cardiac repair 
in patients with chronic ischaemic heart failure. These small clinical studies 
have suggested that progenitor cell therapy may improve various functional 
characteristics of patients with chronic heart failure10-14. The need for larger 
randomised controlled studies to further investigate this potential benefit has 
been clearly outlined15. Additional questions relating to the ideal cell type, use 
of adjunctive cytokine therapy and the method of cell delivery remain to be 
answered as the field moves forward and attempts to translate the positive 
findings of preclinical experiments into clinically meaningful benefits. There is 
also clearly a need for clinical mechanistic studies to define the biological 
effects of cell therapy on human cardiac tissue.   
 
The Randomized Controlled Trial to compare the Effects of G-CSF and 
Autologous Bone Marrow Progenitor Cells Infusion on Quality of Life and Left 
Ventricular Function in Patients with Heart Failure secondary to Ischaemic 
Heart Disease (REGENERATE-IHD) is a single centre double-blind, 
randomised controlled study being conducted at The London Chest Hospital16. 
This is the only trial of its kind in the United Kingdom and addresses some of 
the unanswered questions mentioned above regarding cell therapy in heart 
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failure. The trial investigates the potential for autologous BMSCs to improve 
cardiac function and symptoms in patients with chronic ischaemic heart failure 
and no further treatment options. As well as testing routes of administration, it 
uses a novel approach of administering granulocyte-colony stimulating factor 
(G-CSF) as adjunctive cytokine therapy. 
 
In this thesis, chapter 2 provides background to the relevant pathophysiology 
of ischaemic heart failure and the current treatment options available. The 
potential role of adult stem cell therapy and results of previous clinical trials 
are also described. In chapter 3 the specific hypotheses and aims of this 
thesis are presented. Chapter 4 then presents the methods and results of the 
intramyocardial arm of the REGENERATE-IHD trial which examines the safety 
and efficacy of NOGA® guided intramyocardial injection of G-CSF mobilised 
BMSCs in patients with chronic ischaemic heart failure. The study 
methodology and trial design are described and the safety and efficacy results 
are presented and discussed in detail. The data from this chapter has been 
submitted for publication in a leading international medical journal.  
 
Chapter 5 describes a study of bone marrow progenitor cell characteristics in 
patients recruited to the whole REGENERATE-IHD study as well as in patients 
recruited to two other cell therapy clinical trials being performed at The London 
Chest Hospital. This study assesses the effects of age, disease state and G-
CSF on progenitor cell concentration and function. This analysis is pertinent 
as there is growing evidence to suggest that efficacy of autologous cell 
therapy maybe attenuated by patient related factors affecting the quantity and 
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quality of the cell product. The data from this chapter has been published in 
the Stem Cell & Development Journal17- a leading journal in the field of stem 
cell therapy.  
 
Chapter 6 describes the preliminary results of a novel clinical imaging 
technique to detect angiogenesis potentially related to BMSC therapy. Despite 
numerous studies suggesting beneficial cardiac effects of cell therapy there 
remains considerable conjecture regarding the actual biological mechanism(s) 
through which this occurs. One of the proposed mechanisms demonstrated in 
preclinical experiments is neoangiogenesis either directly by differentiation into 
endothelial cells18 or indirectly through secretion of paracrine factors19. This is 
yet to be demonstrated clinically and hence this novel imaging technique 
represents a major step forward in this field and may provide an exciting 
insight into whether there is clinically relevant neoangiogenesis following 
BMSC therapy in humans.   
 
Chapter 7 provides an insight into the future directions for the field of cardiac 
cell therapy and the thesis conclusions are summarised in chapter 8. The 
appendices include an additional small retrospective study evaluating the 
incidence of left ventricular thrombus (LVT) in patients with ischaemic heart 
failure. This analysis was prompted by the withdrawal of 3 patients from the 
intramyocardial arm of the REGENERATE-IHD study due to LVT being 
diagnosed on baseline imaging tests. Finally, the appendices also include a 
list of publications and presentations arising from this period of research. 
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CHAPTER 2: BACKGROUND 
2.1 Heart Failure 
2.1.1 Epidemiology 
 
Ischaemic heart disease (IHD) is the commonest cause of death in the world 
accounting for 7.2 million deaths per year (approximately 12% of all reported 
deaths)20. Acute myocardial infarction (AMI) affects around 250,000 people 
each year in the United Kingdom (UK)21 and subsequent heart failure with left 
ventricular systolic dysfunction (LVSD) is relatively common. In the 
HORIZONS-AMI trial, a contemporary study of AMI treatment, the incidence of 
new-onset heart failure was 4.7% at 1-year and this was associated with 
significantly increased rates of mortality and adverse ischaemic events22. The 
overall prevalence of heart failure is estimated to be 3% of people aged over 
45 in the UK23  and this is likely to increase, partly because of an aging 
population but also because of improved interventions that prolong survival 
after AMI24. In approximately 30% of patients, heart failure is secondary to 
causes other than IHD/AMI, such as diastolic dysfunction and dilated 
cardiomyopathy25. Regardless of aetiology heart failure is associated with 
significant morbidity and mortality reflected by a 5-year mortality varying from 
26-75%26, a prognosis that is worse than most cancers. Patients with heart 
failure can be significantly limited in term of exercise capacity which can vary 
from being breathless on moderate exertion to being breathless at rest. 
Furthermore, once admitted with an episode of decompensated heart failure, 
the subsequent rate of re-hospitalisation is high- 19% at 30 days in one recent 
study27. This has a major impact on quality of life as well as leading to a major 
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socioeconomic cost burden. The annual cost of heart failure in the UK is just 
over £625 million, thus consuming 2–2.5% of the total National Health Service 
(NHS) budget28. It has also been estimated that IHD cost the economy £3.9 
billion in lost productivity in 200829. These financial considerations are also 
important drivers behind the search for novel therapies for heart failure. 
 
2.1.2 Normal resting cardiac function 
The principle function of the heart is to generate a cardiac output that sustains 
an arterial blood pressure necessary to provide adequate perfusion of organs. 
In a healthy person, cardiac output is matched to the body’s metabolic 
demand and is a product of stroke volume (SV) and heart rate. SV is the 
volume of blood ejected from the ventricle in one cardiac cycle and is 
approximately 70ml in an adult human at rest. The ventricular end-diastolic 
volume (EDV) is the volume of blood in the ventricle just prior to contraction 
and is typically 120 ml. The end-systolic volume (ESV) is the residual volume 
after contraction and is therefore usually 50 ml of blood. Left ventricular 
ejection fraction (LVEF), the most commonly used measure of cardiac 
function, is calculated as SV/EDV ((EDV-ESV)/EDV)) i.e. it measures the 
fraction of the EDV that is ejected with each heart beat and is normally 55-
60% in an adult human at rest.  
 
There are three major mechanisms that regulate EDV and ESV, and therefore 
SV: preload, afterload and myocardial contractility (inotropy). The concept of 
preload regulating myocardial performance was described in the late 19th 
century by physiologists Frank and Starling. Otto Frank showed that the 
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strength of ventricular contraction in isolated frog hearts was increased by 
stretching the ventricle prior to contraction17. This work was extended by 
Ernest Starling and others who found that increasing venous return, and 
therefore the EDV and filling pressure of the ventricle, led to increased stroke 
volume in dogs18. The ability of the heart to change its force of contraction and 
therefore stroke volume in response to changes in EDV is termed the Frank-
Starling mechanism (figure 1). This important physiological concept is not 
dependent on neural or humoral activations. The molecular pathway 
underlying this mechanism involves myofilament length-dependent activation 
although the exact processes through which sarcomeres detect changes in 
length and translate this into increased sensitivity to activating calcium 
remains to be fully defined30. The Frank-Starling mechanism is attenuated in 
states of reduced inotropy, such as following a large myocardial infarction, and 
stroke volume may not increase significantly in response to increased EDV31 
(figure 1). 
  
 
 
 
 
 
 
Figure 1. Frank-Starling curves depicting the relationship between end diastolic volume (EDV) 
and stroke volume. In a normal heart (black line) cardiac output continually increases in 
response to an increase in pre-load. In states of increased inotropy there is augmented 
cardiac output at the same EDV (green line). In heart failure (deceased LV contractility) the 
curve is shifted down and is flattened so that stroke volume and cardiac output do not 
increase significantly in response to increased EDV leading to further deleterious increases in 
EDV and end-diastolic pressure. 
End diastolic volume (EDV)
Stroke volume
Normal 
Increased inotropy
Heart Failure
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2.1.3 Pathophysiology of ischaemic heart failure 
 
Ischaemic heart failure is a disease state in which cardiac contractile function 
is impaired secondary to myocardial necrosis resulting in an insufficient 
cardiac output to adequately perfuse the body’s organs. Several natural 
compensatory mechanisms are initiated in patients with ischaemic heart failure 
in an attempt to counteract the fall in cardiac output and maintain sufficient 
blood pressure to perfuse vital organs. These include: (1) changes to 
circulatory haemodynamics, (2) neurohormonal alterations and (3) ventricular 
remodelling. 
 
2.1.3.1 Changes to circulatory haemodynamics 
A large myocardial infarction resulting from prolonged occlusion of a major 
coronary artery leads to myocardial necrosis and loss of upto a billion 
cardiomyocytes32. This leads to impaired contractility of the heart reflected by 
a reduction in left ventricular ejection fraction (LVEF) and stroke volume 
leading to increased ESV.  This, in addition to normal pulmonary venous 
return, leads to an increase in EDV. In a normal heart increased EDV would 
increase contractility (via the Frank-Starling mechanism) but in a failing heart 
EDV and therefore end diastolic pressure (EDP) remains elevated (figure 1). 
In the presence of impaired left ventricular systolic function this produces a 
vicious cycle of further elevations in EDV and EDP and progressive dilatation 
of the ventricle as seen in patients with chronic heart failure. During diastole 
the persistently elevated EDP is transmitted to the left atrium and to the 
pulmonary veins and capillaries causing transudation of fluid into the 
pulmonary interstitium and symptoms and signs of pulmonary congestion. One 
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of the major hopes of cellular therapy is potential regeneration of myocardium 
with subsequent improvement in contractile function (LVEF) and inotropy 
leading to reduction in EDV/ESV (figure 1). This is partly the reason why 
improvement in LVEF has been chosen as the surrogate marker to assess the 
efficacy of cell therapy in the clinical trial described in this thesis (chapter 4). 
 
2.1.3.2 Neurohormonal changes 
Neurohormonal activation involves three important compensatory mechanisms 
in response to reduced cardiac output and hypotension: the stimulation of the 
sympathetic nervous system, the renin-angiotensin-aldosterone system 
(RAAS), and the release of natriuretic peptides. In part, these mechanisms 
serve to increase systemic vascular resistance (SVR) to  maintain arterial 
blood pressure in the setting of reduced cardiac output (blood pressure= 
cardiac output x SVR).  
 
The fall in cardiac output is sensed as decreased perfusion pressure by 
baroreceptors in the carotid sinus and aortic arch. This activates the 
sympathetic adrenergic system which stimulates catecholamine synthesis 
leading to increased heart rate and SVR in an attempt to maintain blood 
pressure and perfusion. 
 
The RAAS is activated early in patients with heart failure and this is mediated 
through an increase in renin release from the juxtaglomerular cells of the 
kidney in response to decreased renal artery perfusion pressure and also 
direct stimulation of juxtaglomerular β2 receptors by the activated adrenergic 
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system. Renin is an enzyme that cleaves circulating angiotensinogen to form 
angiotensin I, which is then rapidly cleaved by endothelial cell-bound 
angiotensin-converting enzyme (ACE) to form angiotensin II (Ang II) which is a 
potent vasoconstrictor33. Ang II also stimulates release of aldosterone from the 
adrenal cortex which expands the intravascular volume by increasing sodium 
reabsorption by the kidney.  
 
Activation of the adrenergic and RAAS systems is initially beneficial in 
maintaining a cardiac output but in the long-term continued activation typically 
proves harmful. The increased intravascular volume adds to the increasing 
preload/EDV in a failing heart (figure 1) and leads to pulmonary and peripheral 
oedema. Continuous sympathetic activation results in down-regulation of 
cardiac β-adrenergic receptors and up-regulation of inhibitory G-proteins, 
contributing to a decrease in the myocardium’s sensitivity to circulating 
catecholamines and a reduced inotropic response34. These neurohormonal 
mechanisms also play an important role in adverse LV remodelling. 
 
In contrast, the natriuretic peptides are potentially beneficial hormones 
secreted in heart failure in response to activation of stretch receptors by the 
increased intra-cardiac pressure. The best studied of these are atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP). BNP was 
originally identified in extracts of porcine brain35 (hence the name), although in 
humans it is produced mainly in the cardiac ventricles36. The physiological 
actions of BNP (and ANP) include sodium and water excretion, vasodilation, 
inhibition of renin secretion and antagonism of the effects of Ang II37. These 
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effects are beneficial to patients with heart failure although are not usually 
sufficient to fully counteract the vasoconstriction and volume-retaining effects 
of the other activated neurohormonal systems. BNP is co-secreted along with 
a 76 amino acid N-terminal fragment (NT-proBNP) which is biologically 
inactive. The biological half-lives of BNP and NT-proBNP are at least twice as 
long as that of ANP making these peptides more suitable for diagnostic blood 
testing38. However, the measurement of BNP is not yet routine in clinical 
practice but has potential uses in the diagnosis of heart failure, monitoring 
response to treatment and prognostication. Studies have shown that BNP 
levels correlate with heart failure severity and clinical outcome37. Also, greater 
percentage reduction in BNP with treatment of decompensated heart failure 
maybe associated with better event-free survival39. We have therefore 
assessed for changes in NT-proBNP level in patients in our REGENERATE-
IHD clinical trial (chapter 4) with the hypothesis that if cell therapy improves 
cardiac function this maybe reflected in a reduction in NT-proBNP level. 
 
In addition to these well recognised neurohormonal mechanisms it is now 
becoming increasingly realised that there exists a ‘cardiac-bone marrow axis’ 
which is affected by myocardial injury40. Several experimental and clinical 
studies in myocardial infarction have shown activation of a bone marrow niche 
with release of pro-angiogenic cells and various types of haematopoietic stem 
cells (HSCs)41, 42. This effect appears to be beneficial with the extent of initial 
mobilisation of HSCs shown to be an independent predictor of a more 
favourable remodelling process following AMI43. 
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2.1.3.3 Left ventricular remodelling 
Following a large myocardial infarction, there are changes in the structure of 
the both the infarcted and non-infarcted ventricular muscle and these changes 
in chamber size and thickness (remodelling) affect long-term ventricular 
function and prognosis44. Figure 2 summarises the recognised 
pathophysiological processes that are thought to be involved in producing left 
ventricular remodelling. 
 
 
 
 
 
Figure 2. Schematic representing the pathophysiology of left ventricular remodelling following 
myocardial infarction. The many concomitant processes involved in early and late remodelling 
are shown in this diagram and discussed in the text. ACE: angiotensin converting enzyme; AII: 
angiotensin II; ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; ECM: extracellular 
matrix; ET: endothelin; MMP: matrix matalloproteinases; SVR: systemic vascular resistance. 
Reproduced with permission from Lippincott Publishing45. 
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In the early stages following an MI, the infarct area is infiltrated by 
macrophages, monocytes, and neutrophils and there is infarct expansion 
which results from the degradation of the inter-myocyte collagen bridges by 
serine proteases matrix metalloproteinases (MMPs) released from 
neutrophils46. This inflammatory process is necessary to remove necrotic cells 
but at the same time is detrimental to surviving cardiomyocytes. Infarct 
expansion produces wall thinning and ventricular dilatation (figure 3), 
increased wall stresses and risk of ventricular rupture47. Increased wall stress 
is a potent stimulus for hypertrophy of non-infarcted segments which is 
mediated partly through intracellular signalling via Ang II release48. This 
increased mass of muscle fibres serves as a compensatory mechanism that 
helps to maintain contractile function and counteracts the elevated ventricular 
wall stress45. The inflammatory processes involved in early infarct expansion 
produce a hostile environment and may partly explain why the beneficial 
effects of stem cell therapy in AMI seem to be limited to when cells are 
delivered between 4-7 days after the infarct49. 
 
Late remodelling principally involves myocyte hypertrophy and collagen scar 
formation as mechanisms to alleviate the increased wall stresses and 
counteract the distending forces50. There is considerable change to the 
extracellular matrix during this remodelling process. Myocyte hypertrophy is 
initiated by activation of neurohormonal pathways, mechanoreceptors, local 
tissue RAAS and paracrine factors45. Increased diastolic wall stress leads to 
the synthesis of new sarcomeres in series with the old causing the myocytes 
to elongate51. The radius of the ventricular chamber therefore enlarges, doing 
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so in proportion to the increase in wall thickness- this is termed mural (or 
eccentric) hypertrophy52, as illustrated in figure 3.  
 
 
 
 
 
 
 
Figure 3. Illustration of the pathological consequences of LV remodelling following an acute 
myocardial infarction. Early remodelling involves infarct expansion of wall thinning and the 
initiation of fibrous scar formation. Late remodelling involves increased interstitial collagen and 
myocyte hypertrophy in non-infarcted segments leading to LV eccentric hypertrophy with 
spherical ventricular dilation. 
Reproduced with permission from Elsevier Science53.  
 
In humans post infarct healing consists predominantly of myocardial fibrosis 
and scar formation which is triggered by release of the cytokine transforming 
growth factor-β1 (TGF-β1) from necrotic myocytes54. This cytokine is important 
in the proliferation of myofibroblasts which are responsible for collagen 
production55. Deposition of collagen occurs predominantly in the infarct zone; 
however, it also occurs in non-infarcted myocardium (figure 3). Collagen can 
be detectable within 1 week post infarct and by 4 weeks the necrotic myocytes 
are entirely replaced by fibrous tissue46. There is evidence to suggest that 
native bone marrow stem cells are involved in this reparative process by 
homing to the infarct area, transforming into myofibroblasts and contributing to 
scar tissue remodelling and neoangiogensis8. Unlike  humans, zebrafish have 
been show to fully regenerate myocardium, without any scar formation, within 
8 weeks of injury56. Understanding the processes involved in this ‘scar-less’ 
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healing process will hopefully provide insight into the barriers that prevent 
efficient regeneration in humans. 
 
The early remodelling process is considered an adaptive and necessary 
process to stabilise the infarct area and augment cardiac output. However, 
beyond the early stages, remodelling predominantly involves hypertrophy of 
non-infarcted segments resulting in increased wall mass, chamber 
enlargement, and a shift from an elliptical to a more spherical chamber 
configuration57, 58 (see figure 3). These changes result in a progressive decline 
in cardiac function and LV dilatation with the eventual development of signs 
and symptoms of congestive heart failure.  
 
2.1.3.4 Myocyte loss and cellular dysfunction 
Acute myocardial infarction leads to the loss of a large number of 
cardiomyocytes through cellular necrosis. In chronic ischaemic heart failure 
there is continued cell loss through apoptosis which maybe triggered by 
elevated catecholamines, Ang II, inflammatory cytokines and mechanical 
strain on the myocytes59. Even viable myocardium in heart failure is abnormal 
at a cellular and molecular level59. Mechanical wall stress, neurohormonal 
activation, and inflammatory cytokines, such as tumour necrosis factor α 
(TNF-α), are believed to activate changes in the genetic expression of 
contractile proteins, ion channels, catalytic enzymes, surface receptors and 
secondary messengers in the myocyte60.  These detrimental processes were 
thought to be irreversible but recently the demonstration of mitotic cells within 
the human heart following injury61 and chimerism of transplanted hearts62 
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suggests the potential for myocardial repair/regeneration. It is for these 
reasons that cell therapy has emerged as a potential treatment option with the 
hope that it can lead to cardiac repair through preventing apoptosis and 
improving cellular function in addition to potential myocyte regeneration and 
reverse remodelling. This is discussed in more detail in section 2.2. 
 
2.1.4 Morbidity and mortality 
The predominant symptom in patients with heart failure is dyspnoea on 
exertion. The mechanism of this is partly due to pulmonary interstitial oedema 
and also due to reduced perfusion of respiratory muscles. Reduced cardiac 
output and impaired perfusion of organs is responsible for other multiple 
symptoms seen in heart failure including lethargy, weakness and dulled 
mental status. The increase in intravascular volume secondary to maladaptive 
neurohormonal activation can also lead to peripheral oedema. The New York 
Heart Association (NYHA) classification can be used to give a simplified 
assessment of the functional capacity of an individual patient (Table 1).  
Furthermore, it is now well recognised that NYHA classification is also a strong 
independent predictor of prognosis with more symptomatic patients having a 
higher mortality63, 64.  
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Table 1. The New York Heart Association Classification of Heart Failure 
NYHA 
Class 
Definition Annual 
mortality 
I No limitation of physical activity 
 
3-5% 
II Slight limitation of activity. Dyspnoea and fatigue 
with moderate physical activity (e.g. walking up 
stairs quickly) 
10% 
III Marked limitation of physical activity. Dyspnoea 
with minimal activity 
12-16% 
IV Severe limitation of activity with symptoms even at 
rest 
15-20% 
 
 
Current therapies which improve clinical outcomes in heart failure also 
improve NYHA class65, 66 and hence clinical trials of therapies in heart failure 
routinely use improvement in NYHA functional class as a surrogate marker of 
efficacy. We have therefore assessed change in NYHA class at 6-months and 
1-year post treatment as a secondary end-point in our study.  
 
Patients with ischaemic heart failure can also suffer from angina and this can 
be graded according to the Canadian Cardiovascular Society (CCS) 
classification system67: Grade 1: No angina, Grade 2: angina on moderate 
exertion, Grade 3: angina on mild exertion, Grade 4: angina at rest. The 
change in CCS angina class has also been assessed in patients in our study, 
although this is not a pre-defined secondary end-point. 
 
2.1.5 Current treatment options for heart failure 
There are three main goals of current medical and device therapy in patients 
with heart failure: 
1. Management of symptoms with vasodilators and diuretics 
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2. Attenuation of the neurohormonal response to help prevent/retard 
adverse ventricular remodelling in order to slow progression of LV 
dysfunction 
3. Improvement of long-term prognosis 
 
Standard pharmacologic treatments include ACE inhibitors, angiotensin 
receptor blockers, β-blockers, aldosterone antagonists, and diuretics. These 
treatments block key neurohormonal pathways and counteract salt and water 
retention, thus interrupting the vicious cycle responsible for progressive 
cardiovascular remodelling, volume overload and decreased exercise 
tolerance. The European Society of Cardiology heart failure guidelines provide 
detailed recommendations of how and when to introduce the different medical 
and device therapies in patients with heart failure68. A relatively brief 
description of the current available therapy is provided below.  
 
Angiotensin-converting enzyme (ACE) Inhibitors 
Angiotensin-converting enzyme (ACE) inhibitors are an important class of 
drugs in the management of patients with heart failure and LVSD. The 
mechanism of improvement with ACE inhibition is multifactorial and includes  
peripheral vasodilatation, ventricular unloading, and the attenuation of 
ventricular dilatation and remodelling. Importantly, ACE inhibition appears to 
have a direct effect on myocardial tissue preventing the inappropriate growth 
and hypertrophy stimulated by Ang II and other growth factors69, 70. A number 
of large studies have demonstrated a survival benefit when ACE inhibitors 
have been used in all patients with myocardial infarction71, 72 and selectively in 
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patients with left ventricular dysfunction or heart failure73. V-HEFT2 was the 
first clinical trial of ACE inhibitors in heart failure. In this study, enalapril 
therapy led to a 28% reduction in mortality as compared to vasodilator therapy 
with hydralazine/nitrate74. The survival benefit of ACE inhibitors compared with 
other vasodilators further indicates important biological tissue action in 
addition to vasodilatation75. 
 
Angiotensin receptor blockers (ARBs) 
ACE inhibitors can be associated with a dry cough in a proportion of patients 
and this is thought be related to accumulation of bradykinin secondary to 
inhibition of ACE. Angiotensin receptor blockers (ARBs) avoid this problem as 
they act downstream of ACE inhibitors by blocking the type-1 angiotensin 
receptor, thereby attenuating the biologic effects of Ang II. The largest clinical 
trials of ARBs in patients with chronic heart failure are Val-HEFT76 and 
CHARM77. Both of these studies showed that ARBs were equivalent to ACE 
inhibitors with regard to heart failure mortality reduction. Therefore, ARBs are 
generally considered an acceptable alternative for patients who are intolerant 
of ACE inhibitors68. 
 
Beta-blockers 
In addition to inhibition of the RAAS, antagonism of the sympathetic system 
with beta-blocker therapy is mandatory for all patients with LVSD. Several 
randomised trials (including CAPRICORN78, MERIT-HF79) have demonstrated 
significant reduction in cardiovascular mortality by up to 48%. The mortality 
benefit from beta-blockade is due to a reduction in both progressive heart 
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failure and sudden death. Additional heart rate lowering with Ivabradine (a 
selective If channel blocker acting on the sinus node) has been shown to 
improve symptoms and outcomes in heart failure80. 
 
Aldosterone antagonists 
Aldosterone is an adrenal hormone and its production is stimulated by RAAS 
activation amongst other pathways. Aldosterone has been shown to lead to 
direct adverse effects on the myocardium including fibrosis and remodelling. 
The effects of inhibiting aldosterone in heart failure were first investigated in 
the RALES trial81, where treatment with spironolactone resulted in a 30% 
reduction in mortality and 36% less hospitalisation in patients with NYHA class 
III-IV heart failure. More recently, in the EMPHASIS-HF trial82 eplerenone was 
shown to reduce death and rehospitalisation in patients with only mild (NYHA 
class II) heart failure symptoms. Aldosterone antagonists are therefore now 
recommended in all symptomatic heart failure patients.  
 
Implantable Cardiac Defibrillators (ICDs) 
Sudden cardiac death (SCD) from ventricular tachycardia/fibrillation is a major 
cause of death in patients with heart failure. The ICD represents a significance 
advance in the primary prevention of SCD. The MADIT-I and MADIT-II 
studies83 showed absolute survival benefit of approximately 1-1.5% per year 
with ICD therapy in patients with ischaemic heart failure and ejection fraction 
less than 30%. The National Institute of Clinical Excellence (NICE) in the UK 
recommends ICD therapy should be considered in patients with ischaemic 
heart failure and LVEF < 35%84.  
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Cardiac Resynchronisation Therapy (CRT) 
Mechanical ventricular dyssynchrony is present in upto a third of patients with 
LVSD. CRT with biventricular pacing is designed to resynchronise LV 
contraction and improve cardiac function and therefore symptoms. In the two 
largest trials of CRT, COMPANION85 and CARE-HF86, biventricular pacing 
was associated with an improvement in symptoms and a reduction in 
hospitalisation compared to optimal medical therapy alone. NICE recommends 
CRT should be considered in patients with symptomatic heart failure with 
LVSD and QRS duration >150 milliseconds.  
 
Heart transplantation and left ventricular assist device (LVAD) therapy 
Currently, heart transplantation is the only definitive therapy for end-stage 
heart failure but is limited to the sickest patients due to donor-organ shortage 
and approximately 15 to 30% of potential cardiac recipients die while waiting 
for a donor heart87. Furthermore, patients with ischaemic heart failure tend to 
be older and have significant co-morbidities which would exclude them from 
consideration for transplant. 
 
Due to donor organ shortage and prolonged waiting times for a donor heart, 
there is growing use of mechanical left ventricular assist devices (LVAD) as a 
means of bridge to transplantation. There is also evidence (such as the 
REMATCH trial88) to suggest that LVADs can be used as ‘destination’ therapy 
in selected patients who are not suitable for transplantation. Interestingly, 
LVAD therapy appears to have biological beneficial effects on the native heart 
with evidence of reverse remodelling and in some cases significant recovery of 
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cardiac function89. This has led to the possibility of using LVAD therapy as a 
‘bridge to recovery’ in patients with failing hearts and appears to be achievable 
in some patients90. This provides further evidence that the human heart is 
capable of recovery of contractile function given the right environment such as 
mechanical unloading of the ventricle. In an attempt to improve the success of 
‘bridge to recovery’ there have been positive case reports of the adjunctive 
use of cell therapy at the time of LVAD implantation90. Clinical trials are 
underway to investigate this combination further and theoretically a volume 
unloaded ventricle may provide a better environment for transplanted cells to 
survive and engraft.  
 
Despite the current available medical and device therapy the morbidity and 
mortality in patients with heart failure remains considerable. In a recent 
Canadian study of trends in heart failure outcomes, the 1-year risk-adjusted 
mortality only decreased from 17.7% in 1997 to 16.2% in 200791. Hence, there 
are several novel therapeutic interventional strategies being investigated such 
as vagal nerve stimulation92, cardiac contractility modulation therapy93, 
surgical ventricular reconstruction94 and percutaneous LV partitioning95. Over 
the past decade stem cell transplantation has emerged as a biological therapy 
with huge potential which may lead to cardiac repair with initial pilot studies 
suggesting improvements in cardiac function, symptoms and long-term 
prognosis in patients with heart failure. The next section provides a review of 
the field of cardiac stem cell therapy, particularly with regards to ischaemic 
heart failure. 
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2.2 Stem Cell Therapy for Heart Disease 
2.2.1 Introduction 
 
Myocardial infarction and heart failure are associated with significant loss of 
cardiomyocytes with subsequent fibrosis and scar formation leading to 
inevitable remodelling and left ventricular dilatation. Despite the wide variety of 
contemporary medical and device therapy there is no treatment that targets 
the primary problem of myocyte loss. The human heart seems unable to repair 
itself despite evidence of ongoing cell division61 and renewal62, 96 and it is 
possible that these innate self-repair mechanisms are overwhelmed by the 
magnitude of cell loss following injury. This is in contrast to non-mammalian 
vertebrates such as the zebrafish which are capable of regenerating up to 
20% of myocardium following injury56. The aims of cardiac regenerative 
medicine are to induce repair of the human heart following injury either by up-
regulation of its own repair mechanisms or by the addition of biological 
therapy, such as genes or stem cells. The demonstration of adult stem cell 
plasticity and in particular the potential for cardiomyocyte differentiation has 
prompted intense basic and clinical research with the aim of harnessing the 
regenerative properties of stem cells in order to repair damaged myocardium, 
improve cardiac function and improve patient morbidity and mortality. 
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2.2.2 Stem cell potential- an overview 
Stem cells are defined by two unique characteristics: they are uncommitted 
cells capable of unlimited self-renewal and secondly they can differentiate into 
more specialised cells and organs. The most primitive and ultimate stem cell is 
the zygote  which can develop into all cell types including the embryonic 
membranes- this potential is termed totipotent. The developing embryo 
contains embryonic stem cells (ESCs) which are pluripotent as they can 
develop into cells from all three germinal layers (i.e. mesoderm, endoderm and 
ectoderm) and produce all the tissue types needed to form a functional 
organism. There are also multipotent stem cells, such as haematopoietic stem 
cells (HSCs), which can produce a small range of differentiated cell lineages 
appropriate to their location 
 
Developed adult organs also contain undifferentiated stem cells but in far 
fewer numbers, these are called adult (somatic) stem cells (ASCs). These 
cells were thought to be limited in differentiation potential and only able to 
replenish and repair injured tissue in the organ that they resided in. However, 
more recently adult stem cells have been shown to ‘transdifferentiate’ into cell 
types from different germ layers, a property referred to as plasticity, and this 
has been demonstrated in several scientific studies97, 98. Regenerative 
medicine is an emerging interdisciplinary field of research which hopes to 
utilise the properties of ESCs and/or ASCs in clinical applications focusing on 
the repair and regeneration of cells, tissues, or organs.  
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2.2.3 What is the ideal cell type for cardiac repair 
The ideal cell type for the purposes of cardiac repair should possess the 
following characteristics:– 
• Ability to repair/regenerate damaged myocardium 
• Easy to obtain and expand 
• Safe (no tumour formation) 
• No immunogenicity issues 
• Easy to store  
• Easy to deliver 
• No ongoing ethical issues 
• Cost-effective 
 
A variety of cell types have been explored for the purposes of cardiac repair 
(see Table 2). 
 
Table 2 Different cell types that have been investigated for use in cardiac 
repair 
Allogeneic Autologous  
Embryonic stem cells (ESCs) 
Fetal Cardiomyocytes 
Human umbilical cord derived cells 
Allogeneic mesenchymal stem cells 
 
Induced Pluripotent Stem cells (iPSC) 
Adipose derived stem cells 
Resident cardiac stem cells (cardiospheres) 
Epicardium derived stem cells 
Skeletal myoblasts 
Mesenchymal stem cells (MSCs) 
Bone marrow derived: 
   Endothelial progenitor cells (EPCs) 
   Mononuclear cells (MNCs) e.g CD34+ 
   Mesenchymal stem cells (MSCs) 
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Embryonic Stem Cells (ESCs) 
Given that multiple cell types are generated from a single embryonic stem cell 
(ESC) origin during embryonic development, the potential of such a cell for 
cardiac repair is obvious. ESCs have diverse potential and current work has 
already shown that their differentiation can be controlled to produce specific 
cell types useful for clinical application. The potential of ESCs is limited by 
several significant drawbacks: collection of cells from embryos raises ethical 
concerns; implanted cells will require immunosuppression in recipients to 
prevent rejection; and lastly; the potential of growth and differentiation that 
makes ESCs desirable for cellular repair can result in tumour formation. 
Hence, although ESCs have significant potential for cardiac repair, the 
inherent drawbacks have prompted researchers to actively investigate the 
possible use of adult stem cells instead.  
 
Fetal cardiomyocytes 
Fetal cardiomyocytes were one of the first cell types to be investigated as 
potential candidates for cardiac repair. Animal studies have shown fetal 
cardiomyocyte transplantation improves the function of ischemic and globally 
failing hearts99, 100. However, the use of fetal cardiomyocytes has similar 
concerns to ESCs including availability, immunogenicity, and ethics thus other 
cell types have surpassed this as likely candidates for use in cardiac repair. 
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Human Umbilical Cord Derived Stem Cells 
Umbilical cord blood is blood that remains in the placenta and in the attached 
umbilical cord after childbirth. It has been shown to be a potent source of 
haematopoietic stem cells. Human umbilical cord blood mononuclear cells 
(hUCBCs) are currently used clinically for repopulating bone marrow in 
patients being treated for bone marrow disorders such as acute leukaemia. 
Cord blood contains a large number of non-haematopoietic stem cells which 
rarely express HLA class II antigens and appear to be immunologically naive 
thus reducing the risk of rejection and are therefore an attractive option for 
regenerative therapy101. In animal models of acute myocardial infarction 
injection of hUCBCs is associated with significant reductions in infarct size 
particularly when given by the intramyocardial route102.  Phase I clinical 
studies are being planned/performed with the use of hUCBCs for the 
treatment of patients with dilated cardiomyopathy and refractory angina. 
 
Unlike ESCs, autologous adult stem cells are virtually free from the risks of 
teratoma formation and immune rejection although display more limited 
differentiation potential. Adult stem cells that have been studied to date 
include induced pluripotent stem cells, adipose derived stem cells, tissue-
resident cardiac stem cells, skeletal myoblasts, mesenchymal stem cells, 
circulating endothelial progenitor cells and most commonly bone marrow–
derived mononuclear stem cells. 
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Induced Pluripotent Stem Cells (iPSCs) 
An exciting alternative to ESCs is emerging in the form of inducible Pluripotent 
Stem Cells (iPSCs)- these are adult stem cells that have been successfully 
reprogrammed back to an undifferentiated pluripotent state by inserting four 
genes, Oct3/4, Sox2, KL4 and c-Myc, into differentiated somatic cells103-105. 
These cells have the morphological phenotype of ESC cells and have been 
demonstrated in vivo and in vitro to have the same differentiation potential as 
ESCs (i.e. able to form all three germ cell layers). Functioning 
cardiomyocytes106 have already been produced from iPSCs demonstrating 
their potential use in cardiovascular regenerative medicine. Despite the 
potential inherent ability to produce patient individualised iPSCs, problems 
remain that must be solved before they can be used in clinical trials. The main 
concern is tumourigenesis. The majority of iPSC lines have been derived by 
inserting putative oncogenes using integrating retroviruses, e.g., lentiviruses, 
into the host genome which have the potential to cause cancer. One study 
demonstrated up to 20% of off-spring derived using iPSCs developed 
tumours107. 
 
Another practical barrier to clinical use of iPSCs will be the ability to produce 
sufficient cells for therapeutic purposes. Experiments to date have shown low 
conversion rates in the percentage of cells treated compared to those that are 
successfully induced into an iPSC phenotype. The percentage of conversion 
to iPSCs in the literature varies from 1–0.0006%108. Once the complete 
mechanism of reprogramming is understood, and the tumourigenesis problem 
has been resolved, there are considerable expectations that iPSC production 
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can be up-scaled to provide a patient specific source of cardiovascular cells 
for use in regenerative medicine. Until these aims are accomplished, the main 
cell types in use for cellular therapy remain adult tissue derived stem cells. 
 
Adipose derived stem cells (ADSC) 
Adipose tissue has been investigated as a source of adult progenitor/stem 
cells for the purposes of cardiac repair as this tissue contains a 
heterogeneous mixture of endothelial, haematopoietic and mesenchymal 
progenitor cells which can be easily harvested by liposuction109. Preclinical 
studies have shown that adipose derived stem cells (ADSC) are associated 
with improvement in ejection fraction in animal models of myocardial infarction 
and neoangiogenesis via paracrine factors has been postulated as a potential 
mechanism of action of ADSCs110, 111.  Clinical trials are currently ongoing and 
include the APOLLO Study (ClinicalTrials.gov Identifier: NCT00442806) and 
PRECISE Study (ClinicalTrials.gov Identifier: NCT00426868) which are 
assessing the safety and efficacy of ADSCs in acute myocardial infarction and 
chronic myocardial ischaemia respectively. 
 
Resident Cardiac Stem Cells 
The heart has been considered a terminally differentiated organ lacking self-
renewal capabilities but this dogma has been challenged recently, particularly 
with the demonstration of continued cell division within the adult heart 
following injury such as myocardial infarction61. The discovery of myocardial 
chimeras further increased the suspicion of the existence of a cardiac stem 
cell (CSC). Myocardial chimerism was demonstrated by testing for the 
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presence of Y chromosome in explanted hearts of male patients who had 
received female donor hearts. Male derived myocytes and endothelial cells 
were revealed within the female heart62. This finding was interpreted as 
representing cardiac repair affected by circulating progenitor cells. A second 
similar study, in which the hearts of females who had received male bone 
marrow were examined for presence of the Y chromosome, concluded that 
bone marrow progenitor cells were capable of transit to the heart and its 
subsequent repair112. 
 
The chimera studies suggest the existence of a population of cardiac 
progenitors recruited from a non-cardiac source such as bone marrow. 
However, several independent investigators have now presented strong 
evidence for a resident population of cardiac progenitor cells within the heart. 
The isolated cardiac progenitor cells have standard stem cell defining 
characteristics and are capable of differentiating into multiple cardiac cell 
lineages such as cardiomyocytes, endothelial and vascular cells113, 114.  Similar 
findings have been replicated in mice, rats, dogs and humans. In animal 
models, the CSCs have been shown to repair and improve cardiac function 
following myocardial ischaemia115. Thus, CSCs are an attractive option for use 
in clinical trials, as they are intrinsically more aligned to producing all the cells 
needed to repair the damaged heart. However, they are significantly more 
difficult to harvest and isolate compared to BMSCs and the way ahead may be 
activation and stimulation of patients’ own intrinsic CSCs rather than 
transplantation. There is preclinical evidence to suggest that bone marrow 
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derived stem cell therapy maybe able to stimulate endogenous CSC 
proliferation to induce cardiac repair116. 
 
A harvesting technique has been described that involves obtaining human 
myocardium from surgical or endomyocardial biopsies which were then 
partially enzymatically digested followed by culture for 14–24 days114. Small 
round cells were seen to bud off from the primary ex-plant and divide in 
suspension. The isolated cells were then grown in suspension culture, in 
differentiation media, which induced formation of a ball of cells that has been 
termed a cardiosphere114. When cardiospheres were grown in co-culture with 
rat neonatal cardiomyocytes, approximately 20% of cardiospheres were seen 
to contract spontaneously. Moreover, spontaneous calcium transients were 
seen in a small percentage of these contracting cells. 
 
Human cardiosphere derived cells, when injected into the border zone of 
mouse model of myocardial infarcts engrafted and migrated into the infarct 
zone. After 20 days, the percentage of viable myocardium within the infarct 
zone was greater in the treated group than in the fibroblast treated control 
group; likewise, echocardiography performed on day 20 post-infarct revealed 
a higher LVEF in the cardiosphere treated group (42.8±3.3%) than in either 
the fibroblast-treated (25.0±2.0%, P<0.01) or the control (26.0±1.8%, P<0.01) 
group117.  The CArdiosphere-Derived aUtologous Stem CElls to Reverse 
ventricUlar dySfunction (CADUCEUS) study118, which is a Phase 1 Study of 
30 patients to receive intracoronary autologous cardiosphere-derived stem 
cells, recently published 6-month follow-up results. Biopsy samples yielded 
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prescribed cell doses within 36 days. Compared with controls at 6 months, 
MRI analysis of patients treated with CSCs showed reductions in scar mass, 
increases in viable heart mass and regional contractility, and regional systolic 
wall thickening. However, changes in end-diastolic volume, end-systolic 
volume, and LVEF did not differ between groups by 6 months. 
 
Epicardium derived progenitor cells 
It has recently been demonstrated that the zebrafish can fully regenerate 
myocardium after cryo-induced injury/infarction of up to 20% of the ventricle56, 
119
. Recent experimental evidence suggests that this regeneration may occur 
through limited dedifferentiation of existing cardiomyocytes followed by 
proliferation120 and through activation and expansion of surrounding epicardial 
tissue which supports the regenerating myocardium121. These studies in 
zebrafish suggest that the epicardium may play an important role not only in 
adult heart repair but also during continuous growth of the adult heart122. A 
subset of epicardium derived cells (EPDCs) expressing known markers of 
stem cells, c-kit and the CD34, have been identified in the subepicardial space 
of fetal and adult human hearts123. Experimental studies have demonstrated 
that EPDCs have the potential to differentiate  into cardiomyocytes124 and 
intramyocardial injection of human EPDCs in a mouse model of myocardial 
infarction has been shown to improve cardiac function supporting the 
hypothesis that EPDCs may play an important role in cardiac repair. The 
question arises why human EPDCs remain dormant following myocardial 
injury and current work is focusing on whether paracrine factors may play a 
role in activating these cells. A potential stimulus has been identified in the 
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form of thymosin β4 (Tβ4), which is an actin monomer-binding protein that has 
been shown to activate EPDCs to a pluripotent state, possibly by an 
epigenetic effect- a chemical change to DNA which alters gene expression125. 
In a recent landmark experiment, pre treatment of mice with Tβ4 prior to 
inducing a myocardial infarct led to activation of EPDCs which underwent 
cardiomyocyte differentiation and infarct size and overall ejection fraction were 
significantly better in the treated mice compared to controls126. This study 
provides evidence that activation and up-regulation of the hearts own repair 
mechanism may be possible without the need for additional biological therapy. 
A clinical study on the safety and efficacy of injecting thymosin β4 for treating 
acute myocardial infarction has already been planned (ClinicalTrial.gov 
Identifier NCT01311518). 
 
Skeletal myoblasts  
Skeletal myoblasts have been widely studied due to several favourable 
characteristics: their muscle phenotype with hope for contractile function when 
transplanted into the heart; autologous source of cells avoiding immune 
rejection; minimal risk of tumour formation after transplantation; easily 
harvested; cell numbers can be increased significantly prior to transplantation; 
and finally, they are relatively resistant to ischaemia which may help long-term 
survival in the hostile environment within the diseased heart. Early preclinical 
animal studies have demonstrated the ability for skeletal myoblasts to engraft, 
form myotubules, and enhance cardiac function after transplantation into 
infarcted myocardium127. However, not all of the pre-clinical studies have 
provided positive results. For example, consistently, studies have 
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demonstrated significant cell loss: up to 84% loss in the first 24 hours and 
death of the transplanted myoblasts within a few days128, 129. Furthermore, 
transplanted cells down-regulate the major adhesion and gap junction 
proteins, N-cadherin and connexin43, of the intercalated disk130 and are 
functionally isolated from the host myocardium with no evidence of 
electromechanical coupling131. This may account for the increased incidence 
of arrhythmias seen in hearts after myoblast transplantation132. 
 
Human studies (discussed in more detail later) have shown that epicardial 
injection of these cells during coronary artery bypass (CABG) surgery is 
feasible with potential functional benefits133. The main limitations regarding the 
use of skeletal myoblasts is that they remain committed to the skeletal muscle 
lineage and have been associated with arrhythmias134, the mechanism of 
which is yet to be fully defined but may involve the processes described 
above. 
 
Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) can be found in bone marrow, muscle, skin 
and adipose tissue. They have a fibroblast-like morphology, and can 
differentiate into bone, cartilage, and fat cells135. In addition to this well 
described tri-lineage potential, MSCs have been shown to transdifferentiate in 
vitro and in vivo towards cardiomyocyte136 and vascular cell phenotypes. In 
vivo pre-clinical studies have demonstrated that MSCs have the capacity to 
instigate both myocardial repair and neovascularisation in animal models of 
cardiac injury137.  Differentiation of MSCs into cardiomyocytes and endothelial 
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cells in vivo when transplanted into the heart in injury models has also been 
demonstrated. Such transdifferentiated cells have been strictly characterised 
by immunohistochemistry and positively stain for cardiac and endothelial 
specific markers, as well as gap junction proteins138. Furthermore, MSC 
transplantation in acute MI111 and in ischaemic cardiomyopathy139 has been 
reported to induce functional benefits that include reduced scar formation and 
infarct size, improved regional and global ventricular function, and increased 
vascular density and myocardial perfusion. There has also been evidence of 
benefit in studies using non-ischaemic models such as dilated 
cardiomyopathy140.  
 
MSCs also appear to be relatively immunoprivileged as they lack various 
major histocompatibility complex and co-stimulatory cell-surface antigens and 
therefore may be used as an allogeneic graft141. This avoids the need for 
harvest procedures such as bone marrow aspiration or liposuction and MSCs 
can potentially be given intravenously as they have been shown to home to 
injured myocardium following acute myocardial infarction (AMI) in animal 
models142.  The safety of intravenous allogeneic MSCs (Prochymal™, Osiris 
Therapeutics) has been demonstrated in a Phase I randomised controlled trial 
of patients with AMI. In this trial of 53 patients adverse event rates were similar 
in the MSC and placebo treated groups and interestingly ejection fraction was 
significantly higher in the MSC treated group at 6-months. A larger Phase II 
study is currently underway to investigate these findings further. As mentioned 
above, clinical trials of adipose tissue derived stem cells (containing MSCs) 
are also in progress. 
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MSCs are an attractive option for clinical cardiovascular therapy because of 
their demonstrated ability to facilitate myocardial and vascular repair. They are 
easy to collect, manipulate and expand once in tissue culture, and there is 
potential for their use in allogeneic transplantation. However, many aspects of 
the biology of their therapeutic use remain to be fully understood and 
optimised. Continued research into the basic physiology of MSCs, especially 
with respect to their therapeutic uses, is needed if clinical potential is to be 
realised. 
 
Endothelial Progenitor Cells 
Successful cellular therapy for cardiac regeneration will require transplantation 
of functioning cardiomyocytes and concomitant generation of an adequate 
blood supply. Endothelial progenitors cells (EPCs) can contribute to tissue 
revascularisation and can be isolated from adult bone marrow or from the 
peripheral circulation (termed circulating endothelial progenitor cells- CEPs). 
Adult derived EPCs and CEPs can be distinguished from mature endothelial 
cells by a functional in vitro assay due to their high proliferation rate. Mature 
endothelial cells, EPCs and CEPs share several endothelial specific markers. 
However, only EPCs and CEPs express AC133 (CD133)143. The current 
accepted definition of EPCs is co-expression of CD133+VEGFR2+ markers144. 
Human CEPs have shown potential to differentiate to cardiomyocytes. When 
co-cultured with neonatal rat cardiomyocytes, human CEPs formed cells with a 
cardiomyocytic phenotype as defined by positive staining for cardiac specific 
markers, such as troponin, atrial naturetic peptide and MEF-2145. EPCs and 
CEPs play an important role in neovascularisation in vivo 146. Circulating EPCs 
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are mobilised in response to organ ischaemia, trauma and acute myocardial 
infarction147. The increase in CEPs post-MI is mirrored by a rise in the growth 
and migratory cytokine VEGF-A, and suggests a role for this factor in the 
mobilisation of progenitor148. Also, HMG-CoA reductase inhibitors (statins) 
have been shown to augment mobilisation of EPCs. This important 
observation may provide an alternative mechanism by which statins decrease 
morbidity and mortality in patients with ischaemic heart disease 149. 
 
Transplantation of EPCs and CEPS has been shown to promote 
neovascularisation of the ischaemic heart and improve function. 
Transdifferentiation to endothelial cells, smooth muscle cells and 
cardiomyocytes has been characterised by immunohistochemistry150, 151. In 
animal models of MI, transplantation of EPCs or CEPs causes a significant 
increase in capillary density, regional blood flow and collateral formation in the 
ischaemic heart. In addition, cardiac function is also significantly improved 
following transplantation 152, 153. Encouraging results such as these has led to 
human clinical studies of EPC transplantation. Two studies have been 
completed to date; EPCs or CEPs were transplanted either intracoronary 
following acute MI or transepicardial at the time of coronary bypass surgery. 
There were no adverse outcomes and both studies were able to show an 
increase in cardiac function with improved myocardial perfusion 154, 155. A 
major limitation of therapeutic use of EPCs in cardiac repair is the current 
debate  regarding their true phenotype156. Close consideration of the definition 
of this cell type is needed to ensure agreement and consistency in the 
preclinical research and subsequent translation to the clinical arena.  
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Bone marrow derived stem/progenitor cells (BMSCs) 
 
The most widely studied of the adult stem cells has been bone marrow derived 
stem cells (BMSCs). These consist of two distinct cell populations: 
mesenchymal stem cells (MSCs) and mononuclear cells (BM-MNCs). BM-
MNCs include haematopoietic stem cells (HSCs) and endothelial progenitor 
cells (EPCs). All three cell types (MSC, HSC and EPC) have shown the 
potential to transdifferentiate to a cardiomyocyte phenotype138, 145, 157. BMSCs 
can also be characterised by specific cell surface markers, for example CD34, 
which is expressed on primitive stem cells and differentiated HSCs cells, and 
is absent on mature haematopoietic cells. Additionally, cell populations can be 
further distinguished by the lineage marker (Lin) which if present represents 
cells committed to a particular lineage, and the stem cell factor receptor c-kit 
and the stem cell antigen-1 (sca-1) which are both markers of primitive stem 
cells.  
 
The developmental potential of BMSCs is now recognised to expand beyond 
the haematopoietic lineages with numerous reports indicating that cells 
derived from bone marrow were capable of giving rise to multiple unexpected 
cell types. These include neural cells158, skeletal muscle97 and hepatic cells159. 
This plasticity of BMSCs, has led to considerable excitement in using BMSCs 
in cell-based therapies and as vectors to deliver therapeutic agents. This is 
particularly attractive clinically because bone marrow can be readily obtained 
from patients by aspiration from the marrow itself or by harvest from the 
peripheral circulation following mobilisation with cytokines such as granulocyte 
colony stimulating factor (G-CSF).  
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In a controversial landmark animal study5, Lin-c-kit+ (markers of 
undifferentiated stem cells) BMSCs were injected directly into the contracting 
wall bordering a myocardial infarct which had been acutely induced by 
coronary artery ligation. The transplanted cells appeared to undergo 
transdifferentiation to cardiomyocytes with newly-formed myocardium 
occupying a significant proportion of the infarcted area with significant 
improvement in LV function just 9 days after cell transplantation5. This 
transdifferentiation event has not been universally reproduced and in fact has 
been challenged by different groups, which have demonstrated that injected 
BMSCs develop into haematopoietic cell types after transplantation rather 
than cardiomyocytes7-9. However, even in the absence of transdifferentiation 
there appeared to be a beneficial effect on cardiac function9. There have also 
been studies in large animal (porcine) models of chronic myocardial ischaemia 
which have shown improvement in cardiac function following BMSC 
treatment160, 161. 
 
There have been few experimental studies comparing the efficacy of different 
cell types in improving cardiac function. In a mouse model of AMI, 
bioluminescence imaging after intramyocardial cell injection suggested better 
tissue retention of BM-MNCs which appeared to be present at 6 weeks whilst 
MSCs and skeletal myoblasts could not be detected after 3 weeks162. 
Furthermore, BM-MNCs had a more favourable effect on cardiac function 
compared to the other cell types although interestingly there was no evidence 
of transdifferentiation on histological evaluation. Another study, in a large 
animal (canine) model of chronic ischaemic heart failure, showed 
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intramyocardial injection of BM-MNCs to again be superior to MSC injection 
with regards to improvement in cardiac function, reduction in infarct size and 
NT-proBNP levels163. Interestingly, functional improvement was associated 
with a neoangiogenesis. 
 
In summary the different cell types described above offer a range of 
therapeutic options. The BMSC has to date had the most application in clinical 
studies through ease of use and positive effects on cardiac function. The ESC 
continues to offer the greatest therapeutic potential whilst the iPSC may well 
provide the best compromise between these and the BMSC population. Much 
work is still needed to identify a cell type that meets the ideal criteria and 
moves the field closer to delivering a viable biological therapy that can be 
used in routine clinical practice.  
 
2.2.4 Proposed Mechanism(s) of Actions of Stem Cell Therapy  
 
The mechanism(s) by which adult stem cell therapy appears to improve 
cardiac function and perfusion following pathological injury remains an area of 
ongoing investigation and debate. The initial theory was that transplanted 
stem cells formed new cardiomyocytes and endothelial cells directly leading to 
improved myocardial contraction and perfusion. This was based upon 
individual publications which appeared to demonstrate transdifferentiation of 
transplanted BMSCs. However, this finding has not been consistently 
reproduced by other investigators leading to the ongoing debate regarding the 
contribution of transdifferentiation to functional benefit and it is now thought 
that the beneficial effects seen are multi-factorial in origin164. Possible 
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additional mechanisms include neovascularisation by differentiation into an 
endothelial phenotype, cell fusion, paracrine effects of the cell infusate 
including  promotion of angiogenesis and stimulation of the resident cardiac 
stem cell population116, 164, 165 (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Illustration of the proposed mechanisms of action of stem/progenitor cell therapy. 
Cell therapy is now thought to exert beneficial effects through one or a combination of the 
processes shown. An additional recognised mechanism is the stimulation of resident cardiac 
stem cells.  
Reproduced with permission from American Society for Clinical Investigation164.  
 
The direct transdifferentiation theory was formed from several findings. 
Initially, the concept of exogenous cell delivery as a possible means of 
improving cardiac function was demonstrated. For example, when 
transplanted into the heart, embryonic cardiomyocytes formed stable grafts166 
while foetal cardiomyocytes improved cardiac function after cryoinjury100. 
Following on from these findings, adult stem cells started to be seen as 
possible donor cells. Such hope was based upon evidence of adult stem cell 
plasticity, particularly those found within the bone marrow. Animal experiments 
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demonstrated that circulating endothelial cells of bone marrow origin could 
contribute to neovascularisation in adult tissues167. Evidence for 
haematopoietic stem cells contributing to cardiac muscle and vasculature were 
also seen157. Furthermore, human mesenchymal stem cells (MSCs) were 
shown to have multi-lineage potential168 and were able to form cardiomyocytes 
in vitro when chemically treated136. These findings were given support from the 
examination of human cardiac sex-mismatch transplants that demonstrated 
cardiomyocyte and vascular chimerism, i.e. de novo post natal formation of 
cardiac and vascular tissue- this supported the idea of a native circulating 
progenitor cell being able to contribute to cell repair62. 
 
Multiple pre-clinical studies continued to support the transdifferentiation 
hypothesis, initially suggesting that all three cell lines (MSCs, HSCs and 
EPCs) from adult bone marrow were able to contribute to cardiac regeneration 
in small animal models of myocardial ischaemia. MSCs were shown to engraft 
into ischaemic myocardium, and express muscle proteins in murine models of 
myocardial infarction137, 138. Human EPCs were able to simulate 
neoangiogenesis within the infarcted vascular bed, reducing apoptosis and 
improving cardiac function in a mouse model151. In one prominent study bone 
marrow derived cells were shown to regenerate substantial amounts of 
myocytes, endothelial cells and smooth muscle cells when injected into the 
hearts of mice following myocardial infarction5. The latter study remains 
controversial and favour for the direct transdifferentiation theory has receded 
ever since muscle generation and transdifferentiation were not seen in two 
high profile studies of bone marrow progenitor therapy, although a small 
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functional benefit was still seen7, 9. Other studies observed that the rare 
transdifferentiation events that were thought to be de novo cardiomyocyte 
formation could be attributed to donor and host cell fusion169, 170. Furthermore, 
recent studies suggest that BMSCs stimulate proliferation of resident cardiac 
stem cells and this maybe an important mechanism of cardiac repair116. 
 
The search for a complete explanation behind the benefits gained with stem 
cell treatment has led to the proposal that local release of paracrine factors 
could be the significant key effect of transplanted cells rather than 
myogenesis. Supporting this, it is clear adult stem cells are capable of 
secreting a wide range of cytokines171. The released paracrine factors have 
been shown to induce a number of beneficial effects, including induction of 
angiogenesis in host tissues151, reduced apoptosis171 and immunomodulation 
of injury172.  A further documented paracrine benefit is the proposed 
stimulation of the recently described resident cardiac progenitor cells165 173. 
There is a growing body of literature demonstrating the use of stem cells in 
therapeutic angiogenesis18, 174, 175. Furthermore, BMSCs transplanted into 
injured myocardium express several signalling factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF) and 
transforming growth factor (TGF), all key signalling factors involved in 
angiogenesis, cytoprotection and survival176.  
 
Two noteworthy studies support the hypothesis for an acute paracrine effect of 
adult stem cells. Akt (protein kinase B) is a kinase that regulates several 
cellular processes, including cell cycle progression, transcription, glucose 
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uptake and apoptosis. In a rat MI model, both MSCs transfected with Akt and 
Akt-MSC conditioned media significantly limited infarct size when administered 
into the infarct border zone one hour after ischaemia was established177. The 
genes for VEGF, FGF-2, HGF, IGF-1, and Tβ4 were all found to be up-
regulated within the Akt-MSCs, especially in the setting of hypoxia. These data 
strongly support a paracrine mediated mechanism for myocardial protection in 
AMI. The second supportive study used cardiac cryoinjury in rats; immediately 
following injury MSCs were injected into the border zone178. Infarct size was 
assessed 10 weeks later and found to be significantly reduced, but no 
evidence of myogenesis or angiogenesis could be found- indirect evidence for 
a paracrine effect over transdifferentiation. Furthermore, bone marrow 
mononuclear cells have been demonstrated in vitro and in vivo to significantly 
reduce ischaemia-reperfusion injury.  The mechanism of this benefit has been 
suggested to be due to a paracrine related triggering of mediators of the 
reperfusion injury salvage kinase (RISK) pathway, the final common beneficial 
mediator of both pre- and post-conditioning179-181. The RISK pathway refers to 
a group of protein kinases that, when specifically activated during myocardial 
reperfusion, provide cardioprotection by preventing lethal reperfusion injury. 
The RISK pathway is thus a mediator of cell survival182, 183. Another 
component of the amelioration of reperfusion injury, aside from activation of 
the RISK pathway, could be a direct effect on reactive oxygen species (ROS). 
MSCs in particular can reduce ROS generation. MSCs express the enzymes 
required to manage ROS, in particular high levels of glutathione peroxidise184, 
and have been shown to produce superoxide dismutase185. 
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It is possible that different mechanisms are important at different time points 
as the pathophysiological processes change during the evolution form acute 
myocardial infarction to chronic heart failure. The mechanism of acute repair 
could be considered more likely to be related to the release of local factors 
that act on cells within the myocardium reducing ischaemia-reperfusion injury 
and thus reducing infarct size. This is unlikely to be the case for chronic heart 
failure where there is no acute injury and in fact there are no studies that 
demonstrate benefit of reperfusion injury modulation in this setting186. It is 
more likely that robust reparative processes leading to angiogenesis and 
myogenesis will be required to improve chronically scarred myocardium. 
Understanding the complete pathways involved and how they interact at 
specific time points in the progression from acute myocardial infarction to 
chronic heart failure will be essential to utilising and optimising adult stem cells 
in clinical therapy.  
 
A major criticism of clinical trials, using progenitor cell therapy for the 
treatment of patients with end-stage heart failure, is that they fail to address 
mechanistic questions, given an overall lack of understanding of how this 
approach may lead to an improvement in cardiac function and symptoms187, 
188
. It is clear that the field of translational medicine in general is in need of 
novel new imaging techniques that will help bridge the transition from the 
bench to bedside. This thesis presents the preliminary results of a ‘first in man’ 
feasibility study to detect angiogenesis following BMSC transplantation using 
nuclear imaging and a novel radio-tracer (Technetium-99m labelled cyclic 
 58 
RGD peptide: 99mTc-NC100692; GE Healthcare) targeted at the αvβ3 integrin 
that is expressed by vessels undergoing angiogenesis189, 190.  
 
 
2.2.5 Delivering Stem Cells to the Heart 
 
There are currently five available methods for delivering cell therapy, as 
illustrated in figure 5: (1) peripheral infusion; (2) cell mobilisation with cytokines 
such as G-CSF; (3) transvenous via the coronary sinus; (4) intracoronary 
infusion; (5) intramyocardial injection- which can be either transepicardial, 
transendocardial or trans-coronary-venous injections.  
2. Subcutaneous 
cytokine injection
1. Peripheral 
infusion of cells
4. Intracoronary 
infusion of cells
3. Coronary sinus 
infusion of cells
5. Intramyocardial 
injection of cells
 
Figure 5. Available methods of delivery for cell therapy. There are currently five different 
methods for delivering cell therapy: (1) peripheral infusion; (2) cell mobilisation with cytokines 
such as G-CSF; (3) transvenous via the coronary sinus; (4) intracoronary infusion; (5) 
intramyocardial injection- which can be either transepicardial, transendocardial or trans-
coronary-venous injections.  
Adapted from Gersh et al. Mayo Clin Proc. 2009;84(10):876-892. 
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All the techniques remain in the early stages of clinical investigation and it 
remains to be determined which of these will prove to be the most efficacious 
approach. A limitation common to all current techniques is the low target area 
cell retention achieved which has been highlighted in a preclinical study191 that 
demonstrated maximal cell retention rates within the myocardium of 11% with 
intramyocardial injection, 3% with intracoronary injection and 3% with 
intravenous infusion. There is ongoing work trying to elucidate the reasons for 
these losses and finding solutions to improve the efficiency of acute cell 
retention such as combining the cells with a biological scaffold192. Numerous 
scaffold designs have been created for use in cardiac applications using 
gelatin, fibrin, collagen, and alginates in the form of gels or 3D scaffolds 193, 194.  
 
2.2.5.1 Peripheral Infusion 
 
Peripheral intravenous infusion of stem cells would be an attractive non-
invasive method of stem cell delivery due to its simplicity and applicability. 
Human bone marrow cells have been shown to ‘home’ to peri-infarct areas 
when infused into the peripheral circulation of a mouse model of acute 
myocardial infarct 151. However, this technique may not be suitable in the 
chronic heart failure setting which lacks the temporarily up-regulated biological 
homing signals present in the AMI setting. Another significant limitation is that 
only a few cells appear to reach the affected area due to trapping of the cells 
in the microvasculature of the lungs, liver, and lymphoid tissues 195. Peripheral 
infusion has been extensively used in animal models but there has been only 
one human study to date- a placebo controlled study assessing primarily the 
safety of peripheral infusion of allogeneic human mesenchymal stem cells 
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(Prochymal™) after acute myocardial infarction196. This was confirmed as a 
safe delivery method and the treatment group showed significant improvement 
in symptoms, LV ejection fraction as well as evidence of reverse remodelling 
on Cardiac MRI. However, given the already small numbers of injected cells 
that are known to be retained by the heart it is likely that more direct 
interventional injection will be more efficacious. 
 
2.2.5.2 Cell Mobilisation  
Cell mobilisation provides an indirect method of introducing cell therapy to the 
injured myocardium.  In the clinical setting, one of the most studied mobilising 
factor is granulocyte-colony stimulating factor (G-CSF). Endogenous G-CSF is 
a potent hematopoietic cytokine that affects progenitor cell proliferation, 
maturation and functional activation and enhances the mobilisation and 
recruitment of stem cells from the bone marrow to the blood circulation197. G-
CSF activates progenitor cell releasing factors such as neutrophil elastases 
and matrix-metalloproteinase to release the stem cells from the bone 
marrow198. G-CSF is also proposed to have a range of direct effects on the 
myocardium, including creating a favourable environment for homing and 
engraftment of stem cells, inhibiting apoptosis and promoting cardiomyocyte 
survival, including angiogenesis and reducing fibrosis associated with adverse 
cardiac remodelling 199. G-CSF is generally well tolerated with most common 
side effects being bone pain and fevers.  
 
Initial preclinical animal studies200  and Phase 1 clinical trials in the setting of 
acute myocardial infarction (AMI) showed that G-CSF treatment appeared to 
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be safe with possible beneficial effects on left ventricular systolic function201, 
202
. However, a subsequent randomised placebo controlled study of 
subcutaneous G-CSF after primary PCI for AMI showed no additional 
improvements in left ventricular function when compared to placebo203. This 
was confirmed in a meta-analysis on the effect of G-CSF in AMI which showed 
no overall benefit although subset analysis showed there may be benefit 
limited to patients with LV systolic dysfunction and if the infusion is started 
early204. Concerns have also been raised regarding the potential of G-CSF to 
cause in-stent restenosis (ISR) as it increases the level of circulating 
neutrophils 205 which may accelerate the process of neointimal proliferation. 
One of the initial clinical trials reported an unexpectedly high rate of ISR in 10 
patients treated with G-CSF following an AM206. However, a more recent trial 
involving patients with large infarcts and late revascularisation did not show 
any increased incidence of ISR207. Furthermore, an intracoronary intravascular 
ultrasound (IVUS) based study, 5 months after stent insertion for AMI, showed 
no increase in in-stent neointimal hyperplasia in the G-CSF treatment group 
compared to placebo208.  
 
In stable coronary artery disease patients with angina and normal LVEF, 
progenitor cell mobilisation with G-CSF was not shown to have any obvious 
beneficial effect on cardiac function or patient symptoms and with the potential 
to cause adverse ischaemic events209. Two small, non randomised, studies 
have shown possible beneficial effects of G-CSF in chronic ischaemic heart 
failure with regards to patient symptoms and improvement in LV function but 
also raised concerns regarding worsening of angina during the treatment 
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phase14, 210. There has also recently been a third small non-randomised study 
which again suggested symptomatic improvement following G-CSF treatment 
in patients with ischaemic heart failure211.  
 
It remains to be determined if G-CSF treatment could be an effective part of a 
treatment strategy combining several cytokines and/or local stem cell delivery. 
The intramyocardial arm of the REGENERATE-IHD trial presented in this 
thesis combines G-CSF treatment with intramyocardial injection of stem cells 
and is the first study to do so in patients with ischaemic heart failure. 
 
2.2.5.3 Coronary Sinus Infusion  
Retrograde infusion of stem cells through the coronary sinus and coronary 
venous system has been achieved in experimental models which suggest that 
this method may provide a more uniform delivery of cells with improved cell 
retention rates129. Theoretically this approach may also be safer than 
intracoronary or intramyocardial injection. There have been sporadic case 
reports212  demonstrating safety of this technique but there have not been any 
published clinical trials of this technique. In this procedure, the coronary sinus 
is cannulated using a guidewire and an angioplasty balloon is advanced to the 
selected cardiac vein related to the coronary artery territory to be treated. The 
venous blood flow is then halted, by prolonged balloon inflation for 
approximately 15 min, while the stem cells are infused under pressure. A 
phase 1 clinical trial of 14 patients with refractory angina suggests this is a 
safe technique with signs of efficacy213. The main limitations to this approach 
are the technical difficulties related to the more variable coronary venous 
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anatomy which can at times be difficult to negotiate with guidewires and 
balloons. This technique may not be possible in patients who already have a 
coronary sinus device in situ such as a LV lead for resynchronisation therapy 
or a coronary sinus annuloplasty device although cells could be administered 
as an adjunct to the implantation of such devices.   
 
2.2.5.4 Intracoronary Infusion 
Intracoronary infusion is the method that has been most widely adapted in 
clinical trials of cell therapy, especially after primary angioplasty for AMI. This 
method has also been used in patients with heart failure secondary to 
ischaemic heart disease although in this setting occluded coronary arteries 
may prevent targeted delivery to the infarcted area. The technique employs 
the basic skills of balloon angioplasty and therefore can be performed by a 
interventional cardiologist with minimal additional training. Cells are infused 
through the central lumen of an over-the-wire (OTW) balloon catheter during 
low-pressure balloon inflation for 2-4 minutes (‘stop-flow’ technique). Standard 
short (6-10mm) balloons are used to minimise endothelial injury and balloons 
are also undersized by 0.5mm less than the reference vessel diameter. 
Balloon inflation time is empirically chosen and the purpose is to prolong the 
contact time between the infused cells and endothelium of the coronary 
macro/micro circulation as well as to provide an ischaemic stimulus which may 
improve homing of cells to the target myocardium. Inflation time may need to 
be curtailed in patients who do not tolerate prolonged occlusion of a clinically 
important coronary artery. In the AMI setting infusion of cells is limited to the 
infarct related artery whilst in patients with chronic heart failure cell infusion 
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may be distributed amongst all patent coronary artery and graft conduits. 
Some more recent animal work suggests that single bolus infusion may be as 
effective 214 although stop-flow seems to be the prominent method in trials.   
 
A preclinical study in dogs raised concerns regarding the possibility of 
mircoinfarcts caused by intracoronary injection of mesenchymal stromal 
cells215 and there is likely to be a safety threshold with regards to the size and 
dose of cells delivered using the intracoronary route. Reassuringly, the safety 
of this technique has been confirmed in multiple clinical trials and a recent 
meta-analysis confirmed that the relative risks of mortality and morbidity, 
measured by incidence of re-infarction, arrhythmias, restenosis, hospital re-
admission, and target vessel revascularisation, were not significantly 
increased in participants who received intracoronary BMSC treatment 
following AMI compared with controls49.  
 
2.2.5.5 Intramyocardial injection 
Intramyocardial injection is the most direct method of administering cell 
therapy and there are several advantages of this technique in patients with 
heart failure and angina.  In contrast to the AMI setting, patients with chronic 
ischaemic cardiomyopathy are unlikely to release signals from damaged 
myocardium to induce stem cell homing and theoretically it maybe more 
effective to use intramyocardial injection to deliver the cells to the target area. 
Also, in the chronic setting the coronary artery subtending the 
infarct/ischaemic area maybe occluded without significant collateral formation 
and intramyocardial delivery may be more effective in these patients. 
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Experimental data using radionucleotide labelled BM-MNCs suggest that 
target area cell retention maybe higher with intramyocardial injection when 
compared to the intracoronary delivery method216. Furthermore, a meta-
analysis of randomised controlled trials of BMSC therapy in heart failure 
patients showed that improvement in LVEF was only seen when cells were 
delivered by the intramyocardial route217. Its use has also been mainly limited 
to chronic conditions due to concerns of myocardial perforation and arrhythmia 
in the acute setting.  
 
There are currently three methods for intramyocardial injection of cells: open 
surgical transepicardial injection, percutaneous transendocardial injection and 
trans-coronary-venous intramyocardial injection of cells. Earlier clinical trials 
have relied on surgical transepicardial injection of cells where results are 
biased by simultaneous coronary bypass surgery 134, 218-220. When bypass is 
not indicated, percutaneous delivery may provide comparable efficacy with 
reduced risk. Comparison studies in swine models of chronic ischaemic heart 
failure have shown that percutaneous and surgical transplantation of skeletal 
myoblasts both lead to similar improvements in LVEF and reverse remodelling 
221
. 
 
Percutaneous transendocardial injection is usually performed via 8Fr 
femoral access although brachial access for transendocardial injection of stem 
cells has been reported 222. A percutaneous approach allows this therapy to 
be delivered to the higher risk population and also provides an option for 
repeated therapy if required. The main additional risks of this approach are 
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ventricular perforation with pericardial effusion/tamponade and procedure 
related ventricular arrthymias although the reported incidences of these have 
been low in the published clinical trials. A deflectable tip injection-needle 
catheter is advanced retrogradely across the aortic valve and cells can be 
injected directly into any area of the left ventricular endocardium. There are 
four commercially available catheter systems currently being used for 
transendocardial cell delivery: the MyostarTM (Biosense Webster), the 
MyoCath™ (BioHeart), the HelixTM (BioCardia) and the StilettoTM (Boston 
Scientific) catheter delivery systems (Figure 6).  
 
A. MyoStar™ (Biosense-Webstar) B. MyoCath™ (BioHeart)
C. Helix™ (BioCardia) D. Stiletto™ (Boston Scientific)
 
Figure 6. The four commercially available catheters for transendocardial/intramyocardial 
injection of biologic material which are currently under investigational use in clinical trials. 
 
 
The Myostar™ catheter system utilises a 3-dimensional (3-D) navigation 
system to guide injection and the other three catheters are guided 
fluoroscopically therefore providing 2-dimensional orientation only. The first 
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two catheter systems are introduced without a guidewire so require 
manipulation when advanced from the femoral artery and across the aortic 
valve whilst the second two catheters are introduced over a traditional 
guidewire system. The relative merits of the different catheter delivery systems 
are now discussed. 
 
The MyostarTM catheter system utilises nonfluoroscopic guidance using the 
NOGA® (Biosense Webster) magnetic electromechanical system for 
intramyocardial navigation and mapping (Figure 7). This technique uses ultra 
low intensity magnetic fields generated by a triangular magnetic pad 
positioned beneath the patient and location sensor on the tip of the mapping 
catheter, which helps determine the real-time location and orientation of the 
catheter tip inside the left ventricle.  
 
The NOGA® system analyses the movement of the catheter tip at the location 
of an endocardial point, timed with systole and diastole, and compares it with 
the movement of neighbouring points- the percentage difference, termed 
linear local shortening (LLS), represents the degree of mechanical function at 
that endocardial point. The mapping catheter tip is also capable of measuring 
endocardial voltage potentials and an electrical map is constructed 
concurrently with the mechanical map. Normal myocardial cells deliver a 
resting unipolar potential of 15 mV, whereas voltage values less than 6.9 mV 
reflect scar tissue; potentials between 7mV and 15 mV suggest viable 
myocardium 223. 
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(A) (B)(A)
 
Figure 7.  An example of an electromechanical map obtained using the NOGA system. 
Electromechanical characteristics, including unipolar voltage and local liner shortening, of 
sampled areas of the endocardial wall are mapped onto a computerised 3D colour-coded 
construct of the left ventricle. (A) The purple/blue end of the colour spectrum in the ‘local linear 
shortening map’ indicates a good wall motion in a healthy viable myocardium as shown on this 
map taken from a normal subject. (B) By contrast, the red end of the colour spectrum in the so 
called ‘voltage map’ represents scarred myocardium devoid of electrical activity as shown in 
this example taken from a patient with chronic ischaemic heart failure. The green/yellow 
border zone on this map represents hibernating myocardium which is targeted for 
intramyocardial injection. Black spots on the map label areas where injections have been 
delivered. 
 
When the map is complete, all the data points are integrated by the NOGA® 
workstation and represented in a 3-D colour-coded reconstruction of the 
endocardial surface which is able to distinguish between normal, ischaemic 
(but viable) or infarcted myocardium (Figure 7).  Furthermore it allows 
accurate manipulation of the injection catheter in the left ventricle and 
therefore precise transendocardial injection. This allows targeted delivery of 
cells into specific areas, for example BMSCs tend to be injected into the peri-
infarct zone as it has been shown that BMSCs do not engraft well into scarred 
myocardium compared to skeletal myoblasts which have been injected into 
scarred myocardium and seem capable of engrafting in fibrotic tissue 224.  
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The Myostar™ catheter (Figure 8) incorporates an integrated injection needle 
and a location sensor at the tip which interfaces with the NOGA® 3-D mapping 
system.  
 
 
 
Figure 8. Percutaneous transendocardial injection using the Myostar™ delivery catheter. (A) 
A flexible, steerable, injection catheter is advanced retrogradely across the aortic valve into 
the LV cavity and injections are guided by electromechanical mapping. (B) The catheter tip 
incorporates a fine nitinol 27-gauge needle which is normally retracted. Images courtesy of 
Biosense Webster. 
 
The 115-cm deflectable-tip catheter consists of an outer shaft and inner core 
lumen which runs the full length of the catheter and culminates distally in a 
nitinol 27-gauge needle. The core lumen can be advanced and retracted 
independently of other catheter movements. The proximal handle contains 
controls for catheter tip deflection, needle advancement and the injection port 
for needle lumen injection. The catheter is prepared by adjusting the 
retractable needle extension length at 0º and 90º flex, setting the needle 
length to a maximal needle-to-wall ratio of 0.6. A 1ml Luer-Lock syringe 
containing the injectate is connected to the injection port and the catheter 
‘dead-space’ is filled with the cell suspension prior to introducing the catheter. 
Multiple injections can be performed at specific sites identified on the 3-D 
NOGA® electromechanical map- at our institution we perform circumferential 
10x0.2mls injections 1-2cms apart into the hibernating myocardium around 
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scar tissue.  Needle injection into the true apex and myocardial segments with 
wall thickness less than 0.8mm should be avoided to minimise the risk of 
perforation. This technology appears to be safe from preclinical and clinical 
studies 223, 225. The main disadvantages of this system are the additional time 
and costs required to produce an accurate electromechanical map to guide 
transendocardial injection. The NOGA-Myostar catheter delivery system has 
been used to deliver therapy in the intramyocardial arm of the REGENERATE-
IHD trial described in this thesis. 
 
The MyoCath™ injection catheter (Figure 9) is similar to the MyoStar™ and 
consists of a 115-cm long deflectable injection catheter that also contains an 
integrated core lumen with a 25-gauge stainless steel needle at its distal end.  
 
                   
 
Figure 9. The MyoCath™ (BioHeart) injection catheter. A- integrated catheter system with 
core lumen containing retractable 25-guage stainless steel needle at its distal end. B- 
deflectable tip manipulated through a combination of axial rotation and deflection of the distal 
aspect (the latter under a separate control mechanism capable of inducing up to 180° of 
flexion). Images courtesy of BioHeart. 
 
The needle can be advanced and retracted from the tip of the catheter and 
provides for multiple injections to a predetermined needle insertion depth. The 
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MyoCath™ is however guided by fluoroscopic guidance and additional 
imaging such as transoesophageal echocardiography is sometimes utilised. 
 
The StilettoTM catheter (Figure 6D) is also guided fluoroscopically and thus 
lacks the precision of the NOGA® system although real time MRI guidance 
has shown promising results226. It contains three separate, independently 
moveable components: two steerable guiding catheters (9Fr and 7Fr), and an 
inner spring loaded needle component. Catheter tip orientation is 
accomplished by guiding catheter manipulation, and the injection needle is set 
to a fixed depth (3.5 mm) and the spring loaded advancement mechanism 
theoretically allows the device to overcome fibrotic scar tissue resistance to 
needle penetration. This technology is still under investigation; preclinical 
studies suggest that this is a safe technique227 although higher than expected 
rates of pericardial effusion has led to the use of the Stiletto™ catheter being 
halted in the GENASIS investigational trial of VEGF-2 biologic for the 
treatment of severe angina. 
 
Biocardia’s Helix™ catheter (Figure 10A) has a small, hollow, distal corkscrew 
needle which is rotated into the endocardium to provide active fixation (similar 
to active fixation pacing leads) and to allow local delivery of biological 
therapeutic products. This catheter is used in combination with the Biocardia 
Morph® Deflectable (steerable) Guide Catheter (Figure 10B) which helps 
catheter navigation within the LV under fluoroscopic guidance only. By 
eliminating the process of electromechanical mapping this technique may 
have advantages in terms of procedural time and cost. Preclinical studies 
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have proven safety and efficacy of this delivery method228 and there is 
preliminary data to suggest this method may be clinically effective229.  
A B
 
Figure 10. Biocardia Helix® Catheter Delivery System. A- The Helical Infusion Catheter for 
transendocardial delivery is advanced through the Morph Guide.  The therapeutic lumen 
discharges at the distal tip of the helical needle.  A second lumen discharges at the base of 
the helix for delivering contrast and confirming positioning.  B- The Morph Universal 
Deflectable Guide Catheter is advanced through the aortic valve over a guide wire and 
provides the ability to guide the Helical Infusion Catheter. Images courtesy of Biocardia.   
 
 
Trans-coronary-venous intramyocardial (TVIM) injection can be performed 
using the TransAccess® catheter system (TransVascular Inc) that is placed 
percutaneously into the coronary sinus and target vein (Figure 11). Then, 
using intravascular ultrasound (IVUS) guidance, a 24-gauge nitinol needle is 
extended to perform transvenous myocardial puncture. A 27-guage 
microinfusion catheter (IntraLume™) is then advanced though the needle to 
the targeted areas for cell delivery. Initial studies have confirmed the feasibility 
and safety of this approach in porcine models 230.  
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Figure 11. TransAccess® (Medtronic) catheter tip with Intralume micro-catheter advanced 
through the needle tip. IVUS tranducer is located at tip of TransAccess Catheter. Image 
courtesy of TransVascular Inc. 
 
A Phase 1 clinical trial has confirmed the safety and efficacy of this delivery 
method of skeletal myoblasts for the treatment of chronic ischaemic LV 
systolic dysfunction 231. Furthermore, an animal study demonstrated that the 
TVIM injection of BM derived mononuclear cells may lead to a greater 
retention of the cellular product at the target area as compared to 
intracoronary infusion 232. The main limitations to this approach are related to 
the technical difficulties due to variable coronary venous anatomy which can at 
time be difficult to access with guidewires and TVIM may be one of the more 
technically demanding procedures.  
 
Transepicardial delivery of stem cells has been performed in patients 
already scheduled for CABG in whom cells are injected into infarct border 
zones and/or areas of infarcted or scarred myocardium under direct 
visualization127. The major disadvantage of this approach is the necessity for a 
sternotomy and therefore is a highly invasive approach which can be 
TransAccess 
Catheter 
IntraLume microcatheter 
Pre-shaped needle 
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associated with significant surgical morbidity. However, in planned CABG 
surgery the concomitant delivery of cell therapy would seem feasible. One 
important advantage of this technique is that it can provide a high 
concentration of cells per unit area injected although not all areas of the 
myocardium (e.g. the septum) can be reached using a this approach. 
 
There have therefore been several techniques utilised for cell delivery in the 
hope of cardiac regeneration in patients with acute and chronic ischaemic 
heart disease. In animal models all routes appear to be equally efficacious 
although the exact mechanisms of action through which cell therapy leads to 
an improvement in cardiac function remain unanswered. There has been 
translation of all the delivery methods from animal models to humans and to 
date the intramyocardial route appears to be the most promising, in particular 
target area cell retention maybe higher with intramyocardial injection when 
compared to the intracoronary delivery method 231, 233. There is yet to be a 
comparative clinical study of different cell delivery methods and our 
REGENERATE-IHD trial has been designed to answer this question. This 
study compares the efficacy and safety of delivering BMSCs using three 
different routes: indirect cell delivery by mobilisation using peripheral infusion 
of G-CSF versus direct injection of cells using the intracoronary or 
intramyocardial route. This thesis presents the results of the intramyocardial 
arm of the study only. 
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2.2.6 Trials of Stem Cell Therapy in Chronic Ischaemic Heart 
Failure 
 
There have been numerous clinical trials in the past decade examining the 
safety and efficacy of stem cell therapy for patients with ischaemic heart 
failure. Studies have been heterogonous in design although percutaneous 
transendocardial injection of cells has been the most widely investigated 
delivery method and skeletal myoblasts and BMSCs have been the most 
studied cell types. This section provides a review of recent clinical trials of 
stem cell therapy in patients with heart failure according to the different 
delivery methods (see Table 3). 
2.2.6.1 Transendocardial Delivery of Cell Therapy 
 
Percutaneous transcatheter intramyocardial injection of skeletal myoblasts has 
shown promise in early Phase I/II clinical studies. A pilot study of 5 patients, 
published in 2003, demonstrated that NOGA® guided injection of skeletal 
myoblasts into the infarcted area of patients with heart failure following 
previous anterior myocardial infarction was safe with no serious adverse 
events related to the procedure. There also appeared to be some 
improvement in regional myocardial thickening as well as global LVEF 234. The 
CAuSMIC study also used NOGA® guided transendocardial injection of 
skeletal myoblasts into areas of viable myocardium in 12 patients with severe 
ischaemic heart failure. There was improvement in NYHA functional class, 
quality of life and evidence of reverse ventricular remodelling when compared 
to controls after 1 year follow-up 235.   
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Table 3. Clinical trials of percutaneous stem cell therapy for chronic 
heart failure 
Study name 
(ref) 
Study 
Design 
n Cell 
type 
Delivery Method Primary Outcome 
Smits et al234 NR 5 SM Transendocardial 
MyoStar™ 
LVEF increased from 36 +/- 
11% to 41 +/- 9% (3 months, 
p = 0.009) 
CAuSMIC235 
(2009) 
NR 23 SM Transendocardial 
MyoStar™ 
Improvement in heart failure 
symptoms, reduction in LV 
dimensions and evidence of 
improved viability in cell 
treated group at 1 year 
SEISMIC236 
(2011) 
RCT 
 
40 SM Transendocardial 
MyoCath™ 
No change in global LVEF but 
there was a trend towards 
improvement in patient 
symptoms 
Perin et al13 
(2004) 
NRC 20 BMSC Transendocardial 
MyoStar™ 
Improvement in myocardial 
perfusion and exercise 
tolerance in cell treated group 
but no significant change in 
LVEF 
Beeres et 
al237 
(2007) 
NR 15 BMSC Transendocardial 
MyoStar™ 
Improvement in regional 
contractility and global LVEF 
Williams et 
al229 
(2011) 
NR 8 BMSC Transendocardial 
Helix™ 
Improvement in regional 
contractility and evidence of 
reverse remodelling 
FOCUS-
HF238 
(2011) 
RCT 30 BMSC Transendocardial 
MyoStar™ 
Improvement in symptoms 
and perfusion but no change  
in global LVEF 
TOPCARE-
CHD10 
(2006) 
RCT 
 
75 BMSC Intracoronary Improvement in global LVEF 
by 2.9% in BMSC treated 
group only at 3months follow-
up 
DanCell-
CHF10 
(2008) 
NRC 32 BMSC Intracoronary 
(two infusions 4 
months apart) 
No improvement in LVEF 
even with repeated infusions 
there was improvement in 
NYHA Class 
STAR-
Heart239 
(2010) 
NRC 391 BMSC Intracoronary Improvement in LVEF and 
survival in cell treated group 
over 5 years follow-up 
CADUCEUS
118
 
(2012) 
RCT 31 CDC Intracoronary Reduction in scar mass, 
increase in viable heart mass 
and regional contractility but 
no improvement in LVEF 
Abbreviations: CDC: Cardiosphere-derived cells; ICM: ischaemic cardiomyopathy; DCM: 
dilated cardiomyopathy; n: number of patients; SM: skeletal myoblasts; BMSC: bone 
marrow stem/progenitor cells; LVEF: left ventricular ejection; NR: non-randomised; NRC: 
non-randomised with control group; RCT: randomised controlled trial 
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In the SEISMIC trial, a randomised multi-centre trial in Europe, 40 patients (14 
controls) with ischaemic heart failure underwent fluoroscopy only guided 
transendocardial injection of skeletal myoblasts 236 directly into the area of 
scar using the MyoCath® catheter.  Adverse events during follow-up were 
similar between cell treated and control group and in particular number of 
arrhythmic events (all patients were required to have an ICD in-situ) were also 
similar. However, although there appeared to be some improvement in patient 
symptoms the study failed to show any significant improvement in LVEF. The 
results of these small studies have prompted the design of larger RCTS 
including the MARVEL Trial (ClinicalTrials.gov Identifier:  NCT00526253) 
which was designed as a randomized, double-blind, placebo-controlled, multi-
centre Phase II/III Trial. Enrolment in the MARVEL Trial began in October 
2007 but unfortunately is currently halted due to limited financial resources. 
 
In view of the underwhelming clinical results with skeletal myoblasts other cell 
types are now being investigated. In particular, transendocardial injection of 
BMSCs has been shown to be safe with potentially beneficial effects. An early 
non-randomised trial in 14 patients with severe chronic ischaemic heart failure 
showed NOGA® guided intramyocardial injection of BMSCs into viable 
myocardium was safe and was associated with significantly improved regional 
and global LV systolic function at 6 months 240. Another non-randomised study 
of 20 patients showed NOGA® guided intramyocardial injection of BMSCs 
was again safe and associated with improvements in exercise tolerance and 
myocardial perfusion13. A further small study also showed improvement in 
patient symptoms and LV function following NOGA® guided intramyocardial 
injection of BMSCs237. A recent Phase 1 (non-randomised) study, using the 
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Biocardia Helix™ catheter system, has confirmed the beneficial effects of 
BMSCs in chronically infarcted myocardium with improvements seen in 
regional contractility and evidence of reverse remodelling229. 
 
The most recent RCT, FOCUS-HF, assessing the efficacy of NOGA® guided 
intramyocardial injection of BMSCs found improvements in symptoms and 
quality of life but no change in global LVEF238. Although the trial was 
randomised and double-blinded, the control group did not receive a ‘sham’ 
injection of placebo but instead underwent a ‘mock’ procedure.  
 
2.2.6.2 Intracoronary Delivery of Cell Therapy 
 
There have been relatively few studies assessing intracoronary delivery of 
BMSCs in chronic ischaemic heart failure. In the randomised, cross over 
design TOPCARE-CHD trial 10, intracoronary delivery of BMSCs showed an 
improvement in LVEF of 2.9% with no major adverse cardiac events. In 
contrast the DanCell-CHF Study 239, in which patients received two repeated 
treatments of intracoronary BMSCs 4 months apart, showed no improvement 
in LV function at 1 year follow-up although there was significant improvement 
in patient symptoms. This study adds to the growing belief that using left 
ventricular ejection fraction (LVEF) as a marker of beneficial effects of cell 
therapy may be inadequate as patient symptoms do seem to improve without 
any significant objective change in LVEF. The STAR-Heart Study is the largest 
study to date of BMSC therapy in chronic ischaemic heart failure241.  Of the 
eligible patients screened 191 patients underwent intracoronary BMSC 
therapy, and the control group consisted of 200 patients who declined to have 
 79 
the active intervention. Over a 5-year follow-up period intracoronary BMSC 
therapy was associated with significant improvement in LVEF as well as 
patients’ exercise capacity. Interestingly, there was a significant decrease in 
long-term mortality in the BMSC treated patients compared with the control 
group.  
 
There has only been one clinical study of a combined approach of 
intracoronary and intramyocardial injection of BMSCs. In the MYSTAR 
study242, 60 patients were treated with a combined approach either early (3-6 
weeks) or late (3-4 months) after myocardial infarction. There appeared to be 
significant improvement in LVEF (by 3.5%) in both groups as well as reduction 
in infarct size.  
 
In summary, there have been numerous studies, using different cell types and 
different delivery methods, assessing whether cell therapy is beneficial in 
patients with established heart failure secondary to ischaemic heart disease. 
Cell therapy appears to be safe with potentially beneficial effects in terms of 
patient symptoms as well as modest improvements in LV function. A recently 
formed task force of the European Society of Cardiology has identified a need 
for appropriately sized randomised controlled trials to try and accurately 
assess the efficacy of cell therapy and to define the ideal cell type, delivery 
method and patient type which will derive the maximum benefit of this 
biological therapy15. There has also been outlined a need for mechanistic 
studies to help further the understanding of the biological processes leading to 
benefit. 
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The REGENERATE-IHD study16 has been designed to try and answer some 
of this questions. This is a unique comparative randomised controlled study of 
different BMSC delivery methods with adjuvant G-CSF cytokine therapy in 
patients with ischaemic heart failure (ClinicalTrials.gov Identifier: 
NCT00747708). This is the only trial of its kind in the UK and is also the first 
study worldwide, that we are aware of, to combine G-CSF with direct cell 
delivery in heart failure patients. The study aims to provide important answers 
regarding the efficacy of cell therapy and the best delivery method. Chapter 4 
of this thesis will present the rationale, methodology and results of the 
intramyocardial arm of the study. 
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CHAPTER 3: THESIS HYPOTHESES AND AIMS 
 
3.1 REGENERATE-IHD Clinical Trial (Intramyocardial Arm) 
3.1.1 Hypotheses 
Combined G-CSF therapy and intramyocardial injection of bone marrow 
derived progenitor/stem cells (BMSCs) may lead to an improvement in cardiac 
function and symptoms in patients with chronic ischaemic heart failure. 
 
3.1.2 Aims 
1. Assess the safety and feasibility of bone marrow mobilisation with 
subcutaneous injection of G-CSF in patients with chronic ischaemic 
heart failure. 
 
2. Assess the safety and feasibility of intramyocardial injection of 
mobilised BMSCs or autologous serum. 
 
3. Measure changes in cardiac function (with cardiac MRI or CT, LV 
angiography and echocardiography) following intramyocardial injection 
of BMSCs or autologous serum. 
 
4. Measure changes in NT-ProBNP levels in patients treated with 
intramyocardial injection of BMSCs or autologous serum 
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5. Assess changes in patients’ symptoms and well-being (using heath 
related quality of life questionnaires) following intramyocardial injection 
of BMSCs or autologous serum.  
 
6. Assess changes in unipolar voltage and local linear shortening (as 
assessed by NOGA® mapping) in patients treated with intramyocardial 
injection of BMSCs or autologous serum. 
 
7. Assess the impact of progenitor cell concentration and function on the 
primary and secondary end-points of the study. 
 
3.2 A Study of Progenitor Cell Characteristics  
3.2.1 Hypotheses 
Bone marrow progenitor cell concentration and function may be affected by 
age and the disease process itself. G-CSF therapy increases peripheral blood 
CD34+ cell concentration although this effect may differ between patients with 
ischaemic heart failure and dilated cardiomyopathy. G-CSF mobilisation may 
also affect the functional capability of peripheral and bone marrow progenitor 
cells. 
 
3.2.2 Aims 
1. Measure the baseline concentration of circulating CD34+ progenitor 
cells and endothelial progenitor cells (EPCs) in patients recruited to the 
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REGENERATE-IHD study and assess for correlation between 
concentration and clinical parameters including patient age.  
 
2. Compare the concentration and function of progenitor cells in patients 
recruited to the ischaemic heart failure study with that of patients 
recruited to two other trials of cell therapy in dilated cardiomyopathy 
and acute myocardial infarction. 
 
3. Assess the effect of G-CSF on bone marrow and peripheral blood 
progenitor cell concentration and function in patients with ischaemic 
heart failure and dilated cardiomyopathy. 
 
3.3 Angiogenesis Imaging Study 
3.3.1 Hypotheses 
BMSC therapy may partly exert its beneficial effects through de novo 
angiogenesis and this may be detected using a novel radio-tracer peptide 
(99mTc-NC100692: proposed International Non-proprietary Name (INN) 99mTc-
maraciclatide) which binds to αvβ3 integrin, an angiogenesis related integrin. 
 
3.3.2 Aims 
Assess the feasibility of using a novel radio-tracer peptide (99mTc-NC100692) 
to detect angiogenesis and specifically aim to show that: 
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1. 99mTc-labeled peptide (NC100692) injection is well-tolerated in heart 
failure patients 
 
2. 99mTc-labeled peptide (NC100692) uptake in heart failure patients 
can be detected 
 
3. 99mTc-labeled peptide (NC100692) uptake is affected by  
intramyocardial injection of BMSCs or serum 
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CHAPTER 4: THE REGENERATE-IHD STUDY 
4.1 Study Design 
 
The Randomized Controlled Trial to compare the Effects of G-CSF and 
Autologous Bone Marrow Progenitor Cells Infusion on Quality of Life and Left 
Ventricular Function in Patients with Heart Failure secondary to Ischaemic 
Heart Disease (REGENERATE-IHD) trial is an ongoing double-blind, 
randomised controlled study being conducted at a single centre in the UK16. 
The trial investigates the potential for autologous bone marrow-derived 
stem/progenitor cells (BMSCs) to improve cardiac function and symptoms in 
patients with chronic ischaemic heart failure and no further treatment options. 
As well as testing routes of administration, it uses a novel approach of 
administering G-CSF as adjunctive therapy. 
 
The study design is depicted in figure 12. There are three arms of the study: 
peripheral mobilization with G-CSF or placebo (saline) injections; intracoronary 
delivery of BMSC or autologous serum (control) following G-CSF mobilisation; 
and NOGA® guided intramyocardial delivery of BMSC or autologous serum 
(control) following G-CSF mobilisation.  
 
The intervention arms of the study are double-blind so that neither the 
participant nor investigator was aware of treatment assignment. The peripheral 
arm of the study is single blind so that only the patient was unaware of 
treatment assignment. The primary outcome measure, change in LVEF, was 
assessed by an independent cardiologist blinded to all treatment assignments. 
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Figure 12. Design of the REGENERATE IHD trial.  
 
We decided to initially complete treatment within the intramyocardial arm (the 
main focus of this thesis) and patients were then randomly allocated to the 
other two arms of the trial. The mains reasons for this were to ensure that 
operators who had undergone training in NOGA® mapping and 
intramyocardial injection were able to maintain an adequate skill level and to 
avoid costly equipment expiring beyond recommended date of use. Following 
allocation to treatment arm patients were further randomised 1:1 to active or 
control groups. This thesis will primarily present the methodology and results 
of the intramyocardial arm of the REGENERATE-IHD Trial. 
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4.2 Study Rationale 
 
The REGENERATE-IHD trial (intramyocardial arm) has several unique 
features. The rationale behind the choice of cell type, delivery method, control 
group and primary end-point are described below.  
 
4.2.1 Bone marrow stem/progenitor cells 
We chose to study BMSCs, specifically the mononuclear cell fraction, as this 
cell type has been the most investigated and has shown the most promise so 
far in preclinical experiments and clinical trials13, 241, 243. The mononuclear cell 
fraction contains a heterogeneous population of cell types including HSCs 
(CD34+), EPCs (CD133+VEGFR2+), MSCs, monocytes (CD14+) and 
lymphocyte subsets characterised by CD3+ (T-cells), CD19+ (B cells) and 
CD16+CD56+ (natural killer cells) cell surface markers. HSCs and EPCs 
comprise only 1-3% of the mononuclear cell fraction and the contribution of 
the other cell types to the process of cardiac repair remains unclear.  For 
example, lymphocytes produce TNF-α, which up-regulates vessel-wall 
expression of VCAM-1244 which is required for homing of stem cells to injured 
tissue245.  In view of the uncertainty regarding which cell type(s) are most 
influential in the healing process we have taken the pragmatic approach of 
using the whole mononuclear cell fraction rather than specific sub-sets. 
Isolation of the bone marrow mononuclear cell fraction requires a density 
gradient medium, a polysaccharide solution of a specific density which acts as 
a liquid filter to remove undesired components, such as granulocytes, platelets 
and red blood cells246.  We have used the Ficoll-Paque™ density gradient 
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medium in our clinical trial as this has been the most widely used in clinical 
trials of BMSC therapy. We have also previously published data from our 
department showing that the composition and quantity of cell types obtained 
using this medium is similar to that obtained from Lymphoprep™- the other 
commercially available density medium247.  
 
4.2.2 Combination of G-CSF therapy and myocardial delivery 
 
As mentioned previously there have been small non-randomised trials of G-
CSF therapy alone in patients with heart failure suggesting possible beneficial 
effect on symptoms210, 211. There has so far only been one study of combined 
G-CSF mobilisation of cells with subsequent direct delivery of cells to the 
heart. In the ACT34-CMI study intramyocardial injection of CD34+ cells 
(obtained by peripheral leukapheresis after 5 days of G-CSF administration at 
a doe of 5µg/kg/day) improved angina symptoms in patients with refractory 
angina248. Of note, in the latter study patients had relatively preserved LVEF 
hence our study is the first to examine combined G-CSF and intramyocardial 
injection in patients with heart failure and severe LV systolic dysfunction. The 
possible advantages of a combined approach include a) the direct beneficial 
effects of G-CSF on myocardial tissue, b) increasing the number of progenitor 
cells that can be harvested and c) potentially improving the quality of 
progenitor cells in patients with ischaemic heart disease who have been 
shown to have impaired bone marrow function249, 250. 
 
G-CSF has been administered at a dose of 10µg/kg/day for 5 days prior to 
bone marrow harvest in our trial. This dose of G-CSF has been shown to 
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improve the yield of CD34+ cells compared to a 5µg/kg/day dose251. Higher 
doses, such as 16µg/kg/day, have been associated with increased side effects 
such as splenic rupture252.  
 
In our trial progenitor cells have been collected by bone marrow aspiration 
rather than peripheral leukapheresis. It remains unclear whether peripherally 
harvested circulating progenitor cells (CPCs) would have the same therapeutic 
effect as the cells found in the bone marrow (BMSCs). In the TOPCARE-CHD 
study intracoronary infusion of CPCs was significantly inferior to BMSCs with 
regards to improvement in LVEF in patients with chronic heart failure10. Based 
on this data and current available evidence we decided to use BMSCs in our 
clinical trial. 
 
4.2.3 NOGA® guided intramyocardial injection 
 
Intramyocardial injection of cells or serum has been performed using the 
NOGA® system and Myostar™ catheter. As described previously the main 
advantage of this system is the ability to delineate the infarcted myocardium 
so that the cells can be injected accurately around the infarct zone/hibernating 
area. This technique appears to be safe and has been used to deliver cells in 
several clinical trials13, 237, 253 with only one reported case of pericardial 
effusion254. 
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4.2.4 Control group (intramyocardial serum injection) 
The control group patients in our clinical trial have also received G-CSF 
therapy followed by bone marrow aspiration. They also underwent NOGA® 
mapping and intramyocardial injection of autologous serum only (without 
cells). This allowed our study to be double-blind thus strengthening the study 
design255, 256. Serum injection (in the control group) also allows us to exclude 
potential confounding effects such as possible beneficial effect of ‘needle 
puncture’ which may elicit a beneficial injury reaction including angiogenesis.  
 
Our study is one of the first trials to perform intramyocardial injection in the 
control group. Previous studies have either used standard care as the control 
group or have performed a ‘mock’ procedure without actually injecting so as to 
maintain patient blinding238. We are only aware of two other studies that have 
performed ‘sham’ intramyocardial injection. In the ACT34-AMI study248 the 
control group received injection of 0.9% normal saline with 5% autologous 
serum. In the recently published FOCUS-CCTRN study257 the control group 
received 0.9% saline with 5% human serum albumin. The injection of 
autologous serum in our trial potentially allows us to assess the effects of 
injection of soluble paracrine factors only on cardiac function and symptoms. 
 
4.2.5 Outcome measures  
The primary outcome measure is change in left ventricular ejection fraction 
(LVEF) measured by sensitive cardiac MRI/CT imaging. This has been chosen 
as the surrogate marker of efficacy because its relevance can be readily 
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appreciated by the clinical cardiology community since it is the most commonly 
used tool to assess cardiac function. Furthermore, the change in LVEF 
following a therapy has been shown to be closely correlated to subsequent 
long-term clinical outcome258. Secondary outcomes measures include change 
in NT-proBNP levels as prior studies of various medical therapies in heart 
failure have demonstrated improved clinical outcomes if reduction in NT-
proBNP level is achieved39. Subjective improvement in symptoms has been 
assessed by change in NYHA functional class and health related quality of life 
(HRQL) questionnaire scores. 
 
4.3 Methods 
4.3.1 Declaration of Helsinki 
This study is conducted in full accordance with the principles of the 
"Declaration of Helsinki" (as amended in Tokyo, Venice, Johannesburg, and 
Edinburgh) and with the laws and regulations of the country. 
 
4.3.2 Ethics and MHRA Approval 
Approvals from the local research ethics committee (LREC) and Medicine and 
Healthcare products Regulatory Agency (MHRA) was granted prior to 
recruitment of any participants. 
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4.3.3 Clinical Trial Registration 
The REGENERATE-IHD study has been registered with the Clinicaltrials.Gov 
website. The identifier is NCT00747708. This is in accordance with the 
International Committee of Medical Journal Editors (ICMJE) initiative requiring 
prior entry of clinical trials in a public registry as a condition for publication. 
 
4.3.4 Patient Recruitment 
4.3.4.1 Inclusion Criteria 
All of the following criteria were required for patients to be considered for the 
study:  
• Impaired left ventricular systolic function secondary to ischaemic heart 
disease 
• At least NYHA class II functional class despite optimal medical therapy 
and no further revascularisation options 
• Patient had been considered for implantable cardioverter defibrillator 
(ICD) and/or cardiac resynchronisation therapy (CRT) as per up-to-date 
clinical guidelines 
 
4.3.4.2 Exclusion criteria 
Patients were excluded if they had any of the following: 
• Recent acute coronary syndrome  
• The presence of cardiogenic shock 
• Decompensated heart failure 
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• LVEF < 10% prior to randomisation 
• Contra-indication for bone marrow aspiration 
• Known active infection 
• Known infection with human immunodeficiency virus (HIV), hepatitis B 
virus (HBV), or hepatitis C virus (HCV) syphilis or HTLV 
• Lifestyle with high risk for infection with HIV, HBV or HCV syphilis or 
HTLV 
• Serum creatinine >200 umol/L 
• Chronic inflammatory disease 
• Serious known concomitant disease with a life expectancy of less than 
one year 
• Female subjects of childbearing potential 
• Atrial fibrillation (unless pacemaker implanted with regular paced 
rhythm) 
• Patients who had recently responded to the implantation of a 
biventricular pacemaker 
• Weight >140kg 
 
4.3.4.3 Patient selection 
Potential candidates for the trial were identified from several sources:  
• ICD follow-up clinic at St Bartholomew’s Hospital 
• Heart failure clinics at The London Chest Hospital, local district general 
hospitals and also from other hospitals nationally 
• Referrals from cardiologists from all regions within the United Kingdom 
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Potential patients were invited to attend an assessment clinic at The London 
Chest Hospital to discuss the trial and assess suitability. A patient information 
sheet (PIS) was sent by post to all patients prior to being seen in clinic. During 
the clinic visit a full medical history was taken and a full physical examination 
performed. Patients also had a baseline electrocardiogram (ECG) and 
screening blood tests including virology testing.   
 
4.3.4.4 Informed Consent 
Suitable patients had the trial explained to them in detail with particular 
reference to the PIS. Patients who agreed to take part then completed the 
consent form. 
 
4.3.4.5 Randomisation 
Randomisation was performed with an online commercial clinical trial 
randomisation software programme (IHD-CLINICAL- http://www.ihd-
clinical.com/).  
 
 
4.3.5 Study Outline 
The outline of the intramyocardial arm of the REGENERATE-IHD is shown in 
figure 13.  The first 30 patients were automatically allocated to this arm of the 
study and following this patients have then been randomly allocated to the 
‘intracoronary’ or ‘peripheral’ arm of the study.  
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Patients allocated 
to Intramyocardial Arm 
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Subcutaneous injection of 
G-CSF 10mcg/kg daily for 5 days
Subcutaneous injection of 
G-CSF 10mcg/kg daily for 5 days
Bone Marrow Harvest 
on Day 6
Bone Marrow Harvest
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LV angiography
NOGA® mapping
Intramyocardial injection of BMSCs
LV angiography
NOGA® mapping
Intramyocardial injection of Serum
LV angiography
NOGA® mapping
Outpatient Clinic Visit
Assessments
BNP     QoL      Echo    MRI/CT
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Inpatient
Admission
6-months follow-up
1-Year follow-up
   
  
  
 
Figure 13. The outline of the intramyocardial arm of the REGENERATE-IHD Study.  
 
4.3.6 Baseline Study Procedures 
Patients were typically admitted on a Tuesday afternoon (Day 0) for the study. 
A baseline contrast echocardiogram was performed on day 0. A Cardiac MRI 
or CT (if there was a contraindication to MRI scanning) was performed on Day 
0 or Day 1 depending on availability. Baseline blood tests were also taken at 
this stage.  
 
 
 96 
4.3.6.1 Baseline assessment of symptoms and quality of life (QoL) 
Patients’ heart failure symptoms were graded according to the NYHA 
classification of functional ability and angina symptoms were graded by the 
CCS classification, both of which have been described in section 2.1.4. We 
also assessed quality of life (QoL) using three well validated health related 
quality of life (HRQL) questionnaires which are discussed below and the full 
questionnaires are provided in appendix B. 
 
• The MacNew Heart Disease HRQL questionnaire was designed to evaluate 
how daily activities and physical, emotional, and social functioning are affected 
by ischaemic heart disease and its treatment259. The MacNew (see appendix 
B) consists of 27 items which fall into three domains (a 13-item physical 
limitations domain scale, a 14-item emotional function domain scale, and a 13-
item social function domain scale)259. The maximum possible score in any 
domain is 7 (high HRQL) and the minimum is 1 (poor HRQL). In our study a 
global HRQL score was calculated as the average of all scored items. The 
MacNew instrument can be used to assess change in QoL after an 
intervention and a change of at least 0.5 is a useful indicator of the minimal 
important difference in the global HRQL score260. 
 
• The EQ5D is a HRQL measure developed by the EuroQol Group261. The 
EQ-5D (see appendix B) consists of 2 parts - the EQ-5D descriptive system 
and the EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system 
comprises the following 5 domains: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each domain has 3 possible 
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responses: no problems, some problems, extreme problems. The responses 
from the EQ-5D descriptive system may be converted into a single summary 
index (as has been done in our study) by applying a formula that essentially 
attaches values to each of the levels in each domain262. 
 
The EQ VAS records the respondent’s self-rated health on a vertical, visual 
analogue scale (0-100) where the endpoints are labelled ‘worst imaginable 
health state’ and ‘best imaginable health state’. This information can be used 
as a simple quantitative measure of HRQL263. The EQ5D has been validated 
for use in patients with ischaemic heart disease264. 
 
• The SF-36 Version 2 (see appendix B) is a 36-item questionnaire that 
measures eight multi-item dimensions of health: physical functioning (10 
items) social functioning (2 items), role limitations due to physical problems (4 
items), role limitations due to emotional problems (3 items), mental health (5 
items), energy/vitality (4 items), pain (2 items), and general health perception 
(5 items)265. For each dimension, item scores are coded, summed, and 
converted into a scale from 0 (worst possible health state) to 100 (best 
possible health state)266. Two standardised summary scores can also be 
calculated from the SF-36; the physical component summary (PCS) and the 
mental health component summary (MCS). The PCS and MCS scores have 
been standardised using means and standards deviations from general United 
Kingdom population survey published previously267. The use of SF-36 HRQL 
questionnaire has been validated for the evaluation of a wide variety of 
medical interventions 268. 
 98 
4.3.6.2 Baseline assessment of cardiac function 
Left ventricular ejection fraction (LVEF) was chosen as the primary surrogate 
marker to assess change in cardiac function following BMSC therapy. We 
have also assessed for change in cardiac volumes. LVEF has been assessed 
with 4 different imaging modalities:  
 
• Transthoracic echocardiography with contrast was performed on Day 0 of 
the patients’ admission. Two-dimensional (2-D) echocardiography with a 
phased-array electronic ultrasound apparatus was performed in the four 
standard views: parasternal long and short views and apical four- and two-
chamber views (figure 14). 
 
a) b)
c) d)
 
Figure 14. Still frames showing contrast echocardiography for assessment of LVEF and 
biplane Simpson’s method for calculation of LV volumes. Apical 4-chamber views on top row, 
a) end-diastolic frame and b) end-systolic frame. Apical 2-chamber views on bottom row, c) 
end-diastolic frame and d) end-systolic frame. 
 
A commercially available contrast agent (Sonovue™) was administered 
intravenously to opacify the LV and improve endocardial definition. LVEF was 
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calculated using the biplane Simpson’s method269 (figure 14). Pulsed wave 
doppler was used to obtain mitral inflow velocity (E) and tissue doppler 
information (TDI) of the mitral annulus relaxation velocity (E’) to obtain the E/E’ 
ratio to assess diastolic function270.  
 
• Left ventricular angiography was performed on day 6, as part of the NOGA® 
mapping procedure. This was performed by obtaining a cine image during 
injection of 30mls of contrast (at a rate of 10mls/second), using a power 
injector, through a pigtail catheter that was placed retrogradely in the left 
ventricle from the femoral access site. Cine images were obtained in right 
anterior oblique (RAO) 30º and left anterior oblique (LAO) 60º views (figure 
15). LVEF was obtained by quantitative left ventriculography (QLV) which was 
performed with dedicated QLV software (QAngio X™). 
 
a) b)
c) d)
 
Figure 15. Still frames showing LV angiography for assessment of LVEF. Top row shows 
RAO 30º a) end diastolic and b) end systolic frames and bottom row shows LAO 60º c) end 
diastolic and d) end systolic frames.   
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• CMR was performed in patients without a contraindication to MRI scanning 
using a Siemens Avanto 1.5T (Siemens Medical Solutions, Erlangen, 
Germany) scanner, using internationally standardised acquisition protocols 271. 
Cardiac magnetic resonance imaging (MRI) is now widely accepted as the 
gold standard assessment for cardiac function. LV volumes and EF were 
analysed using a short axis cine-based contour tracing protocol (figure 16).  
 
Figure 16. Still images showing the evaluation of LVEF by CMR. Short axis views of the entire 
left ventricle from base to apex in diastole (A-L) and systole (M-X). Delineation of the 
epicardial and endocardial contours allows calculation of left ventricular mass, end diastolic 
volume, end systolic volume, stroke volume and ejection fraction.  
 
• Cardiac CT was performed in patients with a contraindication to MRI scan 
which was predominantly the presence of an intra-cardiac device. A Siemens 
256-slice "FLASH" dual-source scanner was used to obtain retrospectively 
gated scans with intravenous iodinated contrast for assessment of cardiac 
structure and function. LV volumes and EF were analysed using a short axis 
cine-based contour tracing protocol, similar to CMR. Studies comparing MRI 
and CT have shown good correlation between the two imaging modalities for 
LVEF assessment 272, 273. All MRI and CT studies were analysed by an 
experienced cardiologist blinded to treatment. 
 101 
4.3.6.3 Baseline blood tests (including NT-ProBNP) 
Blood samples were collected from patients on the day of admission (Day 0) 
for serum NT-proBNP testing. The samples were analysed at an independent 
laboratory (Doctors Laboratory, London, UK) using a high-sensitivity, 
quantitative enzyme immunoassay (Modular Analytics E170, Roche 
Diagnostics). Measurement of cardiac enzymes (creatinine kinase and 
Troponin-T) was performed on day 6 (pre-procedure) and day 7 (post- 
procedure) to assess for procedure related myocardial necrosis/infarction. 
These samples were analysed by the biochemistry laboratory at The Royal 
London Hospital. 
 
4.3.6.4 Peripheral injection of G-CSF (days 1-5) 
Recombinant human G-CSF (Granocyte®, Chugai Pharma, UK) was 
administered subcutaneously at a dose of 10µg/Kg/day for 5 consecutive days 
prior to bone marrow harvest on Day 6. Patients had routine blood tests 
performed daily as well as a sample taken for CD34+ cell count estimation. 
 
4.3.6.5 Bone marrow aspiration (day 6, morning) 
Bone marrow was obtained from the posterior iliac crest. 50 ml of bone 
marrow were aspirated equally into heparin-treated syringes from 3 separate 
sites over the iliac crest. Thirty-six ml of peripheral venous blood was acquired 
immediately prior to bone marrow harvest to obtain autologous serum for 
intramyocardial injections. Blood and bone marrow samples were delivered 
immediately to the Good Clinical Practice accredited Stem Cell Laboratory for 
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processing. Isolation and characterisation of BMSCs were performed by a 
designated lab technician (Natalie Saunders). 
 
4.3.6.6 Isolation of bone marrow mononuclear cells 
The bone marrow sample was layered on a Ficoll-Paque™ preparation density 
gradient medium (Axis shield, Oslo, Norway) and centrifuged at 2500rpm for 
30 minutes. The mononuclear cell fraction was extracted and subjected to 3 
wash cycles in 0.9% saline (Baxter, Norfolk, UK). Cells were resuspended in 2 
ml of autologous serum for intramyocardial injection. Control group injections 
consisted of 2 ml autologous serum alone. Samples were maintained at room 
temperature for the entire procedure and the final injectate of stem/progenitor 
cell suspension or placebo was transported to the cardiac catheter laboratory 
at London Chest Hospital for the intramyocardial or intracoronary injection 
procedure. Viability of the cell preparation was checked with 7-AAD (7-amino-
actinomycin D) staining immediately prior to infusion and was 98.4 ± 0.7% in 
the cell treated group. 
 
4.3.6.7 Flow-cytometry of progenitor cells and CFU-GM assays 
Bone marrow and peripheral blood circulating progenitor cells (CD34+ cells 
and endothelial progenitor cells (EPCs)) were characterised using flow 
cytometry. All flow cytometry analyses were performed using a BD 
FACSCanto Flow Cytometer with BD FACSDiva v 5.0.3 software (BD 
Biosciences). For the identification of HSC populations, cells were incubated 
with fluorescein isothiocyanate (FITC)-labeled antibody against human CD45 
(BD Biosciences, Erembodegem-AALST, Belgium) and phycoerythrin (PE)-
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labeled antibody against human CD34 (BD Biosciences) for 15 min at room 
temperature. 
 
EPCs were analysed by initially incubating samples with mouse serum IgG 
(Sigma, Dorset, UK) for 15 min at 4oC with a cocktail of antibodies comprising 
allophycocyanin (APC)-labelled antibody to CD133 (Miltenyi Biotec, Surrey, 
UK) and PE-labelled antibody to VEGFR-2 (R&D Systems, Abingdon, UK) to 
characterise EPCs and FITC-labelled monoclonal antibodies to CD2, CD13 
and CD22 (Beckman Coulter, High Wycombe, UK) to identify and therefore 
eliminate inclusion of lineage-negative non-progenitor cells. To ensure 
exclusion of nonviable cells in the final EPC count, cells were also incubated 
with a PerCP-Cy5-labelled 7AAD stain (BD Biosciences). Cells were then 
incubated for 15 min at room temperature with 2ml of Pharm Lyse™ buffer 
(BD Biosciences) to lyse red blood cells. Samples were washed once in 
phosphate-buffered saline and 20µl of Accucount flow cytometry beads 
(Saxon Europe, Kelso, UK) were added before analysis. 
 
Functional analysis of CD34+ cells was performed using a colony-forming unit 
(CFU-GM) assay. BM-MNCs (2x104 per dish), Day 0 peripheral blood MNCs 
(2x105 per dish), and Day 6 peripheral blood MNCs (2x104 per dish) were 
seeded, in triplicate preparations, in methylcellulose plates (Methocult H4534, 
including stem cell factor, granulocyte-macrophage colony–stimulating, and 
interleukin-3, Stem cell Technologies). Plates were studied under phase-
contrast microscopy, and granulocyte-macrophage colony forming units (CFU-
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GM; colonies >50 cells) were counted after 14 days of incubation.  Results 
were taken from the mean of the triplicate results.  
 
4.3.6.8 Intramyocardial injection of cells/placebo (day 6, afternoon) 
Intramyocardial injection was performed using the NOGA® mapping system 
and MyoStar™ injection catheter- a detailed description of this delivery system 
has been provided in section 2.2.5.5. After femoral arterial access (8Fr 
sheath), a weight adjusted bolus dose of heparin was given as per routine 
procedure. A LV angiogram was initially performed to assess LVEF and also 
to guide intramyocardial injection. Patients then underwent LV 
electromechanical mapping using NOGA® XP Cardiac Navigation System 
(Biologics Delivery Systems Group, Cordis Corporation, Diamond Bar, CA, 
USA) to delineate the scar area (unipolar voltage <6.9mV) and surrounding 
viable but hibernating myocardium. This was correlated with areas of wall 
dyskinesia on the LV angiogram. Direct intramyocardial injection was 
performed with the MyoStar™ injection catheter (Biologics Delivery Systems 
Group, Cordis Corporation, Diamond Bar, CA, USA) as previously described13, 
225
. The total 2 ml volume of injectate was delivered equally over 10 target 
areas at approximately 1cm intervals. Areas of the myocardium with a wall 
thickness of <5mm were avoided. The electromechanical mapping data 
(unipolar voltages and local linear shortening) were recorded so that they 
could be compared to the follow-up mapping procedure performed at 6-
months follow-up. A NOGA® map and injection sites from a patient’s 
procedure are shown in figure 17. 
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Figure 17. An example of a NOGA® map obtained in a patient in our trial. This map 
represents endocardial unipolar voltage which is depicted in a colour scale with values 
<6.9mV (scar tissue) showing as red. As can be appreciated in this map this patient has 
extensive area of scar tissue. The brown spots represent sites of intramyocardial injection and 
these have been placed around the area of scar tissue. 
 
 
4.3.6.9 Patient monitoring and discharge 
Following the intramyocardial injection procedure all patients had an 
immediate transthoracic echocardiogram performed to exclude pericardial 
effusion. Patients were then admitted to the monitored bed on the cardiology 
ward and had overnight monitoring. A blood sample was taken the following 
morning for measurement of CK/Troponin-T levels and patients were 
discharged home (on day 7) if there were no complications. 
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4.3.7 Follow-up 
Patients were followed up at periods of 6-months at 12-months.  
 
6-month follow-up assessments: 
• Clinical history and physical examination 
• Contrast echocardiography 
• Blood test for NT-proBNP measurement 
• LV angiography 
• NOGA® electromechanical mapping 
• HRQL questionnaires 
 
12-month follow-up assessments: 
• Clinical history and physical examination 
• Contrast echocardiography 
• Cardiac CT or MRI scanning for LV function 
• HRQL questionnaires 
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4.3.8 End-point measures 
All outcome measures were assessed blinded to patient treatment allocation.  
 
4.3.8.1 Primary outcome 
The primary outcome measure was change in global left ventricular ejection 
fraction (LVEF) at 12 months relative to baseline as measured by cardiac MRI 
or CT. 
 
4.3.8.2 Secondary outcome measures 
These included: 
• the occurrence of a major adverse cardiac event (MACE) including 
cardiac death or ventricular arrhythmia 
• change in global LVEF measured by resting contrast echocardiography 
• change in global left LVEF measured by quantitative left 
ventriculography 
• change in serum levels of NT-proBNP 
• change in HRQL questionnaire scores 
• change in unipolar voltage (UV) and local linear shortening (LLS) maps 
as assessed by NOGA® 
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4.3.9 Statistical Analysis 
 
Sample size and power calculations 
The sample size for this trial has been determined so there would be a 
sufficient number of patients to provide a high degree of confidence (power = 
90%) for evaluating progenitor cell transplantation therapy. The study has 
been powered to adequately assess the primary end-point of change in 
cardiac function as assessed by LVEF on cardiac MRI or CT scanning. An 
absolute improvement of 3.5% in this LVEF would be considered both a 
realistic effect and potentially worthwhile. The within patient standard error is 
estimated to be around 2.8%, we used a pessimistic estimate of this as 4%.  
This gives a standard error for the difference of the measurements of before 
and after treatment of (2x4)1/2 = 2.8- conservatively estimated as 3. Therefore 
the standardised effect we aimed to detect is 3.5/3 = 1.17. Using samples size 
tables (table 4.2) from Machin et. al 274, to detect this targeted difference with 
a significance level of 5% and power of 90% requires 11 patients per group.  
Allowing for a (pessimistic) dropout of 4 patients per group we aimed to recruit 
15 patients per group i.e. 30 patients in each arm of the study. 
 
Statistical analysis 
Analysis is on a per-protocol basis. Continuous variables are presented as 
means (±SD) or (±SEM) and categorical variables are presented as 
percentages. Statistical comparisons of continuous variables were made by 
the parametric 2-sided t-test or Wilcoxon signed-rank test for paired variables 
or Mann-Whitney U test for independent variables.  Categorical variables were 
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compared by means of Fisher’s exact test. A P value of < 0.05 was considered 
to indicate statistical significance. All reported P values are two-sided. 
Statistical analyses were performed using Graphpad Prism version 5.0 
(GraphPad Software, San Diego, CA) and SPSS 19. Results were reviewed 
by Professor Mahesh Parmer, Director of the Medical Research Council’s 
Clinical Trials Unit (CTU). 
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4.4 Results 
4.4.1 Patient recruitment and baseline characteristics 
The flow diagram below depicts patient recruitment and treatment.  
 
751 patients assessed for 
eligibility
714 patients excluded
37 patients randomised to receive NOGA 
guided intramyocardial injection of 
autologous BMSCs or serum
7 patients unsuitable for intramyocardial injection
and allocated to intracoronary arm of study
15 patients randomly allocated 
to receive intramyocardial 
injection of autologous BMSCs 
(in serum)
15 patients randomly allocated 
to receive intramyocardial 
injection of autologous serum 
only (control)
Primary end-point analysis (1-year)
14 assessed for change in LVEF 
- 1 patient lost to follow-up
Secondary end-point analyses (6-months)
14 assessed for change in NT-proBNP
- 1 patient lost to follow-up
14 assessed for change in symptoms and QoL
- 1 patient lost to follow-up 
Secondary end-point analysis (1-year)
14 assessed for change in symptoms and QoL
Primary end-point analysis (1-year)
13 assessed for change in LVEF 
- 1 patient death
- 1 patient received LVAD
Secondary end-point analyses (6-months)
14 assessed for change in NT-proBNP
- 1 sample lost
15 assessed for change in symptoms and QoL
Secondary end-point analysis (1-year)
13 assessed for change in symptoms and QoL
- 1 patient death
- 1 patient received LVAD
30  patients received subcutaneous G-CSF injections 
10mcg/kg/day for 5 days
 
Figure 18. Flow diagram of patient recruitment and treatment 
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A total of 751 patients were assessed for eligibility between October 2009 and 
November 2010 (Figure 18). 714 patients were unsuitable based on the 
predefined exclusion criteria described in the methods (major reasons being 
atrial fibrillation, NYHA class 1 status, creatinine>200umol/l, ongoing 
medical/device optimisation, patients declining and randomisation into a 
separate study). A total of 37 patients were randomised into intramyocardial 
arm of the study with a final 15 patients receiving intramyocardial injection of 
bone marrow mononuclear cells suspended in serum and 15 patients 
receiving intramyocardial serum injections alone. 7 patients (of the initial 37) 
did not receive treatment as they were not suitable for intramyocardial injection 
(reasons described below). 
 
The baseline characteristics of the 30 patients who underwent treatment are 
shown in table 4. Patients in the two different treatment groups were generally 
well matched although there was a trend towards higher number of 
implantable cardiac devices in the BMSC treated group. It is important to note 
that the mean left ventricular ejection fraction (LVEF) was 29% and NT-
proBNP was 1048 pg/ml- reflecting a cohort of patients with truly advanced 
ischaemic heart failure. 
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Table 4.  Baseline characteristics of patients 
 All Patients 
(n=30) 
BMSC group 
(n=15) 
Control (serum) 
group (n=15) 
p-value 
Age, years 63 ± 10 65 ± 9 60 ± 11 0.202 
Male sex, No (%) 30 (100) 15 (100) 15 (100) - 
Medical history 
   Diabetes (%) 
   Previous MI (%) 
   CABG (%) 
 
8 (27) 
26 (87) 
10 (33) 
 
4 (27) 
13 (87) 
4 (27) 
 
4 (27) 
13 (87) 
6 (40) 
 
0.659 
0.701 
0.350 
Time from last MI 
(years) 
8.5 ± 7 8.0 ± 6.2 8.9 ± 8 0.749 
LVEF (%) 29 ± 9 31 ± 8 29 ± 10 0.607 
NT-proBNP (pg/ml) 1048 ± 1263 1299 ± 1499 796 ± 959 0.283 
Medications at 
recruitment  
    Statins 
    ACEI/ARB 
    β-blocker 
    Aldos Antagonist 
    Diuretics              
 
 
27 (90) 
30 (100) 
25 (83) 
21 (70) 
22 (73) 
 
 
13 (87) 
15 (100) 
14 (93) 
12 (80) 
12 (80) 
 
 
14 (93) 
15 (100) 
11 (73) 
9 (60) 
10 (66) 
 
 
0.500 
- 
0.165 
0.213 
0.341 
Devices 
    ICD (%) 
    CRT (%) 
 
21 (70) 
9 (30) 
 
13 (87) 
7 (47) 
 
8 (53) 
2 (15) 
 
0.054 
0.054 
Total number of 
cells isolated  
    MNC (x106) 
    CD34+ (x106) 
 
 
N/A 
N/A 
 
 
138 ± 99 
3.7 ± 1.5 
 
 
128 ± 141 
3.5 ± 2.7 
 
 
0.816 
0.857 
Data presented as number and (% of patients) or mean ± SD; LVEF: left ventricular ejection 
fraction; MNC: mononuclear cells; N/A: not applicable; NS: not significant. P-value based on 
comparison between BMSC and control group. 
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4.4.2 Feasibility and Safety of G-CSF mobilisation 
All patients completed the subcutaneous injection of G-CSF phase of the trial. 
This was well tolerated in all the patients. The most common complaint was 
bone pain which was experienced by 5 (17%) patients. Only 1 (3%) patient 
had clinically evident splenomegaly which resolved by discharge (day 7) and 1 
(3%) patient had pyrexia > 380C. G-CSF also led to transient rise in liver 
function tests (LFTs) but these were clinically non-significant and all resolved 
after completion of G-CSF treatment.  There were no episodes of worsening 
angina and no significant elevations in cardiac enzymes during G-CSF 
treatment. 
 
There were no complications of the bone marrow aspiration procedure 
performed on day 6. 
 
4.4.3 Feasibility and safety of intramyocardial injection 
4.4.3.1 Feasibility of NOGA® mapping and intramyocardial injection 
6 patients who were initially randomised to the intramyocardial arm of the 
study had to be changed to the intracoronary arm. The reasons were: 
• 3 patients were found to have LV thrombus which is a contraindication 
for NOGA® mapping. 
• 1 patient had ventricular tachycardia during NOGA® mapping and it 
was felt that intramyocardial injection would pose too high a risk. 
• 1 patient was felt to have high risk LV anatomy with areas of LV wall 
thickness <0.5cm. 
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• 1 patient had to be changed due to a technical issue with Cardiac 
Catheter Lab being unable to perform NOGA® procedure on that day. 
1 patient was withdrawn as no scar tissue was found on NOGA® mapping. 
 
4.4.3.2 Safety of NOGA® intramyocardial injection 
The intramyocardial injection was well tolerated in most of the patients. There 
were 3 (10%) arrhythmia episodes: 
• 1 patient had ventricular tachycardia during NOGA® mapping (changed 
to intracoronary arm) 
• 1 patient had self-limiting episodes of paroxysmal atrial fibrillation 
• 1 patient had ventricular tachycardia with haemodynamic compromise 
requiring emergency DC cardioversion during intramyocardial injection. 
The procedure was then completed without any further complications. 
 
Only 1 patient developed a small pericardial effusion which had resolved on a 
repeat scan the next day. 
 
There were 5 (17%) access site complications although all of these apart from 
one were small femoral haematomas which did not delay discharge for the 
patients. However 1 (3.3%) patient had bleeding from the puncture site which 
did not seal with manual pressure and he required vascular surgery to repair 
his femoral artery. 
 
There were no significant arrhythmias during overnight monitoring post 
procedure. Cardiac enzymes were checked the day after the procedure and 
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results are shown in Figure 19. Although there was a statistically significant 
rise in Troponin-T level (mean 0.049 ng/ml), this did not meet the criteria for 
defining a peri-procedure myocardial infarction275.  
 
Creatinie Kinase (CK)
Intramyocardial Injection (n=30)
CK
(IU/L)
Pre Post Treatment
0
50
100
150
200 p=0.1024
Troponin T
Intramyocardial Injection (n=30)
Troponin T
(ng/ml)
Pre Post Treatment
0.00
0.02
0.04
0.06
0.08 p<0.0001
 
Figure 19. Bar graphs representing changes in cardiac enzymes 1-day post intramyocardial 
injection. Although there is an overall statistically significant rise in Troponin T level this did not 
meet the threshold for diagnosis of peri-procedural myocardial infarct.  
 
 
4.4.4 Safety of BMSC therapy 
In general there was a relatively low rate of serious adverse events (SAEs) for 
the whole cohort of patients during the 1-year follow-up period. In total, there 
were 7 SAEs which are shown in table 5. 
 
Table 5  List of serious adverse events (mean follow-up 380 days) 
Serious adverse event BMSC treated  
(n=15) 
Control (serum) 
group (n=15) 
Death (all cause) 0 1 
Cardiac death 0 0 
Myocardial Infarction 0 0 
Coronary revascularisation 0 0 
Arrhythmia episode 0 1 
Hospitalisation for heart 
failure 
1 1 
Hospitalisation for chest 
pain 
1 0 
Hospitalisation for other 
cause 
0 2 
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The incidence of serious adverse events during 1-year follow-up is depicted 
graphically in figure 20 using a Kaplan Meir curve comparison of event free 
survival. The incidence of events was not significantly different between the 
two groups (hazard ratio 0.392, 95% confidence interval 0.089-1.730). 
 
Time (days)
Percent
event free (%)
0 100 200 300 400
0
50
100 BMSCs
Control group
Hazard Ratio
Ratio
95% CI of ratio
0.3924
0.08903 to 1.730
 
Figure 20. Kaplan Meir curves comparing event free survival (composite of all cause 
hospitalisation and mortality) between BMSC treated and control (serum) groups. 
 
4.4.5 Effect of BMSC therapy on cardiac function 
4.4.5.1 Cardiac CT/MRI 
The change in left ventricular ejection fraction (LVEF) and cardiac volumes 
was assessed in all patients who completed 1-year follow-up: 14 patients in 
the BMSC treated group (1 patient lost to follow-up) and 13 patients in the 
control group (1 patient death and 1 patient received LVAD therapy hence was 
not included).  
In the BMSC treated group there was a significant increase in LVEF at 1 year 
(33.57 ± 11.03% vs 28.59 ± 10.24%, p=0.037). There was also a trend 
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towards improvement in the control group but this was not statistically 
significant (33.15 ± 9.91% vs 29 ± 9.21%, p=0.246): 
 
 
 
 
 
 
Figure 21. Graphs representing change in LVEF in BMSC treated and control groups at 1-
year, measured by CT/MRI. Error bars indicate mean and 95% confidence intervals. 
 
 
 
There were no statistically significant changes in the end-diastolic or end-
systolic volumes (EDV or ESV respectively) in either group although there was 
a trend towards reduction in ESV (204±73 vs 196±76 mls, p=0.546) in the 
BMSC treated group: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Graphs representing change in cardiac volumes in BMSC treated and control 
groups at 1-year, measured by CT/MRI. Error bars indicate mean and 95% confidence 
intervals. 
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The magnitude of change in ejection fraction in the BMSC treated group 
appeared to be related to be related to the in vitro functional potential of the 
cells as measured by a colony forming unit assay (CFU). See section 4.4.8 for 
more details. 
 
4.4.5.2 Quantitative Left Ventriculography (QLV) 
Quantitative left ventriculography (QLV) analysis was performed using 
dedicated software- QAngio® XA (Medis). An example of QLV analysis for 
one of the patients is shown in figure 23: 
Baseline 6-months
 
Figure 23. Still images of quantitative left ventriculography (QLV) calculation using the 
QAngio® XA software. Contour tracing of the LV cavity in end-diastole (red line) and in end-
systole (yellow line) was performed to calculate cardiac volumes and ejection fraction. 
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Overall, there was no significant difference in LVEF, measured by QLV, 6-
months after intramyocardial injection of BMSCs or serum alone (control 
group): 
BMSC treated group Control group
LVEF (%)
Baseline 6-months
0
20
40
60
80 p=0.545
LVEF (%)
Baseline 6-months
0
20
40
60
80 p=0.288
 
 
Figure 24. Graphs representing change in LVEF in BMSC treated and control group at 6-
months, as measured by quantitative left ventriculography (QLV). 
 
 
There was also no significant change in LV end-diastolic volume in either the 
BMSC treated (209±59 vs 203±69, p=0.719) or control (214±56 vs 205±61, 
p=0.43) groups 6-months post treatment: 
 
BMSC treated group Control group
EDV (mls)
Baseline 6-months
0
100
200
300
400 p=0.719
EDV (mls)
Baseline 6-months
0
100
200
300
400 p=0.432
 
 
Figure 25. Graphs representing change in end-diastolic volume (EDV) in BMSC treated and 
control group at 1-year measured by quantitative left ventriculography (QLV). 
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4.4.5.3 Contrast transthoracic echocardiography 
There was no significant overall change in LVEF, measured using the biplane 
Simpson’s methods on contrast echocardiography, in either treatment group at 
6-months or 1-year post treatment: 
BMSC treated group Control group
LVEF (%)
Baseline 6-months 1-Year
0
20
40
60
80 p=0.440
LVEF (%)
Baseline 6-months 1-year
0
20
40
60 p=0.931
 
 
Figure 26. Graphs representing change in LVEF as measured by contrast echocardiography 
using the biplane Simpson’s method.   
 
 
 
However, there did appear to be some improvement in diastolic function in 
patients treated with BMSCs. The E/E’ parameter improved significantly from 
baseline to 1-year in the cell treated group (12.17± 6.1 to 10.46± 4.1, p=0.043) 
but no improvement was seen in the control group. 
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Figure 27. Graphs representing change in diastolic function (E/E’) measured using 
echocardiography, during follow-up. 
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4.4.6 Effect of BMSC therapy on NT-proBNP levels 
Baseline and 6-month follow-up NT-proBNP levels were available in 14 
patients in each of the treatment groups.  
 
In the BMSC treated group there was a significant reduction in NT-proBNP 
levels at 6-months post treatment (769±754 vs 977±867, p=0.045). 
Interestingly, there was also a significant reduction in NT-proBNP levels in the 
control (serum only) group (408±302 vs 572±424, p=0.024). To investigate 
whether this was an effect of G-CSF, the NT-proBNP levels were assessed in 
patients in the peripheral arm of the REGENERATE-IHD study who received 
either subcutaneous G-CSF or saline injections only. There was no significant 
reduction in NT-proBNP levels in either of these patient groups. The data is 
summarised in figure 28: 
BMSC treated group Control group
Saline only group (n=15)G-CSF only group (n=15)
NT-ProBNP
(pg/ml)
Baseline 6-months
0
500
1000
1500
*p=0.045
NT-ProBNP
(pg/ml)
Baseline 6-months
0
200
400
600
800 *p=0.024
NT-ProBNP
(pg/ml)
Baseline 6-months
0
500
1000
1500 p=0.459
NT-ProBNP
(pg/ml)
Baseline 6-months
0
500
1000
1500
2000
2500 p=0.337
 
 
Figure 28. Bar graphs representing change in NT-proBNP levels in the BMSC treated and 
control groups (top row). Bottom row shows change in NT-proBNP levels in patients receiving 
only subcutaneous G-CSF or saline injections. 
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4.4.7 Effect of BMSC therapy on patient symptoms and QoL 
4.4.7.1 Change in NYHA and CCS class 
There was a significant reduction in NYHA functional class in patients treated 
with BMSC therapy at 6-months (2.53 vs 2.01, p= 0.02) and 1-year post 
therapy (2.53 vs 2.07, p=0.04). In the control group there was also a reduction 
in NYHA class at 6-months (2.26 vs 1.80, p=0.003), however this was not 
maintained at 1-year follow-up (2.07 vs 2.26, p=0.501): 
BMSC treated group Control group
NYHA
class
Baseline 6-months 1-Year
0
1
2
3 *p=0.02
*p=0.04
NYHA
class
Baseline 6-months 1-year 
0
1
2
3
*p=0.003
p=0.501
 
Figure 29. Bar graphs representing change in NYHA class during follow-up 
 
 
 
There was no significant change in CCS angina class in the BMSC treated 
group although there was a trend towards reduction in angina in the control 
(serum) group: 
CCS
class
Baseline 6-months 1-year
0.0
0.5
1.0
1.5
2.0
p= 0.337
BMSC treated group Control group
CCS
class
Baseline 6-months 1-year
0.0
0.5
1.0
1.5
2.0
p=0.08
Figure 30. Bar graphs representing change in CCS angina class during follow-up 
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4.4.7.2 Changes in Health Related Quality of Life (HRQL) 
As described in the previous methods section, HRQL was assessed using 3 
different questionnaires, each performed at baseline, 6-months and 1-year.  
 
 
Macnew instrument 
 
The global score was calculated for each patient at the three different time-
points and the change in the mean score for each treatment group was 
assessed. In the BMSC treated group there was a significant increase in the 
mean MacNew global score from baseline to 6-months (3.8 ± 0.9 vs 4.4 ± 0.9, 
p=0.02), however there was no significant difference at the 1-year time-point. 
Interestingly, in the control (serum only) group there was a trend towards 
improved QoL at 1-year compared to baseline (4.95 ± 1.4 vs 4.2 ± 1, 
p=0.052). The data is summarised in figure 31. 
 
BMSC treated group Control group
MacNew
total Score
Baseline 6-months 1-year
0
2
4
6 p=0.349
p=0.052
MacNew
total Score
Baseline 6-months 1-year
0
2
4
6
*p=0.02
p=0.192
 
Figure 31. Bar graphs representing change in MacNew questionnaire total score during 
follow-up  
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SF-36 instrument 
 
The SF-36 questionnaire responses were scored and summarised according 
to the SF36™ Version 2 Manual. Two summary scores were obtained, the 
physical component score (PCS) and mental component score (MCS) and 
both were normalised using UK normative data 267.  
 
In the BMSC treated group the SF36-PCS improved significantly 1-year post 
treatment (29.89±15.42 vs 24.91±12.56, p=0.023) but not at the 6-month time-
point. In the control group there was no statistically significant improvement 
although there was a trend towards this. The SF36-MCS did not improve 
significantly in either group. The data is summarised in figure 32. 
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Figure 32. Bar graphs representing change in SF36 questionnaire scores during follow-up 
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EQ-5D Instrument 
 
The scores from the EQ-5D descriptive system were converted into a single 
summary index using an online calculator:  
(www.economicsnetwork.ac.uk/health/EQ_5D_index_calculator.xls). 
The visual analogue scale (VAS) scores were tabulated for each patient and 
the mean summary index score and VAS score were compared in each group 
over time.  
There was no significant change in the EQ-5D summary index score in either 
the BMSC treated or control (serum only) groups. In the BMSC treated group 
the EQ-5D VAS score improved significantly at 6-months post treatment 
(55.21±21.45 vs 45.13±20.34, p=0.035) but had declined to a similar baseline 
level by 1-year. There was no significant change in the VAS score in the 
control group. 
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Figure 33. Bar graphs representing change in EQ5D questionnaire scores during follow-up  
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Summary of HRQL questionnaire scores 
 
A summary of the numerical HRQL questionnaire scores is provided in table 6: 
 
Table 6 Health Related Quality of Life Questionnaire Scores 
 
Questionnaire Baseline 6-months 1-Year 
MacNew 
   BMSCs group 
   Serum alone group 
 
 
3.88 ± 0.97 (n=15) 
4.26 ± 1.01 (n=15) 
 
 
4.40 ± 0.91* (n=14) 
4.58 ± 1.46NS (n=15) 
 
4.03 ± 1.29NS (n=13) 
4.95 ± 1.47NS (n=13) 
SF36 v2 PCS 
   BMSCs group 
   Serum alone group 
 
SF36 v2 MCS 
   BMSCs group 
   Serum alone group 
 
 
24.91 ± 12.56 (n=15) 
29.91 ± 10.19 (n=15) 
 
 
43.43 ± 10.28 (n=15) 
41.04 ± 16.75 (n=15) 
 
27.13 ± 12.59NS (n=14) 
33.05 ± 10.51NS (n=15) 
 
 
47.50 ± 11.37NS (n=14) 
43.31 ± 15.44NS (n=15) 
 
29.89 ± 15.42* (n=12) 
34.68 ± 10.61NS (n=13) 
 
 
43.95 ± 12.63NS (n=12) 
48.80 ± 15.43NS (n=13) 
EQ5D Index Score 
   BMSCs group 
   Serum alone group 
 
EQ5D VAS Score 
   BMSCs group 
   Serum alone group 
 
0.52 ± 0.26 (n=15) 
0.54 ± 0.26 (n=15) 
 
 
45.13 ± 20.34 (n=15) 
48.36 ± 13.36 (n=15) 
 
0.54 ± 0.27NS (n=14) 
0.62 ± 0.33NS (n=14) 
 
 
55.21 ± 21.45* (n=14) 
54.00 ± 25.93NS (n=15) 
 
0.53 ± 0.41NS (n=12) 
0.64 ± 0.25NS (n=13) 
 
 
46.92 ± 25.95NS (n=12) 
55.00 ± 24.49NS (n=13) 
 
Data presented as mean ± SD 
Significance compared to baseline (NS: non-significant, *= P<0.05, significant results in bold) 
BMSCs: bone marrow stem cells; MCS: mental component score; PCS: physical component 
score; VAS: visual analogue score 
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4.4.8 Effect of progenitor cell concentration and function on 
primary and secondary end-points of study 
 
Table 7 shows the final concentration of peripheral and bone marrow 
progenitor cells in the trial patients following G-CSF mobilisation. There were 
no significant difference between the BMSC treated and control groups with 
regards to peak peripheral blood CD34+ cell concentration following 5-days of 
G-CSF therapy. There were also no differences in the final (product) 
concentration of total mononuclear cells or CD34+ cells obtained from bone 
marrow aspiration. The in vitro functional potential (colony forming units) of the 
bone marrow CD34+ cells was also similar between the two groups. 
 
 
 
Table 7. Progenitor cell concentration and function data 
 
Data presented as mean ± SD, *cells stored in the control group 
MNC: mononuclear cells 
 
 
 
 
 
 BMSC treated 
group (n=15) 
Control group* 
(n=15) 
p-value 
Peak peripheral blood 
CD34+ concentration 
(CD34+ cells/µl) 
46.22 ± 34.9 66.81 ± 72 0.328 
Total MNC/product (x106) 125 ± 89 136 ± 140 0.798 
Total CD34+ 
cells/product 
(x106) 
3.29 ± 1.37 3.37 ± 2.41 0.91 
Colony Forming Units 
(CFUs per BM CD34+ 
cell plated) 
0.07 ± 0.08 
(n=9) 
0.08 ± 0.05 
(n=8) 
0.799 
Cell viability 98.4 ± 0.7 N/A  
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There was no correlation between the total dose of mononuclear or CD34+ 
cells injected and the magnitude of change in LVEF in the BMSC treated 
group. However, there did appear to be a positive relationship between the 
magnitude of LVEF improvement and the in vitro functional potential of the 
injected CD34+ cells, measured by a colony forming unit (CFU) assay, as 
shown in figure 34: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Scatter plot and linear regression diagram demonstrating positive correlation 
between bone marrow CD34+ cell colony forming CFU potential (BM CFU) and magnitude of 
change in LVEF in patients treated with BMSC therapy.  
 
 
There were no other significant correlations between progenitor cell 
concentration/function and outcome measures. 
 
A more detailed analysis of progenitor cell concentration and function has 
been performed in the study presented in the next chapter. This includes 
analysis of all patients recruited to the REGENERATE-IHD trial and compares 
progenitor cell characteristics between the different study populations. 
BM CFU and LVEF change (BMSC treated)
BM CFU (CFU/CD34)
Change
in LVEF (%)
0.1 0.2 0.3
-10
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r=0.795
*p=0.02
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4.4.9 Effect of BMSC therapy on NOGA® measures of myocardial 
contractility and voltage potential 
4.4.9.1 Measuring endocardial voltages 
As has been described in the methods section, endocardial mapping of the left 
ventricle was performed using the NOGA® XP Cardiac Navigation System. 
The endocardial map was displayed as a bulls-eye plot (an example is shown 
in Figure 35) which divides the ventricle into 9 segments: apex, basal anterior, 
mid-anterior, basal lateral, mid-lateral, basal posterior, mid-posterior, basal 
septal and mid-septal. For each segment the mean unipolar voltage (mV) and 
local linear shortening (%) were recorded. NOGA® parameters for comparison 
between baseline and 6-months were available in 12 patients in each of the 
two treatment groups. 
 
Baseline (injection) NOGA® map Follow-up (6-months) NOGA® map
 
Figure 35. An example of a bulls eye plot of NOGA® derived unipolar voltages in a patient on 
the trial. On the left is the baseline map and on the right is the follow-up map at 6-months. In 
this patient there seems to be increased unipolar voltage at the previous injection sites 
suggesting improved viability. 
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4.4.9.2 Changes in unipolar voltage (UV) potential 
In the BMSC treated group there appeared to be possible improvement in 
unipolar voltage (UV) from baseline to 6-months (7.71±3.2 vs 7.97±3.2, 
p=0.637) although this was not statistically significant. Interestingly in the 
control (serum treated) group there was a statistically significant improvement 
in UV at 6-months post treatment (7.06±2.8 vs 7.59±3.1, p=0.02). The data is 
summarised in figure 36: 
Unipolar
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Figure 36. Bar graph representing change in overall unipolar voltage at 6-months follow-up in 
the BMSC treated and control group 
 
 
To examine this further, the change in UV was assessed separately for the 
myocardial areas that had the cells or serum injected.  As shown in figure 37, 
there did not appear to be any significant change in the injected segments. 
Unipolar
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Figure 37. Bar graph representing change in unipolar voltage in the injected myocardial 
segments 
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However, in the non-injected areas there did appear to be a trend towards 
improvement in unipolar voltage in both groups, although this did not reach 
statistical significance (figure 38).  
BMSC treated group Control group
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Figure 38. Bar graph representing change in unipolar voltage in the non-injected myocardial 
segments 
 
 
 
4.4.9.3 Changes in local linear shortening 
There was no significant change in local linear shortening in the BMSC treated 
group 6-months post treatment but in the control group there appeared to be a 
deterioration (statistically non-significant) in this parameter of mechanical 
function: 
 
BMSC treated group Control group
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Figure 39. Bar graphs representing change in local linear shortening at 6-months follow-up. 
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4.4.9.4 Accuracy of NOGA® derived cardiac function 
The data derived from the electromechanical mapping was used to calculate 
cardiac volumes and ejection fraction using an automated computer algorithm 
on the NOGA® workstation. The baseline NOGA® derived EDV, ESV and 
LVEF were compared with those obtained from the baseline MRI/CT scans. 
There appeared to be at least modest correlation between the two methods for 
assessment of cardiac volumes and function (figure 40): 
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a) b)
c)
 
Figure 40. Scatter plots demonstrating correlation between NOGA® and MRI/CT derived 
cardiac volumes and function: a) end-diastolic volume (EDV); b) end-systolic volume (ESV); c) 
left ventricular ejection fraction (LVEF). 
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4.5 Discussion 
In this double-blind randomised controlled study, combined therapy with G-
CSF and intramyocardial injection of BMSCs led to a statistically significant 
improvement in LVEF at 1-year (the primary outcome measure). The degree 
of LVEF improvement appeared to be related to the in vitro functional potential 
of injected cells. A non-significant increase in LVEF was also seen in the 
patients treated with intramyocardial injection of serum (control group). There 
was also improvement in diastolic function seen only in the cell treated group. 
There was a significant reduction in NT-proBNP levels in both groups and 
NYHA functional class was improved at 6-months in both groups but this was 
only maintained at 1-year in the cell treated group. There were significant 
improvements in HRQL questionnaire scores only in the cell treated group. 
NOGA® mapping parameters of viability and contractile function suggested 
improvement in viability after injection of serum with no obvious change in the 
contractile parameter in either group. 
 
4.5.1 Efficacy of intramyocardial injection of mobilised BMSCs 
4.5.1.1 Cardiac function 
Intramyocardial injection of mobilised BMSCs was associated with a significant 
increase in LVEF by 4.99%. The study therefore met its pre-determined 
primary end-point of an aim to detect a change in LEVF of 3.5%. This is one of 
the first RCTs of cell therapy in ischaemic heart failure to show this beneficial 
effect of BMSC therapy. Previous trials have had inconsistent results with 
earlier small non-randomised trials showing LVEF improvement237, 253 but 
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more recent randomised controlled trials (RCTs) not confirming this although 
still showing symptomatic benefit238. The most recent RCT of intramyocardial 
injection of BMSCs, the FOCUS-CCTRN257, was reported as negative for its 
primary end-points of reduction in end-systolic volume (ESV) and 
improvement in MVO2. One of the key differences of our trial protocol is the 
combination of G-CSF with direct delivery via intramyocardial injection and it is 
possible that this maybe the reason why we were able to show a positive 
result. G-CSF is known to have direct beneficial effects on cardiac tissue199, 276 
in addition to its ability to increase the number of circulating progenitor cells. 
G-CSF may also improve the functional ability of circulating progenitor cells- a 
finding we have recently published17 and demonstrated in chapter 5 of this 
thesis. This may correct for impaired cell function that has been increasingly 
recognised in older patients with ischaemic heart disease238, 249. 
 
Another possible reason why our trial was able to demonstrate an 
improvement in LVEF is the use of more sensitive imaging techniques, in the 
form of cardiac MRI or CT, compared to previous trials which used either 
echocardiography or quantitative left ventriculography (QLV). MRI and CT 
have higher spatial and temporal resolution thus reducing the variability of 
function assessment277. As can be seen in the results section, 
echocardiography and QLV failed to demonstrate any significant improvement 
in LVEF in our study even though we found a positive result using MRI/CT. 
Cardiac MRI is widely regarded as the gold standard for measuring cardiac 
volumes and LVEF in patients with heart failure, with the highest level of 
reproducibility278. Unfortunately, cardiac MRI is generally contraindicated in 
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patients with implanted cardiac devices (unless they have ‘MRI safe’ devices) 
and most patients with severely impaired cardiac function will have some form 
of device therapy (ICD ± CRT). This was the case with our study in which only 
8 out of 30 patients were able to have cardiac MRI. However, our second 
choice imaging modality, cardiac CT, performs similarly to MRI with regards to 
accuracy of LVEF measurement. For example, comparison studies, using MRI 
as the reference standard, have shown that cardiac CT is superior to both 
QLV and echocardiography for accurate and reproducible assessment of 
global LVEF272, 279.  
 
The size of our phase II trial required a surrogate marker to assess efficacy 
rather than a hard clinical end-point such as mortality. LVEF was chosen as 
the primary surrogate marker of efficacy as it has been widely used in other 
clinical trials of heart failure therapies and its value is easily appreciated by 
cardiologists and general physicians. LVEF has also consistently been shown 
to be a powerful predictor of mortality280, 281.   Furthermore, a recent meta-
analysis of drug/device interventions in heart failure found a significant 
correlation between longer therapeutic effects on mortality and short-term 
therapeutic effects of a drug or device on LVEF258. Although the magnitude in 
improvement in LVEF in our trial (4.99%) may seem small it is important to 
remember that most current medical therapy following myocardial infarction, 
which have been associated with significant long-term morbidity and mortality 
benefits, have also only been associated with a similar degree of LVEF 
improvement282. It will require an appropriately powered phase III study to 
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determine whether improvement in LVEF with BMSC therapy will also 
translate into significantly improved clinical outcomes such as mortality.  
 
The improvement in LVEF seen in our trial appears to have been mostly 
driven by an improvement in end-systolic volume (ESV). This hints at a degree 
of beneficial reverse remodelling of the left ventricle following mobilised BMSC 
cell therapy. A recent clinical trial of intramyocardial injection of mesenchymal 
stem cells showed significant improvements in cardiac volumes also 
suggesting beneficial reverse remodelling with cell therapy229. As with LVEF, 
improvement in ESV with current heart failure therapies has been shown to be 
associated with significantly better clinical outcomes283 and larger outcome 
trials will be required to determine whether this is also the case with cell 
therapy. 
 
Interestingly, although no improvement in global LVEF was demonstrated on 
echocardiography, there did appear to be some improvement in diastolic 
function assessed using the E/E’ parameter. The ratio of early trans-mitral flow 
velocity (E) to early diastolic septal mitral annulus velocity (E') has been 
shown to be the most accurate non-invasive predictor of elevated LV filling 
pressure284, 285. In our study, BMSC treated patients had a significant 
improvement in this parameter suggesting an improvement in LV end-diastolic 
pressure (EDP). This supports the finding of improved LVEF that was 
demonstrated on MRI/CT imaging, as improved contractile function would lead 
to an increase in stroke volume and thus reduction in EDV and EDP (via 
Frank-Starling mechanism, figure 1). Improvement in diastolic function with 
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BMSC therapy has been previously demonstrated in an animal model of 
chronic myocardial ischaemia161. A recent meta-analysis (including 365 
patients from 6 trials) demonstrated a significant improvement in the E/E’ 
parameter of diastolic function in patients treated with BMSC therapy following 
AMI286. Assessment of diastolic function as a marker of efficacy of cell therapy 
is likely to increase in future trials as it may provide a more subtle and earlier 
marker of improvement in cardiac function than LVEF alone287.   
 
In our study there did not appear to be a direct relationship between the dose 
of mononuclear/CD34+ cells and magnitude of improvement in LVEF in 
patients who were treated with intramyocardial injection of BMSCs. This 
supports other recent studies which suggest that dose of cells may not be a 
critical factor in treating heart failure patients with BMSCs. For example, in a 
recent study of CD34+ cells in myocardial ischaemia, both low (5x106) and 
high (10x106) dose cell injection led to comparable improvements in symptoms 
and perfusion248.  
 
However, the magnitude of improvement in LVEF in the BMSC treated group 
appeared to be related to the functional (colony forming unit (CFU)) potential 
of the bone marrow CD34+ cells. This is an interest finding that has not been 
demonstrated previously in clinical trials. It is being increasingly recognised 
that the functional capacity of BMSCs in patients with heart failure maybe 
impaired288. In a pre-clinical experiment, BMSCs from patients with ischaemic 
heart failure were shown to have reduced CFU potential and this was 
associated with impaired neovascularisation following injection in an animal 
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model of hind limb ischemia289. In the recent FOCUS-HF study, hematopoietic 
and mesenchymal CFU assays showed decreased progenitor cell activity 
particularly in patients aged above 60 years238. Furthermore, in the 
TOPCARE-CHD study, sub-study analysis demonstrated infusion of progenitor 
cells with a high CFU functional capacity was associated with a significantly 
lower mortality during further follow-up290. It appears therefore beneficial effect 
of cell therapy is related to the quality of the injected product and this may be 
a limiting factor for the use of autologous cells. There is therefore growing 
interest in the use of allogeneic cell products such as allogeneic mesenchymal 
stem cells (MSCs) which has the advantage of a more consistent quality of cell 
product and may circumvent the issue of patient related cellular dysfunction.  
 
4.5.1.2 NT-proBNP levels 
NT-proBNP levels decreased significantly in both the BMSC treated group and 
the control (serum) group. This does not appear to be solely related to G-CSF 
treatment received by both groups as NT-proBNP levels did not decrease in 
those patients who had G-CSF treatment only without intramyocardial injection 
(the peripheral arm of the REGENERATE-IHD study). Reduction in NT-
proBNP provides further evidence to suggest a beneficial biological effect of a 
combined approach of G-CSF treatment and intramyocardial injection of 
BMSCs. Current available heart failure therapy that improve ejection fraction 
also lower NT-proBNP levels291 so it is encouraging to see this combined 
therapeutic effect in the cell treated group in our trial. Furthermore, treatments 
that reduce NT-proBNP have been shown to improve clinical outcomes39. In a 
post hoc analysis of a randomised controlled trial assessing inotropic 
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intervention in acute heart failure (SURVIVE study), patients with >30% drop 
in NT-proBNP levels over five days had a 67% reduction in adjusted risk of 
death from any cause over the next month and a 47% decrease over the next 
six months 292.  
 
There is also interest in using NT-proBNP levels to guide intensiveness of 
heart failure therapy and there have been several RCTs evaluating this 
approach. In the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy 
(PROTECT) trial293, BNP guided adjustment of medications (compared to 
standard therapy) led to a significant reduction in cardiovascular events 
(worsening HF, hospitalization for HF, ACS, ventricular arrhythmias, cerebral 
ischemia, or CV death). This biomarker guided therapy approach has been 
validated in a meta-analysis of 6 RCTs comprising 1627 patients 294. Pooled 
analysis showed a significant mortality advantage for biomarker-guided 
therapy (hazard ratio was 0.69, 95% CI 0.55-0.86) compared to control. 
 
Hence, the reduction in NT-proBNP levels seen in our study may represent a 
clinically significant finding and warrants further investigation in future clinical 
trials, particularly in regards to correlation with clinical outcomes. 
 
4.5.1.3 Symptoms and health related quality of life (HRQL) 
It is encouraging to see that in addition to the improvement in cardiac function 
and NT-proBNP levels there were also significant improvements in symptoms 
and HRQL in patients treated with BMSC therapy. Although NYHA function 
class also improved at 6-months in the control group, this effect was only 
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maintained in the cell treated group at 1-year. Also improvements in the HRQL 
questionnaire scores were only seen in the cell treated group.  
 
The use of the NYHA functional class provides a simple tool of assessing 
patients’ symptomatic response to a therapy although has limitations of being 
subjective with only 4 possible outcomes (class I-IV). The use of standardised 
HRQL questionnaires improves the accuracy of assessing symptomatic 
response and the three questionnaires used in our study have been well-
validated for assessing the response of interventions in patients with cardiac 
disease. Given the high morbidity and mortality associated with heart failure 
there is increasing use of HRQL questionnaires as primary and secondary 
end-points in clinical trials in this setting295. Improvements in HRQL have been 
demonstrated in recent clinical trials of cell therapy in patients with heart 
failure and in some cases this has been without evidence of significant 
improvement in cardiac function238, 257. The use of quality of life as an outcome 
measure is also important as it provides healthcare service providers with a 
tool to assess the cost/benefit of potentially approving this novel therapy for a 
broad group of heart failure patients. 
 
4.5.2 Efficacy of intramyocardial injection of autologous serum  
 
Interestingly, the trial results appear to suggest signs of efficacy in the control 
group i.e. patients who received G-CSF followed by intramyocardial injection 
of autologous serum alone. The serum was obtained by peripheral 
venesection after 5-days of G-CSF treatment, at the time of bone marrow 
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aspiration, and was used either as suspension medium for the BMSCs in the 
active treatment group or was injected alone in the control group. Patients in 
the control group showed significant improvement in NT-proBNP levels at 6-
months and there was also a trend towards improvement in ejection fraction 
and symptoms (NYHA class and CCS angina class). 
 
The potential reasons for improvement seen in the control group include: 
a) chance alone 
b) placebo effect 
c) confounding effect of G-CSF 
d) biological efficacy of autologous serum  
e) biological effect of needle puncture of the myocardium 
f) mechanical effect of ‘material’ injection into the myocardium 
 
Placebo effect is unlikely given that there was an objective measure of 
improvement in the control group with statistically significant reduction in NT-
proBNP levels. This is also unlikely to happen by chance in patients who have 
been clinically stable and on optimal medical therapy with no medication 
changes during follow-up. It is possible that the improvement maybe related to 
G-CSF therapy as all patients, including the control group received this.  
However, as shown in figure 28, there was no improvement in NT-proBNP 
levels in patients in the peripheral arm of the REGENERATE-IHD study who 
received G-CSF alone without intramyocardial injection. Therefore, this 
provides evidence that there maybe a positive biological effect of the 
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combined approach of G-CSF treatment and intramyocardial injection of 
serum (which may contain beneficial soluble paracrine factors). 
 
BMSCs produce a wide range of cytokines and chemokines (including VEGF, 
FGF-2, IL-6, PIGF, and MCP-1) that have shown extensive therapeutic 
potential296. These paracrine mechanisms could be as diverse as stimulating 
receptor-mediated survival pathways, inducing stem cell homing and 
differentiation or regulating the anti-inflammatory effects in infarcted areas177. 
There have been preclinical experiments examining the potential benefit of 
these soluble factors secreted by BMSCs. In a rat model of AMI, 
intramyocardial injection of conditioned medium alone improved LVEF to a 
similar extent as bone marrow derived MSC injection although histological 
evaluation showed that the infarct wall thickness was significantly greater in 
the MSC treated group296. Another preclinical experiment in a rat AMI model 
also investigated if soluble factors secreted by MSCs could promote 
cardioprotection297. In rats injected with conditioned medium there was a 
significant reduction in left ventricular end-diastolic pressure and improvement 
in cardiac contractility. The group also assessed in vitro cardioprotection in 
neonatal ventricular cardiomyocytes by quantifying apoptosis after 24 hours of 
serum deprivation associated with hypoxia (1% O2) in absence or presence of 
conditioned medium. The in vitro results showed that conditioned medium was 
able to decrease cardiomyocyte necrosis. These results suggest that soluble 
factors released in vitro by MSCs are able to promote cardioprotection in vitro 
and improve cardiac function in vivo297. Therefore it is possible that the 
potential efficacy of intramyocardial injection of autologous serum seen in our 
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study represents the action of soluble paracrine factors which are likely to be 
present in the serum. Ideally, we would have measured the concentration of 
some of these paracrine factors in the serum being injected and this is the 
subject of ongoing work within the department 
 
An alternative hypothesis is the potential beneficial effect of needle puncture 
of the myocardium alone. Direct myocardial revascularisation (DMR) 
procedures using various mechanical devices and energy sources (e.g. laser) 
have been explored as possible options to produce therapeutic angiogenesis 
in patients with refractory angina with no targets for conventional 
percutaneous or surgical revascularisation298, 299. It has been suggested that 
the likely mechanism associated with the initiation of angiogenesis is the 
induction of local inflammatory processes, and that tissue changes trigger 
expression of variety of angiogenic cytokines which initiate and maintain 
microvessel collateral formation300. Growing clinical experiences derived from 
DMR procedures indicate symptomatic benefit despite inconsistent or lack of 
improvement in myocardial perfusion. In particular, needle insertion has been 
proposed by several investigators to induce angiogenic responses301, 302.  
 
Finally, the possibility of a mechanical beneficial effect of ‘material’ injection 
into the myocardium has been raised. In an elegant study, utilising a validated 
finite element model of an ovine left ventricle with an anteroapical infarct, 
researchers examined the short-term effect of injecting ‘material’ (volume 
ranging from 0.5-1.5ml) into the peri-infarct border zone. The results of 
simulated injections indicated that the addition of non-contractile material  to a 
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damaged left ventricular wall has important effects on cardiac mechanics, with 
potentially beneficial reduction of elevated wall stresses, as well as changes to 
clinical parameters of left ventricular function such as LVEF303. This suggests 
both the significant potential for therapeutic application of material implantation 
to the myocardium as well as potential confounding mechanical effects. 
Further pre-clinical work is ongoing to validate this hypothesis. 
 
4.5.3 Changes in NOGA® electromechanical parameters  
The NOGA® endocardial electromechanical mapping system used in this trial 
enables measurement of endocardial electrical, unipolar voltage (UV), and 
mechanical, local linear shortening (LLS), function. Normal myocardial cells 
deliver a resting UV potential of 15 mV, whereas voltage values less than 6.9 
mV reflect scar tissue; potentials between 7mV and 15 mV suggest viable 
myocardium223, 304.  The cut-off threshold level for normal LLS ratios has 
varied between clinical studies, from 9%304 to 12%305. Regions of 
akinetic/dyskinetic scar are easily delineated by their very low shortening ratio 
(LLS <2–3%)223, while intermediate values (between 3-9%) likely represent  
hibernating myocardium with reversible ischemia306. Measurement of UV and 
LLS enables targeted delivery of BMSCs to hibernating myocardium around 
an area of scar tissue- this is important as BMSCs do not engraft well into 
scarred myocardium224. Furthermore, follow-up mapping procedures may 
allow assessment of changes in UV and LLS as surrogate markers of efficacy 
of cell therapy235, 307. 
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The NOGA® mapping data in this thesis shows a statistically significant 
improvement in overall mean UV (suggesting improved viability) following 
intramyocardial injection of autologous serum (control group).  The BMSC 
treated group also appeared to show possible improvement but this was not 
statistically significant. Exploring this further it appears that the UV 
improvement occurred in the non-injected segments in both groups. Previous 
studies that have performed follow-up NOGA® mapping after BMSC therapy 
have actually shown UV improvement only in the cell injected regions308, 309.  
The suggestion of improvement in non-injected segments seen in our study 
may support the hypothesis of a paracrine effect of the cells/serum on 
adjacent myocardial segments. As discussed previously, paracrine effects of 
BMSCs could include neoangiogenesis151 or stimulation of resident cardiac 
stem cells165. The LLS data did not show any statistically significant changes 
6-months post-treatment although there appeared to be a suggestion of 
deterioration in mechanical function in the control group.  
 
It is difficult to explain why the improvement in UV was statistically significant 
only in the serum treated group and not the cell (suspended in serum) treated 
group. The most plausible reason is likely sample size and the small number 
of patients studied and it is possible that with more patients the improvement 
in the cell treated group may also have been significant. This is supported by 
the finding of a trend towards improvement in the non-injected myocardial 
segments in both groups. The data in this analysis is interesting although must 
be interpreted cautiously as the trial was not powered to detect any changes in 
NOGA® parameters. Also the number of patients in our study are fewer than 
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other studies that have specifically assessed NOGA® parameters. A limitation 
of the diagnostic performance of NOGA® is potential inaccuracy of the 
mapping procedure due to cardiac motion which can be further confounded by 
respiratory variation and subject movement. Also, as NOGA® does not 
provide visual verification of inter-ventricular septal position, variations of 
cardiac anatomy and orientation within the thorax may not be identified 
resulting in possible misrepresentation of LV segments. Furthermore, the 
accuracy and clinical value of comparing NOGA® derived mapping data 
between baseline and follow-up procedures as surrogate markers of treatment 
efficacy remains to be validated. Nevertheless, it is reassuring to see that 
there was reasonable correlation between NOGA® and MRI/CT for the 
assessment of cardiac volumes and function (figure 40) which suggests that 
the mapping procedure was relatively accurate and complete. 
 
4.5.4 Feasibility of intramyocardial injection of mobilised BMSCs 
All patients completed the G-CSF mobilisation phase. However, 4 patients 
who were initially allocated to receive intramyocardial injection of BMSCs had 
to be re-allocated to the intracoronary arm of the trial as they were found to 
have LV thrombus (3) or too high risk LV anatomy (1) on baseline imaging. 
This represents one of the limitations of NOGA® guided intramyocardial 
injection compared to intracoronary injection as there are certain anatomical 
considerations which make intramyocardial injection unsafe.  A retrospective 
analysis (see appendix A) of our own REGENERATE-IHD study population 
revealed an 11.3% incidence of previously undetected LV thrombus. The 
adherence to randomisation could have been improved by baseline imaging 
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prior to randomisation to assess for presence of LV thrombus and to 
accurately delineate the endocardial anatomy. This will be particularly 
important as larger Phase III trials are designed and it maybe prudent to 
screen patients for LV thrombus prior to enrolment. The NOGA® mapping and 
intramyocardial injection was generally well tolerated with only one patient (out 
of 32 attempted) not being able to be complete treatment due to ventricular 
arrhythmia. The other patient who did not complete treatment after NOGA® 
mapping was actually found to have normal myocardial voltages with no area 
of scar tissue. This patient was withdrawn and this may be an advantage of 
the NOGA® procedure as it can confirm the presence of previous myocardial 
infarction and ensure the right patients are being treated in the setting of a 
trial. 
 
4.5.5 Safety of intramyocardial injection of mobilised BMSCs 
The bone marrow mobilisation with G-CSF phase of treatment (days 1-5) was 
well tolerated in all the patients with no major adverse events. Expected side 
effects such as bone pain and pyrexia were seen in a small proportion of 
patients. The NOGA® mapping and intramyocardial injection procedure was 
generally safe. There was only one incidence of pericardial effusion which 
resolved with conservative management. This is in keeping with the published 
incidence from other studies. There was no incidence of acute or short-term 
cerebrovascular events and it is possible that the exclusion of patients with LV 
thrombus detected on baseline imaging helped prevent ischaemic embolic 
events. 
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Overall mortality at 1 year was low with only 1 death, 3.3% of the whole 
cohort. This compares favourably with the 5.5% predicted risk of 1-year 
mortality for this particular group of patients which was calculated using the 
Seattle Heart Failure Model prediction tool 310. This is a well validated model 
for predicting survival in patients with heart failure which was derived by 
retrospectively investigating predictors of survival among 1,125 heart failure 
patients. This multivariate risk model identified age, gender, ischemic etiology, 
NYHA, ejection fraction, systolic blood pressure, K-sparing diuretic use, statin 
use, allopurinol use, hemoglobin, % lymphocyte count, uric acid, sodium, 
cholesterol, and diuretic dose/kg as significant predictors of survival. 
 
There is increasing evidence to suggest that BMSC therapy may lead to 
improved hard clinical outcomes, such as mortality, in addition to improvement 
in cardiac function and symptoms. For example in the STAR-Heart241 study of 
intracoronary infusion of BMSCs in patients with heart failure, there was a 
0.75% per year mortality rate in the cell treated group compared to 3.68% per 
year in the control group (P<0.01) during 5-year follow-up. Furthermore, a 
recent meta-analysis of trials of BMSCs in AMI and IHD, comprising 50 studies 
and 2,625 patients, has shown significantly lower all-cause and cardiac 
mortality in those patients treated with BMSCs compared to controls311. These 
signals from Phase II trials and meta-analysis need to be confirmed and a 
large multi-centre Phase III trial involving 3000 patients receiving BMSC 
therapy following AMI (BAMI trial) has been designed to answer this question 
(ClinicalTrial.gov Identifier NCT01569178).  
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4.6 Study limitations  
The results of this study should be cautiously interpreted as it is a phase II 
study with a relatively small number of patients and uses LVEF as a surrogate 
marker of efficacy for stem cell therapy. The main strength of the 
REGENERATE-IHD trial is the double-blind randomised controlled study 
design. However, the control group in the intramyocardial arm also received 
G-CSF therapy and injection of autologous serum which may have led to a 
biological effect and may explain why there appears to be some signs of 
efficacy in this group. Ideally we would like to have had an additional ‘true’ 
placebo arm where patients received intramyocardial injection of saline so that 
we could explore whether the improvement in NT-proBNP and symptoms in 
the control arm were due to injection of serum or whether this was due to 
‘needle’ effect. It would also have been interesting to measure the 
concentration of soluble paracrine factors such as VEGF in the autologous 
serum of patients undergoing treatment. Finally, although we have 
demonstrated subjective improvement in symptoms and quality of life we 
would ideally have assessed patients’ functional improvement objectively with 
tests such as MVO2 exercise testing or the 6-minute walk test. 
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CHAPTER 5: A STUDY OF PROGENITOR CELL 
CHARACTERISTICS 
 
5.1 Study Rationale 
Although the relative safety of BMSC therapy in cardiac disease has been 
demonstrated, clinical effectiveness has been less consistently shown 236, 239, 
312
. Potential reasons for this include heterogeneity in patient selection and 
clinical trial design. Studies have varied with regards to use of peripherally 
harvested progenitor cells (PBSCs) or BMSCs and have also differed as to 
whether cells have been mobilised with G-CSF or not. Furthermore, the 
number and functional ability of bone marrow progenitor cells has been shown 
to be reduced in patients with advanced heart failure and ischaemic heart 
disease289. In particular, aging has been recognised to adversely affect the 
functional capacity of progenitor cells313 and the mobilising ability of G-CSF314.  
Hence, as the number of clinical trials using autologous cells continues to 
increase, a need has been identified for further mechanistic studies that 
include analysis of cellular composition and function of the BMSC infusate. 
 
The previous chapter presented the results of the intramyocardial arm of the 
REGENERATE-IHD study. We are currently performing two other randomised, 
double-blind placebo-controlled trials in patients with dilated cardiomyopathy 
(REGENERATE-DCM315, clinicaltrials.gov identifier NCT01302171) and acute 
myocardial infarction (REGENERATE-AMI, clinicaltrials.gov identifier 
NCT00765453). The IHD and DCM studies investigate the effects of G-CSF 
alone or in combination with intracoronary or intramyocardial delivery of 
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autologous BMSC therapy on cardiac function and quality of life in patients 
with symptomatic heart failure and no further treatment options. The AMI study 
assesses the safety and efficacy of early delivery of intracoronary BMSC in 
patients treated with primary stenting for acute myocardial infarction. Our 
studies therefore provide an ideal platform to assess the relationship between 
age and cardiac disease state on the concentration of peripheral and bone 
marrow progenitor cells as well as the response to G-CSF mediated 
mobilisation.  
 
5.2 Methods 
5.2.1 Objectives 
This is an exploratory analysis of progenitor cell characteristics in patients 
recruited to three randomised controlled clinical trials of BMSC therapy in 
patients with ischaemic heart failure (IHD), dilated cardiomyopathy (DCM) and 
acute myocardial infarction (AMI). Specifically, we assess the impact of age, 
disease state and G-CSF on progenitor cell concentration and function. 
5.2.2 Subjects 
Peripheral blood and bone marrow samples were obtained from 201 patients 
recruited to the REGENERATE- IHD, DCM and AMI trials. All patients in the 
AMI analysis had a bone marrow sample for analysis. In the IHD/DCM trials a 
proportion of patients were randomised to receive only G-CSF/placebo (saline) 
so did not have a bone marrow sample for analysis. The Local Research 
Ethics Committee has approved the protocols of all three trials which are 
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conducted in accordance with the Declaration of Helsinki. Written informed 
consent has been obtained from each patient prior to inclusion in the trial, 
including consent for biochemical and cellular analysis of peripheral blood and 
bone marrow.  
 
5.2.3 Progenitor cell mobilisation with G-CSF 
Recombinant human G-CSF (Granocyte®, Chugai Pharma, UK) was 
administered subcutaneously at a dose of 10 µg/Kg/day for 5 consecutive 
days to patients enrolled in the DCM and IHD studies. Patients in the control 
group received saline injections. A peripheral blood sample was obtained on 
days 0, 1, 2, 3, 6 and 7 for estimation of peripheral progenitor cell counts. 
Patients in the AMI trial did not have G-CSF treatment and a single peripheral 
blood sample was taken for estimation of baseline progenitor cell count. 
 
5.2.4 Bone marrow aspiration 
Bone marrow aspiration was performed on day 6 in patients enrolled to the 
DCM and IHD studies who had been randomised to receive intracoronary 
injection of cells/placebo. Patients in the DCM/IHD studies who were 
randomised to receive only G-CSF or placebo did not have bone marrow 
aspiration performed. In the AMI study bone marrow aspiration was performed 
within 12 hours of successful primary stenting for acute myocardial infarction. 
Aspiration was performed from the posterior superior iliac spine. 100mls of 
bone marrow was collected in 20 10mls syringes- each syringe contained 1ml 
of heparin into which 5 ml of bone marrow was aspirated. The bone marrow 
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samples, together with peripheral blood, were then delivered immediately to 
the Barts Health NHS Trust Stem Cell Laboratory, which is an accredited 
facility for the production of cellular therapeutic material. Isolation and 
characterisation of the bone marrow mononuclear cell (BM-MNC) fraction was 
performed by a designated lab technician (Natalie Saunders). 
 
5.2.5 Isolation of BM-MNCs 
Bone marrow aspirates from the heparin-treated syringes were pooled into a 
single transfusion bag. The entire volume was then passed through a blood 
component transfusion set with a 200µm filter. Autologous BM-MNCs were 
isolated by Ficoll-Paque (GE Healthcare, Uppsala, Sweden) density gradient 
centrifugation and the heparin was washed off at this stage. 
 
5.2.6 Flow cytometry analysis  
BM-MNCs were characterised using flow cytometry. All flow cytometry 
analyses were performed using a BD FACSCanto Flow Cytometer with BD 
FACSDiva v 5.0.3 software (BD Biosciences). For the identification of HSC 
populations, cells were incubated with fluorescein isothiocyanate (FITC)-
labeled antibody against human CD45 (BD Biosciences, Erembodegem-
AALST, Belgium) and phycoerythrin (PE)-labeled antibody against human 
CD34 (BD Biosciences) for 15 min at room temperature. 
 
EPCs were analysed by initially incubating samples with mouse serum IgG 
(Sigma, Dorset, UK) for 15 min at 4oC with a cocktail of antibodies comprising 
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allophycocyanin (APC)-labelled antibody to CD133 (Miltenyi Biotec, Surrey, 
UK) and PE-labelled antibody to VEGFR-2 (R&D Systems, Abingdon, UK) to 
characterise EPCs and FITC-labelled monoclonal antibodies to CD2, CD13 
and CD22 (Beckman Coulter, High Wycombe, UK) to identify and therefore 
eliminate inclusion of lineage-negative non-progenitor cells. To ensure 
exclusion of nonviable cells in the final EPC count, cells were also incubated 
with a PerCP-Cy5-labelled 7AAD stain (BD Biosciences). Cells were then 
incubated for 15 min at room temperature with 2ml of Pharm Lyse™ buffer 
(BD Biosciences) to lyse red blood cells. Samples were washed once in 
phosphate-buffered saline and 20µl of Accucount flow cytometry beads 
(Saxon Europe, Kelso, UK) were added before analysis. 
 
5.2.7 Colony-forming unit (CFU-GM) analysis  
BM-MNCs (2x104 per dish), Day 0 peripheral blood MNCs (2x105 per dish), 
and Day 6 peripheral blood MNCs (2x104 per dish) were seeded, in triplicate 
preparations, in methylcellulose plates (Methocult H4534, including stem cell 
factor, granulocyte-macrophage colony–stimulating, and interleukin-3, Stem 
cell Technologies). Plates were studied under phase-contrast microscopy, and 
granulocyte-macrophage colony forming units (CFU-GM; colonies >50 cells) 
were counted after 14 days of incubation.  Results were taken from the mean 
of the triplicate results and presented as a ratio of CFU per CD34 cell plated. 
CFU assays were performed in 25 IHD, 10 DCM and 12 AMI patients due to 
availability of assay.  
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5.2.8 Statistical analysis 
Data are expressed as mean ± SD unless otherwise stated. Comparison of the 
distributions of a continuous variable between two independent groups was 
performed using an unpaired two-sided t-test. Correlation was assessed using 
the Pearson r method and a p-value calculated using linear regression. 
Analysis of covariance (ANCOVA) was used to assess for confounders. A p-
value of less than 0.05 was assumed to indicate statistical significance. CD34+ 
stem cell counts are expressed as units per µL (U/µl) and EPC count is 
expressed as cells per µl (EPC/µl). CFU results have been presented as a 
ratio of CFUs per CD34 cell plated (CFU/CD34 cell). Statistical analysis was 
performed with GraphPad Prism version 5.0 (GraphPad Software, San Diego, 
CA, USA) and SPSS 19 (IBM). 
 
5.3 Results 
5.3.1 Baseline characteristics 
We assessed the progenitor cell counts in 201 patients: 110 IHD, 38 DCM and 
53 AMI peripheral blood (PB) samples and 78 IHD, 17 DCM and 53 AMI 
matching bone marrow (BM) samples. Baseline characteristics of all patients 
are shown in Table 8. Patients in the REGENERATE-IHD study were 
significantly older, had a higher incidence of diabetes and were more likely to 
be taking a statin.   
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Table 8. Baseline characteristics of all patients 
 
REGENERATE-
IHD (n= 110) 
REGENERATE-
DCM (n=38) 
REGENERATE-
AMI (n=53) 
p-value 
Age, years 64 ±  9.7 55 ± 9.5 56 ± 10.5 <0.0001 
Male sex, No (%) 105 (95%) 28 (77%) 49 (92%) 0.0003 
Medical history 
   Diabetes (%) 
   Previous MI (%) 
 
30 (27%) 
110 (100%) 
 
3 (8%) 
0 
 
5 (9%) 
3 (5.6%) 
 
0.0038 
<0.0001 
LVEF (%) 33±11 N/A N/A  
Total cholesterol 
(mmol/l) 
4.2 ± 1 5.2 ± 1.4 5.3 ± 1.2 <0.0001 
NT-proBNP 
(pg/ml) 
1286 ± 2151 1177 ± 1489 N/A NS 
Medications at 
recruitment  
    Statins 
    ACEI/ARB 
    β-blocker 
    Aldosterone  
    antagonist             
 
 
97 (88%) 
99 (90%) 
98 (89%) 
75 (68%) 
 
 
15 (40%) 
38 (100%) 
30 (79%) 
25 (65%) 
 
 
7 (13%) 
6 (11%) 
1 (2%) 
0 
 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Data presented as number (% of patients) or mean ± SD. p-value represents ANOVA 
test of difference between the three groups. LVEF: left ventricular ejection fraction; 
N/A: not applicable; NS: not significant.  
 
 
5.3.2 Effect of age on progenitor cell number and function 
We found an inverse relationship between age and PB CD34+ cell 
concentration (r=0.2, p=0.02) (Figure 41a) in the whole study group (n=201). 
There was a trend towards an inverse relationship between age and EPC cell 
concentration but this was not statistically significant (Figure 41b).  
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Figure 41. Correlation between age and peripheral blood progenitor cell concentration in the 
whole study group. a) There was a significant inverse relationship between age and CD34+ 
cell concentration. b) There was a trend towards an inverse relationship between age and 
EPC cell concentration but this was not statistically significant.  
 
 
We also explored the effect of age on the mobilising ability of G-CSF in the 
chronic ischaemic heart failure (IHD) patient group. The median age of 64 
years was used to divide the patients into two groups. We found that the older 
age group had a lower concentration of CD34+ cells in the bone marrow 
following mobilisation with G-CSF (75.49±64.49 CD34 U/µl versus 
113.5±61.03, p=0.0023) (Figure 42a). There was also a trend (p=0.09) 
towards lower percentage increase in circulating CD34+ cells (day 6 
compared to day 0) with G-CSF in those aged above 64 years (Figure 42b). 
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Figure 42. Effect of age on progenitor cell counts following G-CSF. a) There was significantly 
lower CD34+ cell concentration in the bone marrow of ischaemic heart failure patients aged 
over 64 years. b) There was a non-significant trend towards impaired peripheral mobilisation 
of CD34+ cells in patients aged above 64 years as measured by %increase in cells from 
baseline to day 6. 
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5.3.3 Correlation between other clinical parameters and progenitor 
cell concentration 
We did not find any statistically significant independent correlations between 
other clinical parameters and peripheral or bone marrow progenitor cell 
concentrations in the three cohorts of patients investigated (Figure 43). Renal 
impairment appeared to have an inverse correlation with bone marrow CD34+ 
progenitor cell concentration in patients with chronic ischaemic heart failure 
although this was not independently significant following multiple regression 
analysis, possible due to confounding between age and renal impairment. 
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Figure 43. Selected scatter plots demonstrating bivariate relationship between clinical 
parameters and progenitor cell counts. a) left ventricular ejection fraction (LVEF) and 
peripheral blood CD34+ cell concentration in ischaemic heart failure; b) eGFR and bone 
marrow CD34+ cell concentration in ischaemic heart failure; c) NT-ProBNP and peripheral 
blood CD34+ concentration in dilated cardiomyopathy; d) peak troponin T level and peripheral 
blood CD34+ concentration in acute myocardial infarction. 
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5.3.4 Effect of disease state on progenitor cell number and function  
The concentration of circulating CD34+ and EPCs was found to be 
significantly higher in the baseline peripheral blood of DCM patients as 
compared to IHD patients (3.4±2.1 CD34+ U/µl versus 2.6±1.9, p=0.033, and 
0.06±0.1 EPCs/µl versus 0.01±0.03, p<0.0001) (Figure 44a+b). This remained 
significantly different after adjusting for age, diabetes and total cholesterol. In 
AMI patients the number of circulating EPCs was also significantly lower 
compared to DCM patients but similar to IHD patients. Despite there being a 
higher circulating CD34+ cell count in the DCM patients the CFU potential was 
not significantly different (Figure 44c).  
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Figure 44. Comparison of baseline concentration of a) circulating CD34+ and b) EPCs in the 
peripheral blood of dilated cardiomyopathy(DCM), ischaemic heart failure (IHD) and acute 
myocardial infarction (AMI). c) colony forming units (CFU) in the peripheral blood of the three 
different patient cohorts. 
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5.3.5 Effects of G-CSF mobilisation 
The G-CSF treatment (10µg/kg/day for 5 days) led to a substantial and 
comparable increase in the peripheral concentration of CD34+ cells in both 
IHD and DCM patients, day 6 mean concentration of 52.3 CD34 U/µl 
compared to 2.7 CD34 U/µl on day 0 (Figure 45). There was no significant 
increase in cell concentration in patients who received saline injection only 
(day 6 concentration of 2.7 CD34 U/µl from baseline of 2.2 CD34 U/µl). 
REGENERATE-IHD
CD34 U/ul
Da
y 0
Da
y 1
Da
y 2
Da
y 3
Da
y 6
Da
y 7
0
20
40
60
80
REGENERATE-DCM
CD34 U/ul
Da
y 0
Da
y 1
Da
y 2
Da
y 3
Da
y 6
Da
y 7
0
20
40
60
80
 
Figure 45. Effects of G-CSF on peripheral blood CD34+ cell counts in ischaemic heart failure 
(left) and dilated cardiomyopathy (right) showing comparable increase in circulating progenitor 
cells with a similar peak on day 6. 
 
The progenitor cell count in the bone marrow of IHD and DCM patients was 
similar following treatment with G-CSF. The increase in bone marrow 
progenitor cell counts following G-CSF mobilisation can be appreciated by 
comparing the IHD and DCM bone marrows with that of AMI patients who did 
not receive G-CSF (Figure 46). 
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Figure 46. Comparison of bone marrow progenitor cell counts in the three different cohorts 
showing significantly higher bone marrow progenitor cell concentration with 5-days G-CSF 
treatment (DCM and IHD patients) compared to no G-CSF (AMI patients). 
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The concentration of CD34+ cells in the bone marrow aspirated on day 6 was 
significantly higher than in the peripheral blood on the same day (Figure 7 
a+b). However, CFU functional assessment (Figure 47c) suggests that 
peripheral blood cells appear to be more functionally active than bone marrow 
cells (0.15±0.14 CFU/CD34 cell versus 0.08±0.05, p=0.0081). Furthermore the 
CFU/CD34 cell ratio in the peripheral blood increases significantly with G-CSF 
(Figure 47d) suggesting mobilisation of functionally active progenitor cells.  
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Figure 47. Comparison of peripheral blood and bone marrow CD34+ concentration following 
G-CSF mobilisation in a) IHD patients and b) DCM patients.  The concentration of cells is 
higher in bone marrow in both ischaemic heart failure and DCM. c) Comparison of functional 
activity of progenitor cells following G-CSF mobilisation between peripheral blood and bone 
marrow showing significantly higher CFU/CD34 cell in peripheral blood. d) Comparison of 
CFU/CD34 cell in peripheral blood at baseline and day 6 showing a significant increase in 
functional ability of circulating progenitor cells following G-CSF mobilisation. 
 
5.4 Discussion  
The past decade has seen a large increase in the number of clinical trials 
being performed to assess the safety and efficacy of BMSC therapy for 
cardiac disease. Only a few of these studies have examined progenitor cell 
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concentration and function in recruited patients 238, 290, 316, an important 
consideration given the varying degrees of efficacy demonstrated. The data 
from this present study confirm previous reports of an inverse relationship 
between age and PB CD34+ cell concentration in patients with cardiac 
disease (Figure 41). We have also shown that, in ischaemic heart failure 
patients, the concentration of BM CD34+ progenitor cells, following G-CSF 
mobilisation, is lower in patients aged above the median age of 64 years 
(Figure 42a). There was also a trend towards reduced peripheral mobilisation 
by G-CSF in the older age group (Figure 42b). The adverse effects of age on 
progenitor cell number and function has been increasingly recognised 313. In 
healthy individuals and patients with coronary artery disease, increasing age is 
associated with reduced number and function of cultured EPCs and CD34+ 
cells in the bone marrow 313, 317. Older age is also associated with significantly 
reduced BM derived progenitor cell mobilisation in patients after AMI 318.  In 
the recent FOCUS-HF study of intramyocardial injection of BM-MNCs in 
ischaemic heart failure 238, the number and function of progenitor cells was 
significantly higher in patients ≤60 years than in patients >60 years. 
Interestingly, following treatment objective evidence of improvement (by 
MVO2) was only seen in the patients <60 years. Hence, the impact of age on 
bone marrow progenitor cell number and function may limit the efficacy of cell 
therapy in some patients. This may in part explain some of the discrepant 
clinical trial results and further work is required to identify the age group of 
patients that will derive most benefit of cell therapy.  
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We have also shown that concentration of circulating CD34+ cells and EPCs 
are higher in patients with DCM than in those with ischaemic heart failure 
(Figure 44a). The number of circulating EPCs is also lower in AMI patients 
compared to DCM (Figure 44b). This is consistent with previous reports 
showing circulating EPCs inversely correlate with number of risk factors for 
coronary artery disease 249. Although there was a higher concentration of 
circulating CD34+ cells in DCM patients, the CFU analysis suggested that 
there was no difference in functional capability. It is possible that this finding 
maybe due to an adverse effect of heparin on progenitor cell function as has 
been recently reported by Professor Zeiher’s group (unpublished data), 
although our data is based on a small number of CFU assays and heparin 
exposure was similar across all samples. The difference in circulating 
progenitor cells between ischaemic heart failure and DCM has not previously 
been demonstrated suggesting that the atherosclerotic process rather than 
chronicity or severity of disease is the important determinant of the progenitor 
cell concentration. 
 
G-CSF has been used to mobilise bone marrow progenitor cells in patients 
with cardiac disease either on its own, as adjuvant therapy with peripheral 
leukapheresis (peripheral blood stem cells, PBSCs) or bone marrow harvest 
and subsequent direct delivery of progenitor cells to the heart 319-321. It is still 
debated whether G-CSF  treatment leads to an increase in progenitor cells in 
the bone marrow in addition to the mobilisation of these cells into the 
peripheral blood.  Studies in patients undergoing myeloablative therapy 
suggest that transplantation of mobilised allogeneic PBSCs may lead to an 
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earlier recovery in bone marrow function compared to cells obtained from a 
marrow harvest322, 323. Our data shows that the concentration of CD34+ cells 
in the bone marrow following 5-days of G-CSF treatment is higher than in the 
peripheral blood on that day (Figure 47a+b). Conversely, CFU analysis 
suggests significantly higher functional potential of the CD34+ cells in the 
peripheral blood compared to bone marrow (Figure 47c).  Several studies 
have suggested that cytokines can shift early repopulating stem cells out of 
the marrow into the peripheral blood.  A pre-clinical study found that after 5 
days of G-CSF, mice had only 25% of the baseline long-term repopulating 
stem cells in the marrow 324 and in another experiment prolonged G-CSF 
administration to mice led to a depletion of primitive BM stem cells325.  
 
In contrast to bone marrow transplantation following myeloablative therapy, 
there is yet to be a published clinical trial comparing the safety and efficacy of 
mobilised PBSC versus mobilised BMSC for the purposes of cardiac repair. 
There have however been clinical studies comparing the relative efficacy of ex 
vivo expanded PBSCs and non-mobilised BMSCs. The recent HEBE trial 312 
found no improvement in global or regional LV function with either 
intracoronary PBSC or BMSC compared to standard therapy. In contrast to 
this, the earlier TOPCARE-AMI study 154 found significant beneficial effects of 
both PBSCs and BMSCs on LV function. The same group also compared the 
efficacy of intracoronary BMSCs or PBSCs in patients with chronic ischaemic 
heart failure in the TOPCARE-CHD study 10. In this study, only BMSCs 
appeared to have a beneficial effect on improving LV function with no 
significant effect of PBSCs. The potentials reasons given for this include the 
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smaller number of progenitor cells derived from peripheral blood as well as the 
fact that circulating progenitor cells are known to be reduced in number and 
function in patients with heart failure 326. The PBSCs were not mobilised with 
G-CSF prior to harvest which could have led to a positive effect, particularly as 
our study shows that G-CSF can lead to mobilisation of functionally active 
cells (Figure 47d).  
 
Our findings are clinically important and indicate that further work is required to 
define whether peripheral or bone marrow harvest of progenitor cells is best 
for treating patients with heart failure. The possibility that pre-treatment with G-
CSF may correct for deceased CFU potential and hence regenerative capacity 
of cells from patients with ischaemic heart disease is an important observation 
that needs further investigation. 
 
5.5 Study Limitations 
This is an exploratory analysis which limits the conclusions that can be drawn 
but at the same time generates interesting hypotheses to be examined in 
future studies. Our study is limited by the lack of a true normal patient control 
group for comparison although the comparison between disease states 
provides valuable information. Our analysis is also limited by the lack of CFU-
GM assays being performed in all the patients analysed; this was due to an 
issue with availability.  
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CHAPTER 6: ANGIOGENESIS IMAGING STUDY 
 
6.1 Study Rationale 
6.1.1 Angiogenesis as a mechanism of cell therapy 
The mechanism(s) of action of cell therapy are yet to be fully elucidated. There 
are likely to be several other beneficial effects in addition to potential 
transdifferentiation of delivered cells into cardiomyocytes. One proposed 
mechanism is neoangiogenesis either through transdifferentiation to vascular 
endothelial cells or via expression of several signalling factors such as 
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and 
transforming growth factor (TGF), all key signalling factors involved in 
angiogenesis18. Preclinical experiments have demonstrated the ability of 
BMSCs to induce angiogenesis in infarcted myocardium and have implicated 
this as the mechanism of cardiac repair327. Although there continues to be 
growth in the number of clinical trials evaluating the potential of cell therapy, 
there have so far been few mechanistic studies performed in humans. Hence, 
the recent development of radiolabelled imaging probes, utilising single-
photon emission computed tomography (SPECT) imaging, that specifically 
bind to receptors involved in angiogenesis provides an exciting opportunity to 
gain insight into the biological effects of cell therapy on human cardiac tissue. 
6.1.2 The αvβ3 integrin receptor 
Integrins are receptors that mediate the attachment between a cell and the 
tissues that surround it, such as other cells or the extracellular matrix (ECM). 
Structurally, integrins are heterodimers containing two distinct chains, called 
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the α (alpha) and β (beta) subunits and in mammals eighteen α and eight β 
subunits have been characterized328. The αvβ3 integrin receptor (Figure 48a) 
plays a key role in angiogenesis329. It is up-regulated and expressed 
preferentially on proliferating endothelial cells and limited distribution 
elsewhere within tissue188, 330. By serving as a receptor for a variety of 
extracellular matrix proteins containing an arginine-glycine-aspartic acid 
(RGD) sequence, these integrins mediate migration of endothelial cells into 
the basement membrane and regulate their growth, survival, and 
differentiation331.
 
Figure 48. a) The αvβ3 integrin receptor; b) 99mTc-NC100692 binding site to the αvβ3 integrin 
receptor 
 
6.1.3 99mTc-NC100692 as an imaging agent 
99mTc-NC100692 is a radiopharmaceutical agent manufactured by GE 
Healthcare Ltd (Amersham, UK) currently being investigated as a diagnostic 
agent for the detection of angiogenesis. 99mTc-NC100692 is a technetium 
labelled small, cyclical peptide that contains the RGD motif in a configuration 
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that gives the ligand a high affinity for the αvβ3 integrin (Figure 48b). 
Preclinical experiments in murine models of limb ischaemia have 
demonstrated increased focal activity of 99mTc-NC100692 on SPECT imaging 
3-7 days following femoral artery ligation which correlated with ex vivo tissue 
analysis (gamma counting) and immunofluorescence staining190, 332. Clinical 
studies have demonstrated a relationship between tracer uptake, angiogenic 
status (microvessel density) and integrin expression in malignant tumours and 
tissue recovering from ischaemia333. 
 
The high affinity of this agent for the αvβ3 integrin up-regulated in 
angiogenesis makes it an ideal tool for evaluating angiogenesis in clinical 
studies. It can be administered as a single bolus injection and uptake detected 
with SPECT imaging. Excretion is predominantly through the urinary pathway, 
with about 56% of the injected activity excreted in the urine. About 16% of the 
injected activity is excreted in the faeces 334. A phase 1 clinical study in which 
healthy volunteers were administered 99mTc-NC100692 intravenously 
demonstrated only minimal amount of background activity in the thorax but 
increased uptake of the agent in the liver and intestines334. Phase 2a studies 
have also been conducted in breast and lung cancer patients to detect 
angiogenesis and 99mTc-NC100692 was safe and well tolerated333. 
 
We therefore designed a sub-study to assess the feasibility of using 99mTc-
NC100692 to detect angiogenesis in patients undergoing BMSC therapy in our 
trial. This sub-study has been carried out in collaboration with the Nuclear 
Medicine department at University College London Hospital and Department 
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of Advanced Cardiovascular Imaging at Yale (Professor Sinusas). We had 
initially planned to perform these imaging studies in patients recruited to the 
intramyocardial arm but owing to delay in obtaining ethics and MHRA approval 
these scans have been performed in 10 patients undergoing intracoronary 
infusion of BMSCs or serum. Patients have undergone baseline angiogenesis 
imaging with a follow-up scan 4 days post intracoronary infusion to assess for 
de novo angiogenesis. This time-point is based on the experience of Professor 
Sinusas in his pre-clinical work that demonstrated a significant angiogenic 
signal at this time point following a hypoxic stimulus335. Patients have also 
undergone baseline and follow-up perfusion imaging to assess for any change 
in perfusion related to angiogenesis. Patients receiving intracoronary infusion 
of serum will provide a ‘control’ group for the study. The preliminary results 
from the first three patients undergoing this imaging sub-study are presented 
in this chapter. Imaging scans from normal patients will be shown for 
comparison and have been provided courtesy of GE Healthcare. 
 
6.2 Methods 
6.2.1 Angiogenesis sub-study protocol 
Patients allocated to this sub-study underwent the standard procedures of the 
REGENERATE-IHD trial protocol as described in chapter 4, except that they 
had intracoronary infusion of BMSCs/serum instead of intramyocardial 
injection. They underwent 4 additional scans at The Nuclear Medicine 
department at University College London Hospital (UCLH)- the timeline of the 
study protocol is demonstrated in figure 49. 
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Figure 49. Timeline of angiogenesis sub-study 
 
Details of additional imaging studies: 
1. Baseline angiogenesis scan (day 0)- patients received administration of 
99mTc-NC100692 injection 20 minutes before SPECT/CT scan using 
hospital protocol at baseline. 5.5ml of 99mTc-NC100692 was injected 
intravenously at a rate of 2-4mls per second. Each subject received 
75µg of NC100692. 
2. Baseline perfusion scan- patients also underwent a baseline 
assessment of myocardial perfusion using a standard thallium-201 
protocol. 
3. Follow-up angiogenesis scan- a repeat SPECT/CT following 
administration of 99mTc-NC100692 was performed 4 days post 
intracoronary infusion of BMSCs/placebo to assess for therapy induced 
angiogenesis.  
4. Follow-up perfusion scan- a repeat thallium-201 perfusion scan was 
performed 6-months post therapy to assess for changes in perfusion. 
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This coincided with the patients’ normal 6-months follow-up 
appointment for the trial. 
6.2.1 Acquisition and analysis of data 
Image analysis has been performed by the nuclear medicine department at 
UCLH (Dr Maria Holstensson) and includes ongoing work regarding 
quantification of uptake of 99mTc-NC100692 and assessment of relationship to 
measured changes in functional indices and perfusion. 
 
6.3 Results 
6.3.1 Patient Characteristics 
Nine patients from the intracoronary arm of the REGENERATE-IHD Study 
were recruited for this sub-study, the final patient declined consent. The 
baseline characteristics of these patients are shown in table 9. 
 
Table 9 Baseline characteristics of patients recruited to imaging study 
 Patients recruited to ‘angiogenesis’  
imaging sub-study (n=9) 
Age (years) 
Male sex, n (%) 
59 ± 8 
8 (88) 
 
Previous MI, n (%) 
CABG, n (%) 
Time from last MI 
(years) 
 
Diabetes, n (%) 
 
7 (77) 
3 (33) 
 
7.7 ± 7.1 
 
2 (22) 
 
NT-proBNP (pg/ml) 
LVEF (%) 
 
1236 ± 1227 
30 ± 7.5 
ICD/CRT, n (%) 6 (66) 
Data presented as number and (% of patients) or mean ± SD  
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6.3.2 99mTc-NC100692 imaging in normal patients 
The following figure shows the distribution of uptake of 99mTc-NC100692 in two 
‘normal’ patients with no known prior history of cardiac disease. There is no 
appreciable cardiac uptake of the radio-tracer although there is uptake in the 
liver and intestines. 
 
Normal patient 1
Normal patient 2
 
Figure 50. 99mTc-NC100692 imaging in two normal patients showing no appreciable cardiac 
uptake. There is however significant uptake within the liver and intestines. Images courtesy of 
GE Healthcare. 
 
6.3.3 99mTc-NC100692 in study patients 
The baseline and follow-up 99mTc-NC100692 imaging in the first 3 patients 
who underwent this sub-study are shown here. Only the qualitative SPECT 
imaging data is currently available at the time of writing this thesis and 
refinement of quantitative analysis is ongoing. We remain blinded to whether 
these patients received BMSCs or serum alone. 
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Patient 1 
In patient 1 there is detectable myocardial uptake (red/yellow areas) of 99mTc-
NC100692 at baseline and uptake appears to be increased 4 days post 
intracoronary infusion of BMSCs/serum: 
Patient 1. Baseline scan
Patient 1. Follow-up scan, 4 days post intracoronary injection of cells/serum
 
Figure 51. Baseline and follow-up 99mTc-NC100692 SPECT imaging in patient 1. 
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Patient 2 
 
In patient 2 there is again detectable uptake of 99mTc-NC100692 at baseline, 
however there appears to be relatively similar uptake at the follow-up scan: 
Patient 2. Baseline scan
Patient 2. Follow-up scan, 4 days post intracoronary injection of cells/serum
 
Figure 52. Baseline and follow-up 99mTc-NC100692 SPECT imaging in patient 2. 
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Patient 3 
 
In patient 3 there is relatively less uptake of 99mTc-NC100692 at baseline 
compared to the previous two patients and there is no significant increase in 
uptake following intracoronary infusion of BMSCs/serum: 
Patient 3. Baseline scan
Patient 3. Follow-up scan, 4 days post intracoronary injection of cells/serum
 
Figure 53. Baseline and follow-up 99mTc-NC100692 SPECT imaging in patient 3. 
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6.4 Discussion 
This unique study assesses for the first time the uptake of 99mTc-NC100692, a 
novel radio-tracer peptide with a high affinity for the αvβ3 integrin, in patients 
with chronic ischaemic heart failure.  The αvβ3 integrin receptor is highly up-
regulated in endothelial cells undergoing angiogenesis336 thus making it an 
ideal target for assessing possibly neoangiogenesis related to BMSC therapy.  
 
99mTc-NC100692 administration (at baseline and 4 days post intracoronary 
infusion of BMSCs or serum alone) was tolerated well by all nine patients who 
underwent this novel imaging technique.  Patients did not experience any 
adverse symptoms and there were no changes to haemodynamic monitoring 
during infusion of the radio-tracer.  
 
The baseline and follow-up SPECT images for the first 3 patients are shown in 
figures 51-53. The imaging results from two ‘normal’ patients are shown in 
figure 50. As these figures show, there is no appreciable cardiac uptake of 
99mTc-NC100692 in normal patients. However, in the study patients uptake of 
99mTc-NC100692 was seen in all 3 patients at baseline and in one patient 
there appears to be increased uptake following the intracoronary infusion of 
BMSCs/serum. These preliminary results suggest that in patients with chronic 
ischaemic heart failure and remote myocardial infarction there is evidence of 
persistent angiogenesis and there is the tantalising possibility that BMSC 
infusion may lead to an increase in angiogenesis.   
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The ability of this non-invasive imaging technique to demonstrate baseline 
levels of angiogenesis in patients with chronic ischaemic heart failure is novel. 
However, this is not an entirely unexpected finding given that the study 
patients have previous myocardial infarction and severe coronary artery 
disease- likely resulting in local tissue hypoxia337. Previous animal studies 
have shown uptake of 99mTc-NC100692 following surgically induced 
myocardial infarction189, 338, 339. 99mTc-NC100692 SPECT imaging has also 
been assessed clinically to detect infarct angiogenesis in patients with recent 
myocardial infarction340. In this study of 10 patients, uptake was demonstrated 
in the infarct zone, indicating angiogenesis in the healing infarct. Our study 
suggests that angiogenesis continues in the chronic setting as all patients in 
our study were at least 1-year post myocardial infarction. Neoangiogenesis is 
known to play an integral process in the LV remodelling process following 
myocardial although the degree of new capillary network formation is unable 
to match the metabolic demands of the hypertrophied myocardium. This 
mismatch contributes to the loss of viable tissue, infarct extension and fibrous 
tissue formation341.  
 
Therapeutic angiogenesis as a concept has been around for some time and 
aims to improve perfusion via collateral blood vessel formation in ischaemic 
heart and limbs342. Until recently, the focus of this field of research was the 
use of angiogenic cytokines such as vascular endothelial growth factor 
(VEGF) or members of the fibroblast growth factor (FGF) family to stimulate 
angiogenesis336. It is now increasingly recognised that angiogenesis is likely to 
be a significant mechanism through which bone marrow stem cell therapy 
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exerts a beneficial effect on ischaemic cardiac tissue18, 151 and hence cell 
therapy has a major role to play in the field of therapeutic angiogenesis.   
 
Currently, the efficacy of cell therapy in cardiac disease has been assessed 
using surrogate markers such as LVEF and myocardial perfusion. It remains to 
be determined whether an improvement in angiogenesis will be associated 
with a simultaneous improvement in LVEF/perfusion and the final un-blinded 
analysis of our sub-study will provide valuable information regarding this. The 
development of similar molecular imaging techniques that target the biological 
processes implicated in cell therapy may allow direct confirmation of 
engraftment of cells and the monitoring of the beneficial effects such as 
neoangiogenesis.  
 
6.5 Study Limitations 
We would ideally liked to have performed this sub-study in patients 
undergoing intramyocardial injection of BMSCs but due to delay in obtaining 
ethical and regulatory approval this study has been performed in patients in 
the intracoronary arm of the study. We also remain blinded to whether patients 
received stem cells or serum (control group) at the time of this thesis 
submission. The current analysis provides only qualitative information 
regarding the degree of tracer uptake and further work is ongoing to develop a 
method of quantification which will allow more objective assessment of the 
degree of angiogenesis. Nevertheless, there is valuable information that has 
been gained just in these three patients and a paper will be published in due 
course detailing the full results of this sub-study. 
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CHAPTER 7: FUTURE DIRECTIONS 
7.1 General 
The three studies presented in this thesis add significantly to the growing 
evidence base regarding the potential for cell therapy to improve cardiac 
function and symptoms in patients with ischaemic heart disease. The studies 
have also generated interesting hypotheses that warrant further investigation. 
 
The efficacy of the combined approach of G-CSF and intramyocardial injection 
of BMSCs demonstrated in the REGENERATE-IHD study (chapter 4) will need 
confirmation in a larger multi-centre phase III randomised controlled trial. 
Future trials should also be adequately powered to detect a difference in hard 
clinical end-points (such as mortality and re-hospitalisation) as there was a 
hint towards improved clinical outcomes in our study. The results also suggest 
a possible role for the combination of G-CSF and intramyocardial injection of 
serum. This warrants further examination and a trial comparing serum injection 
versus saline injection may help evaluate the efficacy of this combination. It 
will also be important to perform assays to characterise the various constituent 
paracrine factors in the serum which maybe responsible for cardiac repair. The 
final analysis of the full REGENERATE-IHD trial, with the completed 
intracoronary and peripheral arms of the study, will provide valuable insight 
into the ideal route of delivery of BMSCs in patients with ischaemic heart 
failure. 
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In chapter 5, G-CSF was shown to improve the functional potential of 
circulating CD34+ cells compared to those in the bone marrow. This finding 
requires further investigation and a randomised trial of G-CSF followed by 
intramyocardial injection of peripheral (PBSCs) or bone marrow derived stem 
cells (BMSCs) may be helpful. Previous trials comparing PBSCs versus 
BMSCs have shown differing results10, 154 but G-CSF was not administered in 
those trials and this maybe an important factor. 
 
The novel nuclear imaging technique, presented in chapter 6, is a potentially 
exciting tool which will allow the assessment of possible therapeutic 
angiogenesis related to BMSC therapy. The full results of this study are not 
yet available but are highly anticipated as there did appear to be an increase 
in tracer uptake in one of the study patients. This technique is very much in 
the early phase of development and there is ongoing work to refine the 
qualitative and quantitative assessment of tracer uptake. However, this 
technique could play a major role in the field of stem cell therapy as it may 
allow indirect confirmation of cell engraftment as well as measuring the 
therapeutic angiogenic response. Hence, it may become established as one of 
the key modalities to assess efficacy in future larger trials in this field. 
Furthermore, angiogenesis imaging could have a wider application in the field 
of general/interventional cardiology and in other therapies that aim to improve 
angiogenesis such as direct myocardial revascularisation. 
 
There are several other ongoing developments in this rapidly developing field 
of cell therapy for cardiac disease. These can be grouped into: (1) identifying 
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the ideal cell type; (2) refining the delivery method; (3) improving cell 
engraftment and retention; (4) performing mechanistic studies and large phase 
III clinical trials with hard clinical end-points; (5) developing imaging 
techniques to identify and monitor cell engraftment as well as subsequent 
biological effects. The key developments are discussed in detail below.  
 
7.2 Cells 
In addition to BMSCs, there are several other cell types undergoing clinical 
evaluation for their effects on cardiac repair. In particular, cardiac resident 
stem cells (CSCs) have shown promising efficacy results in the setting of AMI 
(CADUCEUS trial118) and ischaemic heart failure (SCIPIO trial343). Other 
developments include allogeneic products and modification of cells prior to 
delivery. 
 
Allogeneic cell products 
It is now increasingly recognised that patient related factors such as age and 
severity of disease state can adversely affect the function of autologous cells. 
The advantages of an allogeneic cell product include the ability to provide an 
‘off the shelf’ therapy with uniform quality and consistency and avoid the 
problem of patient related cell dysfunction. This would also avoid harvesting 
cells from patients which could reduce time and costs of cell therapy. The 
main disadvantages relate to potential immune mediated cell rejection. 
Allogeneic MSCs (Prochymal™) have already been used in the clinical setting 
and have shown promise in improving cardiac function following myocardial 
infarction196. MultiStem® (Athersys) is another allogeneic product containing 
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bone marrow derived multi-potent adult progenitor cells (MAPCs). MAPCs 
demonstrate tri-lineage differentiation potential and have been shown to 
expand in high numbers in culture344. MAPCs also appear to be 
immunoprivileged making this an ideal allogeneic cell product. A phase 1 
clinical trial of MultiStem® injection using a novel adventitial delivery technique 
in the AMI setting has demonstrated potential efficacy345. 
 
Cell modification  
There is growing interest in guiding the transdifferentiation of cells into a 
cardiopoietic phenotype (i.e. lineage specified) prior to transplantation into 
infarcted myocardium in an attempt to improve the efficacy of cell therapy. Cell 
modification may also overcome the issue of patient related cellular 
dysfunction. This has been successfully demonstrated in a murine model of 
myocardial infarction where epicardial injection of lineage specified 
cardiopoietic MSCs (obtained from human bone marrow) achieved superior 
cardiac functional and structural improvements compared to injection of 
unguided MSCs346. This is also being examined in the C-Cure trial which is an 
ongoing phase II/III trial evaluating the safety and efficacy of intramyocardial 
injection of guided cardiopoietic MSCs in patients with ischaemic heart failure 
(ClinicalTrial.gov Identifier NCT00810238).  
 
7.3 Delivery systems 
New interventional techniques to deliver cell therapy have been developed 
and an overview of delivery systems has been provided in section 2.2.5 of this 
thesis. There is ongoing development due to the need for better delivery 
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systems to improve cell retention. For example, a recent feasibility study has 
assessed the safety of a novel percutaneous intracoronary micro-needle 
adventitial delivery technqiue345.  The development of specialised delivery 
systems requires that interventional cardiologists acquire the necessary 
training and proficiency in these techniques if and when cell therapy is 
established as potentially beneficial therapy in selected patients. Training 
programmes are already being established around the world following 
guidelines by the International Society for Cardiovascular Translational 
Research (ISCTR) providing recommendations for successful training in 
methods of delivery of biological therapeutic material for cardiac 
regeneration347. 
 
7.4 Engraftment 
A major limitation of current cell delivery techniques is the low rate of 
engraftment of transplanted cells. This was highlighted in a preclinical study 
that demonstrated maximal cell retention rates within the myocardium of only 
11% with intramyocardial injection, 3% with intracoronary injection and 3% 
with intravenous infusion191. There are therefore various ongoing 
developments to try and improve cell engraftment and retention, some of 
which are described below. 
 
 
Cell Sheets 
 
Cell sheet-based tissue engineering has been developed by harvesting two-
dimensional (2D) cell sheets from culture plates and stacking the sheets to 
create three-dimensional (3D) tissues without the use of scaffolds348. Stacked 
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cardiomyocyte sheets have been demonstrated to contract simultaneously 
and have been shown to improve cardiac function following surgical 
transplantation in rat, canine and pig models348. A clinical trial of transplanting 
cell sheets in heart failure patients has already been instigated and there are 
reports of promising early results349. 
 
Cardiac Patch 
In this technique stem cells are seeded on 3D porous alginate scaffolds which 
are then surgically transplanted onto the epicardial surface of infarcted hearts.  
In a rat infarct, these patches were shown to stimulate intense 
neovascularisation and attenuate LV dilatation350. A clinical study has 
compared epicardial injection of BMSCs alone versus implanting a collagen 
matrix seeded with BMSCs in patients with impaired cardiac function 
undergoing CABG. The matrix group appeared to show better improvements 
in cardiac structure and function compared to injection of BMSCs suggesting 
an improvement in the efficiency of cellular cardiomyoplasty351. This technique 
is limited by the need for a surgical procedure. 
 
CellBeads® 
 
CellBeads® (CellMed AG, Germany) are 170 µm alginate microspheres that 
contain MSCs genetically modified to express glucagon-like peptide-1 (GLP-1) 
in addition to inherent paracrine factors. GLP-1 is known to have anti-apoptotic 
and cardioprotective effects352. CellBeads® have been shown to have upto 
90% myocardial retention following intracoronary infusion in a porcine model 
of AMI353. In this study, there did not appear to be any impairment of coronary 
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blood flow and there were positive signs of efficacy with reduction in 
apoptosis. This technology may improve myocardial cell retention as well as 
providing a means of prolonged secretion of beneficial paracrine factors by the 
encapsulated cells. 
 
7.5 Clinical trials 
The number of clinical trials evaluating cell therapy in cardiac disease 
continues to increase- at the time of submission of this thesis there were 458 
trials registered with ClinicalTrials.gov. The European Society of Cardiology 
Task Force on cell therapy has provided guidance on the design of future 
trials15. This includes recommendations for large phase III studies assessing 
clinical end-points and well-designed mechanistic studies. 
 
Phase III trials 
So far, there have been many relatively small clinical trials assessing the 
safety and efficacy of cell therapy in acute and chronic cardiac disease. The 
relative safety of cell therapy has been uniformly demonstrated but 
demonstration of efficacy (using surrogate end-points such as LVEF) has 
been inconsistent. Meta-analyses of cell therapy suggest that there is a 
modest but significant improvement in cardiac function following cell therapy in 
AMI and chronic ischaemic heart failure217, 311. Interestingly these analyses 
also suggest improved clinical outcomes such as mortality following cell 
therapy49, 311. Hence, there are now plans to perform large phase III trials to 
assess the effects of cell therapy on hard clinical end-points. One such study 
is the proposed BAMI trial which will be a European multi-centre trial recruiting 
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3000 patients post-AMI to assess the impact of BMSC therapy on mortality 
(ClinicalTrial.gov Identifier NCT01569178). There is also a US phase III trial 
evaluating the efficacy and safety of autologous CD34+ stem cells to increase 
exercise capacity in patients with chronic myocardial ischemia. This study, 
sponsored by Baxter (USA), follows on from the ACT34-AMI248 study and aims 
to recruit 450 patients across 50 sites in the US (ClinicalTrial.gov Identifier 
NCT01508910). 
 
Head to head comparison of cells 
 
In view of the multiple different cell types undergoing clinical evaluation there 
is a need for clinical trials comparing the efficacy of different cell types in 
different disease states. The first pre-clinical comparison of cell types showed 
superior survival pattern and efficacy of BM-MNCs compared to MSCs and 
skeletal myoblast in a murine model of AMI162. The most recent pre-clinical 
experiment showed that cardiac derived stem cells were superior to BM-MNCs 
and MSCs in their ability to improve cardiac function in AMI354. Clinical studies 
have so far only compared PBSCs and BMSCs with mixed results10, 154, 312. 
Our own data presented in this thesis suggests that G-CSF treatment may 
lead to PBSCs having more functional potential than BMSCs17 and this 
warrants further investigation in the design of future trials. In a recent meta-
analysis of BMSC trials in AMI and IHD patients, BM-MNC transplantation 
appeared to have better efficacy results compared to CD133+ or CD34+ cells 
alone311. This also warrants further investigation. 
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Other mechanistic studies 
Proposed mechanistic studies include assessing the roles of stromal cell-
derived factor-1 (SDF-1) and microRNAs in cardiac repair. SDF-1 is 
chemokine that is transiently expressed following tissue injury and is thought 
to promote stem cell homing to the myocardium355. It also limits cardiac injury 
by initiating a number of protective molecular pathways that are both anti-
inflammatory356 and anti-apoptotic357. A recent preclinical study injected naked 
plasmid DNA encoding SDF-1 into the infarct border zone in a rat model of 
chronic heart failure358. Compared to controls the SDF-1 treated animals 
showed increased angiogenesis, improved cardiac function and evidence of 
scar remodelling.  
 
MicroRNAs are small strings of oligonucleotides that regulate molecular 
switches in cells that control the expression of hundreds of genes (i.e. a class 
of post-transcriptional regulators)359. Specific microRNAs have been shown to 
be capable of inducing direct cellular reprogramming of fibroblasts to 
cardiomyocyte-like cells in vitro360. Furthermore, administration of microRNAs 
into ischemic mouse myocardium resulted in evidence of direct conversion of 
cardiac fibroblasts to cardiomyocytes in situ360. This early work is fascinating 
and if reproduced by others may have huge therapeutic potential.  
 
7.6 Imaging 
Currently the role of imaging in cell therapy is limited to the assessment of 
surrogate end-points of efficacy such as LVEF and cardiac volumes. There are 
also developments to use real-time MRI guidance to help guide 
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transendocardial injection of cells361. However, there is a lack of clinical 
imaging techniques targeted at the cellular level and an inability to track the 
fate of injected cells. Preclinical experiments have utilised direct labelling (with 
MRI and nuclear imaging) to assess immediate cell distribution216, reporter 
genes to assess long-term survival358 and optical fluorescence imaging to 
estimate transdifferentiation and engraftment116. There are yet to be clinical 
translation of these methods mainly due to concerns regarding manipulation 
and disruption of cells prior to delivery. The ‘angiogenesis’ imaging technique, 
described in chapter 6 of this thesis, utilising SPECT imaging and a radio-
tracer with high affinity for an angiogenesis related integrin is the first clinical 
study of its kind and once completed may represent a big step forward with 
regards to clinical imaging of the biological actions of transplanted cells. 
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CHAPTER 8: CONCLUSIONS 
This thesis has presented three clinical studies evaluating the role of bone 
marrow stem cell (BMSC) therapy in patients with ischaemic heart failure. The 
aims of these studies were to address some of the unresolved questions 
regarding this novel therapy, in particular: the delivery method and the role of 
adjunctive cytokine therapy, the effect of patient-related factors on progenitor 
cell concentration and function and the possible mechanism(s) of action of cell 
therapy. 
 
In the first study, complete 1-year follow-up data from the intramyocardial arm 
of the REGENERATE-IHD were presented. Combined G-CSF treatment and 
intramyocardial injection of BMSCs in patients with chronic ischaemic heart 
failure led to a significant improvement in LVEF, NT-proBNP, symptoms and 
quality of life. There was also improvement in diastolic function in the cell 
treated group. The improvement in LVEF was related to the in vitro functional 
potential of injected cells.  
 
Interestingly, there were also signals of efficacy seen in the control group who 
received G-CSF therapy and intramyocardial injection of autologous serum. 
There was a significant reduction in NT-proBNP and a statistically non-
significant improvement in LVEF. This raises the possibility that there maybe 
some therapeutic potential of G-CSF therapy combined with direct delivery of 
soluble paracrine factors. 
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In a separate study of progenitor cell characteristics, ageing appeared to have 
an inverse relationship with circulating CD34+ cell concentration. In older 
patients with ischaemic heart failure, bone marrow concentration of CD34+ 
cells following G-CSF treatment was lower and peripheral blood (PB) 
mobilisation was also impaired. The disease process itself also appeared to 
have an effect on peripheral blood progenitor cell concentration. Non-
ischaemic heart failure (DCM) was associated with significantly higher 
baseline PB CD34+ and EPC concentration compared to IHD. Following G-
CSF treatment, CD34+ cell concentration was greater in the BM compared to 
PB, however the PB CD34+ cells appeared to have a greater and improved 
(compared to baseline) functional potential. These results suggest treatment 
with G-CSF improves the functional potential of mobilised circulating 
progenitor cells compared to those in the bone marrow.  
 
The preliminary results of a sub-study assessing the feasibility of a novel 
imaging technique to detect angiogenesis related to BMSC therapy has also 
been presented. In this study the uptake of 99mTc-NC100692, a radio-tracer 
peptide with a high affinity for the αvβ3 integrin (which plays a key role in 
angiogenesis), was assessed in patients undergoing intracoronary infusion of 
BSMCs or serum. SPECT imaging demonstrated uptake of the radio-tracer in 
patients prior to any treatment providing evidence for a degree of persistent 
angiogenesis in patient with chronic ischaemic heart failure. In one patient 
there appeared to be an increase in tracer uptake following treatment raising 
the tantalising possibility that BMSC transplantation may lead to an increase in 
angiogenesis in human cardiac tissue.  
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The field of cell therapy for the treatment cardiovascular disease continues to 
gather pace. The results from the intramyocardial arm of our REGENERATE-
IHD add valuable insight and suggest a role for combined G-CSF therapy and 
intramyocardial injection of BMSCs. Signals of efficacy demonstrated in the 
control group warrants further investigation of intramyocardial injection of 
soluble paracrine factors. The current aims are to translate the beneficial 
findings seen in preclinical experiments and small clinical studies into 
improved clinical outcomes in a large number of patients in the setting of 
phase III clinical trials. This will require close collaboration between scientists 
and clinicians to refine cell products, delivery systems and methods to improve 
cell retention in targeted tissue. Novel imaging techniques which allow 
detection of cell engraftment and biological action will play a key role in 
facilitating the refinement of cell therapy. The future holds great promise for 
cellular therapy which will hopefully provide a realistic treatment option for a 
large number of patients with heart failure who remain symptomatic and would 
otherwise continue to suffer a poor outcome. 
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APPENDIX A: LV THROMBUS STUDY 
 
 
Study Rationale 
 
In the REGENERATE-IHD Study presented in chapter 4, three patients had to 
be withdrawn from the intramyocardial arm due to the finding of previously 
undiagnosed left ventricular thrombus (LVT) on baseline cardiac imaging. 
Hence, we sought to examine the incidence of LVT in patients recruited to our 
whole REGENERATE-IHD Study to ascertain whether we should routinely 
screen patients for LVT as part of the assessment clinic prior to inclusion in 
future trials. This is particularly important in view of the imminent design of 
larger Phase III studies recruiting hundreds-to-thousands of patients. The 
overall feasibility of NOGA® intramyocardial injection is discussed in section 
4.5.4. 
 
Patients with heart failure and left ventricular systolic dysfunction (LVSD) are 
recognised to be at an increased risk of developing arterial and venous 
thrombo-embolic complications, but reports of the incidence of these events 
vary widely362, 363. In addition to atrial fibrillation, the development of LVT is a 
possible causal mechanism responsible for thromboembolism in these 
patients. There are currently no guidelines as to whether patients with LVSD 
should be screened for the development of LVT and if so at what time interval 
this should be performed. There is also no firm consensus regarding the 
period of anticoagulation once LVT has been identified. Hence, current 
 193 
guidelines and recent clinical trials of anticoagulation in heart failure are also 
discussed in this study. 
 
Methods 
 
Study objectives 
We sought to assess the incidence of previously undiagnosed LVT in 
consecutive patients with severe chronic ischaemic heart failure recruited to 
our REGENERATE-IHD study. We also examined the sensitivity of contrast 
echocardiography imaging compared to cardiac CT/MRI for the diagnosis of 
LVT. 
 
Patient population 
The study population comprised of all the patients who have so far completed 
follow-up in the REGENERATE-IHD Study. 
 
Cardiac Imaging 
The presence of LVT was assessed in all baseline and follow-up imaging 
studies that were performed in recruited patients. All imaging studies were 
reviewed by an imaging specialist. 
 
Contrast echocardiogram 
Two-dimensional transthoracic echocardiogram (TTE) was performed in all 
patients at baseline, 6-months and 1-year post treatment. An ultrasound 
contrast agent, Sonovue™, was used in all patients to improve delineation of 
the LV endocardial border.  
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Cardiac MRI (CMR) 
CMR was performed in patients without a contraindication to MRI scanning 
using a Siemens Avanto 1.5T (Siemens Medical Solutions, Erlangen, 
Germany) scanner, using internationally standardised acquisition protocols271. 
The presence of LVT was assessed following administration of an intravenous 
contrast agent, gadolinium doterate, (Dotarem, 0.15mmol/kg). 
 
Cardiac CT 
Cardiac CT was performed in patients with a contraindication to MRI.  A 
Siemens 256-slice "FLASH" dual-source scanner was used to obtain 
retrospectively gated scans with intravenous iodinated contrast for 
assessment of cardiac structure and function. 
 
 
 
Results 
 
71 patients have so far completed 1-year follow-up in the whole 
REGENERATE-IHD trial. All baseline and follow-up imaging studies were 
evaluated for the presence of previously undiagnosed left ventricular thrombus 
(LVT).  All patients were in sinus rhythm. There were no statistically significant 
differences between patients with and without LVT in terms of baseline 
characteristics or severity of LV systolic dysfunction (table 10). 
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Table 10. Characteristics of patients with and without left ventricular 
thrombus 
 Patients without 
LVT (n=63) 
Patients with 
LVT (n=8) 
p-value 
Age, years 63.5 ± 9.6 57.4 ± 7.9  0.09 
Medical history 
   Previous MI (%) 
   Time from prior MI (years) 
   LVT at time of prior MI (%) 
   Previous CABG (%) 
   Previous TIA/CVA (%) 
 
50 (74) 
8 ± 7 
2 (3.2) 
21 (33) 
4 (6.3) 
 
8 (100) 
11± 6 
1 (14) 
3 (38) 
1 (12.5) 
 
0.33 
0.28 
0.30 
0.55 
0.46 
LVEF (%) 
LVEDD (cm) 
31.9 ± 10.9 
6.2 ± 0.9 
27.6 ± 5.1 
6.2 ± 0.8 
0.28 
0.99 
NT-proBNP (pg/ml) 1124 1048 0.90 
Medications at 
recruitment  
    Aspirin (%) 
    DAPT (%) 
    Warfarin (%)             
 
 
53 (84) 
19 (30) 
12 (19) 
 
 
8 (100) 
4 (50) 
0 
 
 
0.28 
0.23 
0.21 
Data presented as number (% of patients) or mean ± SD; DAPT: dual anti-platelet therapy; 
LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter; LVT: left 
ventricular thrombus 
  
 
Incidence of LVT 
A total of 8 (11.3%) patients had LVT detected during cardiac imaging 
performed as part of the trial protocol. 6 patients had LVT detected at baseline 
and 2 patients had LVT identified during follow-up scans at 6 months and 1 
year.  Of the 7 patients who had LVT diagnosed with CMR (n=4) or CT (n=3), 
the corresponding contrast TTE was positive in only 2 of these patients, giving 
a sensitivity of only 30% compared to CMR/CT. The 2 cases diagnosed 
accurately on TTE were large protuberant thrombi and in the 5 cases detected 
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only by CMR/CT the LVT were smaller, laminated or adherent to the antero-
septum of the LV cavity (Figure 54). 
(b)(a)
(c) (d)
 
Figure 54. Comparison of contrast echo and cardiac CT/MR for diagnosis of left ventricular 
thrombus. (a) contrast echo accurately demonstrating a moderate sized apical LVT (black 
arrow) which was subsequently confirmed on CT which is shown in (b); (c) contrast echo in a 
patient which does not appear to show LVT, however on subsequent MRI with gadolinium 
contrast (d) a small, non-mobile laminated apical LVT is clearly demonstrated (white arrow). 
 
Management of LVT 
All the patients who had LVT identified were commenced on oral 
anticoagulation with warfarin following discussion of risk/benefit. There have 
not been any bleeding complications and we have decided to continue 
anticoagulation indefinitely in these patients.  
 
Thrombo-embolic episodes during follow-up 
Only one patient (1.4%) developed a thrombo-embolic complication during 
follow-up. This was a pulmonary embolism in a patient without LVT and not on 
warfarin.  
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Discussion 
 
We have shown an 11.3% incidence of LV thrombus (LVT) in a population of 
optimally treated patients with severe LVSD secondary to ischaemic heart 
disease. In addition we found no statistical difference in the rates of prior MI, 
CABG or TIA/CVA between patients with and without LVT. There was also no 
difference between these groups with regards to LVEF and LV end diastolic 
diameter. There was no difference in the prior use of anti-platelet therapy; 
however none of the 8 patients with LVT were taking warfarin compared to 
19% of patients without LVT. This was not statistically significant which is most 
likely due to the relatively small study cohort. Finally we established that 
contrast TTE has a sensitivity of only 30% compared to cardiac CT/MRI for the 
detection of LV thrombus.  
 
The incidence of LVT in patients with ischaemic LVSD remains considerable 
despite contemporary therapy. The incidence found in our cohort of patients is 
similar to other recent published series. In their recent papers Weinsaft et al. 
quote an incidence of 7-10% in patients with significant LVSD364, 365. Their 
data is based on studies comparing transthoracic echocardiography (TTE) and 
delayed enhancement-CMR (DE-CMR). The sensitivity and specificity of TTE 
were 33% and 91% respectively compared to DE-CMR which is similar to the 
finding in our study. Follow-up in the former study supported DE-CMR as a 
reference standard, with >5-fold difference in endpoints (embolic events) 
between patients with versus without LVT by DE-CMR (p = 0.02). This is 
further supported by another study comparing TTE, TOE and DE-CMR for the 
detection of LV thrombus in patients with surgically/pathologically confirmed 
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LVT. In this study of 160 patients with all 3 imaging modalities performed 
within 30 days of surgical or pathological confirmation, contrast-enhanced MRI 
had the highest sensitivity and specificity (88% +/- 9% and 99% +/- 2%, 
respectively) compared with TTE (23% +/- 12% and 96% +/- 3.6%, 
respectively) and TOE (40% +/- 14% and 96% +/- 3.6%,  respectively) for 
thrombus detection366. TTE remains the most widely used modality of LV 
imaging for the detection of LVT due to its ease of use, non invasive nature 
and low cost. However, with the recent expansion in availability of CMR this is 
rapidly becoming the imaging modality of choice for assessment of cardiac 
structure and function. Cardiac CT with contrast also provides a more 
sensitive approach to LVT detection than TTE; however the associated 
radiation and contrast exposure make this unattractive as a screening tool. 
 
The incidence of thromboembolism during follow-up was low (1.4%) in our 
study, although the eight patients with LVT were all commenced on long-term 
anticoagulation with warfarin. This incidence is in keeping with published data 
such as the SOLVD study in which the annual risk of stroke was 1.5% in 
patients with mild to moderate systolic dysfunction and 4% in those with 
severely reduced EF, as compared with 0.5% in the general population367. In 
another study of 264 ambulatory patients with HF (mean EF 27%), the rate of 
stroke or transient ischaemic attack was again low (1.7%/year) over a mean of 
24±9 years368. However, LVT was identified in half the cases, and patients 
with thrombus had a significantly higher rate of thrombo-embolism (5.3%/year) 
than those without thrombus (p=0.03). Furthermore, an embolic event in 
patients with heart failure may increase mortality as was shown in a study in 
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which patients with an embolic event suffered a significantly higher mortality 
during follow-up when compared to those without an embolic event 
(p<0.001)369. 
 
There are limited national and international guidelines regarding 
anticoagulation in patients with LVT. Currently, the 2008 American College of 
Chest Physicians do not recommend oral vitamin K antagonists in patients 
with non-ischemic HF unless another indication above and beyond heart 
failure itself is present370. Similarly, the ACC/AHA 2009 heart failure guidelines 
state that warfarin is most justified in patients with heart failure who have other 
indications for anticoagulation (e.g. previous embolic event or AF)371. In 
keeping with US guidelines, the 2008 ESC heart failure guidelines recommend 
that oral Vitamin K antagonist therapy be instituted for patients with heart 
failure and concomitant AF (Class I, Level A) or those with a proven intra-
cardiac thrombus or evidence of thromboembolic complications (Class I, Level 
C). However, current guidelines do not provide recommendation regarding the 
duration of anticoagulant therapy.  
 
The lack of definitive guidance reflects the limited clinical evidence available 
based on 3 small randomised trials (WASH372, WATCH373 and HELAS374). 
Hence the recent presentation of the results of the WARCEF trial375 was highly 
anticipated. This was a double-blind, multi-centre study comparing aspirin 
(325mg) or warfarin in 2,305 patients with LVEF <35% and NYHA classes I-III 
heart failure who were in sinus rhythm. The study showed no difference in the 
primary end-point of death, ischaemic stroke and intra-cerebral haemorrhage 
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between the two groups over a mean follow-up period of 3.5 years (HR 0.93 
(0.79-1.10), p = 0.4). However when the primary outcome was separated in its 
component parts there was a highly significant benefit of warfarin over aspirin 
for the prevention of ischaemic stroke (HR 0.52 (0.33-0.82) p = 0.005). This 
came at the cost of higher rates of major haemorrhage with warfarin, although 
rates of intra-cerebral haemorrhage were similar between the two groups. This 
study therefore appears to support current guidelines which do not 
recommend routine anticoagulation in heart failure without another indication 
such as AF.    
 
However, the recent development of novel oral anticoagulant therapy with 
lower bleeding risks may re-open the question of anticoagulation in heart 
failure. Dabigatran, a direct thrombin inhibitor, has recently been approved for 
the prevention of stroke in patients with non valvular AF. In the RE-LY trial, 
dabigatran at the higher of 2 doses reduced the risk of stroke and peripheral 
embolic events by 34% and the risk for hemorrhagic stroke by 74% compared 
to warfarin376.  Rivaroxaban is a novel direct factor Xa inhibitor approved in the 
United States for the prevention of stroke in non-valvular AF patients. In the 
ROCKET-AF trial377 rivaroxaban was non-inferior to dose-adjusted warfarin for 
the prevention of stroke. Major and non-major clinically relevant bleeding were 
not different between the two groups, but significant reductions in intracranial 
haemorrhage (0.5% vs. 0.7%, P=0.02) and fatal bleeding (0.2% vs. 0.5%, 
P=0.003) were seen in the rivaroxaban group. Apixaban is another oral direct 
factor Xa inhibitor which has been shown to be superior to warfarin in 
preventing stroke or systemic embolism and caused less bleeding in the 
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recently published ARISTOTLE study378. The improved safety profile of these 
newer agents warrants their evaluation in patients with ischaemic heart failure 
and LVSD particularly in the sub-group of patients with LVT who are known to 
have higher embolic risk which is associated with adverse morbidity and 
mortality.    
 
Finally, as our analysis shows that the presence of LVT appears to be 
relatively common in patients with LVSD, it maybe prudent to screen (with 
MRI/CT rather than echocardiography) for the presence of thrombus prior to 
randomisation of patients in future trials involving invasive intra-cardiac 
procedures such as transendocardial injection. This would avoid the issue of 
withdrawing patients after randomisation which can impact the statistical 
interpretation of trial results. From a clinical perspective, the relatively common 
finding of LVT in heart failure patients may limit the number of patients able to 
receive cell therapy via the transendocardial route. Furthermore, as discussed 
above there is currently no consensus guideline regarding anticoagulation in 
patients with heart failure and sinus rhythm. There is also no recommendation 
regarding the length of anticoagulation once LVT is diagnosed in the chronic 
setting. Patients with LVT may still be able to receive transendocardial therapy 
if there is resolution of thrombus following a period of anticoagulation. 
 
 
Study Limitations 
 
 
The analysis of the incidence of previously undiagnosed LV thrombus is an 
exploratory analysis, the findings of which need to be confirmed in a larger 
prospective database of heart failure patients.  
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APPENDIX B: HRQL QUESTIONNAIRES 
 
The three Health Related Quality of Life (HRQL) questionnaires (MacNew, 
SF36 Version 2 and EQ5D) are provided in this appendix.  
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MACNEW Questionnaire 
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SF36 Version 2 Questionnaire 
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EQ5D Descriptive Questionnaire 
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EQ5D Visual Analogue Score 
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APPENDIX C: PUBLICATIONS AND PRESENTATIONS 
 
 
Publications in peer reviewed journals: 
• Mathur A, Mozid AM et al. Combined G-CSF and Intramyocardial 
Injection of Bone Marrow Cells in Heart Failure Improves Cardiac 
Function and Symptoms at 1-Year. (submitted to Lancet) 
 
• Mozid AM, Jones D, Arnous S, Saunders N, Wragg A, Martin J, 
Agrawal S, Mathur A. The Effects of Age, Disease State and 
Granulocyte-Colony Stimulating Factor on Progenitor Cell Count and 
Function in Patients Undergoing Cell Therapy for Cardiac Disease. 
Stem Cells Dev. 2012 Jul 26.  
 
• Mozid AM, Arnous S, Sammut E, Mathur A. Stem Cell Therapy for 
Heart Diseases (review). Br Med Bull 2011; 98(1): 143-159. 
 
• Arnous S, Mozid AM, Martin J, Mathur A. Bone marrow mononuclear 
cells and acute myocardial infarction. Stem Cell Research & Therapy 
2012, 3:2. 
 
• Arnous S, Mozid AM, Mathur A. The Bone Marrow Derived Adult Stem 
Cells for Dilated Cardiomyopathy (REGENERATE-DCM) Trial– Study 
design. Regenerative Medicine 2011; 6(4):525-33. 
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Textbook chapters: 
• Mozid AM, Arnous S, Lovell M, Mathur A. Chapter 3.49 Cell Based 
Regenerative Therapy. Percutaneous Interventional Cardiovascular 
Medicine- The PCR-EAPCI Textbook. First Edition 2012. 
 
Presentations at Conferences: 
• European Society of Cardiology (ESC) Annual Congress (August 2011, 
Paris): 
Poster presentation of pilot phase of REGENERATE-IHD trial of bone 
marrow derived cells for patients with heart failure. 
 
• Cell Therapy for Cardiovascular Disease (January 2012, New York): 
Poster presentation of progenitor cell study results. 
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